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these pathogenic differences between rJHM.SD and rA59 by assessing: 1) the involvement of known viral
receptors in CNS infection and spread and 2) the induction and modulation of antiviral CD8 T cell responses
during acute and chronic CNS disease. Using primary CNS-derived cells and quantitative RT-PCR, we
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ABSTRACT 
 
RECEPTOR UTILIZATION AND ANTIVIRAL CD8 T CELL RESPONSES DURING CENTRAL 
NERVOUS SYSTEM INFECTION WITH A MURINE CORONAVIRUS  
Susan J. Bender 
Susan R. Weiss 
Murine coronavirus (mouse hepatitis virus, MHV) infection of the CNS provides a model system 
for studying viral and host factors affecting pathogenic outcome. CNS infection with the highly 
neurovirulent rJHM.SD is characterized by extensive viral antigen distribution throughout the 
brain and few antiviral CD8 T cells at the site of infection, and infected mice succumb to disease 
by approximately seven days post-infection. In contrast, the less neurovirulent rA59 strain 
establishes acute infection in the CNS and liver; a robust antiviral CD8 T cell response peaks in 
the brain at day seven post-infection and coincides with clearance of infectious virus. Mice 
surviving acute rA59 infection later develop immune-mediated demyelination, and viral RNA 
persists at low levels in the CNS for the life of the mouse. We aimed to evaluate these pathogenic 
differences between rJHM.SD and rA59 by assessing: 1) the involvement of known viral 
receptors in CNS infection and spread and 2) the induction and modulation of antiviral CD8 T cell 
responses during acute and chronic CNS disease. Using primary CNS-derived cells and 
quantitative RT-PCR, we demonstrate differential expression of MHV receptor genes in CNS cell 
types and virus strain-specific differences in receptor requirements in neurons, the predominant 
cell type infected in vivo. Using adoptive transfer methods, we demonstrate that naïve virus-
specific CD8 T cells are poorly primed during CNS infection with rJHM.SD; however, a robust 
antiviral CD8 T cell response is elicited following peripheral inoculation of rJHM.SD, suggesting a 
passive mechanism specific to CNS infection. Finally, by comparing the quality of antiviral CD8 T 
cells during different scenarios of viral persistence, we show that rA59 persistence in the CNS 
modulates the differentiation of effector CD8 T cells into protective memory cells. Together, these 
results support the idea that extent of viral dissemination and induction/modulation of antiviral 
CD8 T cells collectively contribute to pathogenic outcome during MHV infection. 
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CHAPTER 1 
 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from the review article “Pathogenesis of murine coronavirus in the 
central nervous system” by S. J. Bender and S. R. Weiss. In press, Journal of Neuroimmune 
Pharmacology. 
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BACKGROUND AND SIGNIFICANCE 
 The family Coronaviridae is comprised of large, enveloped, RNA viruses that induce a 
variety of diseases in avian and mammalian species, including humans, poultry, livestock, and 
domestic animals. Coronaviruses, along with toroviruses and roniviruses, are members of the 
order Nidovirales (“nido” meaning “nest”), so named because of the nested set of subgenomic 
RNAs generated during the life cycle of these viruses (28). Coronaviruses are typically 
categorized into three groups based on antigenic similarity, with viruses in all groups being able 
to infect a range of different host species. Several human coronaviruses have been identified, 
including the mild respiratory pathogens HCoV-229E (31) and HCoV-OC43 (66), an etiologic 
agent of croup known as HCoV-NL63 (9, 102), and most notably SARS-CoV, the causative agent 
of severe acute respiratory syndrome (SARS) (16, 43, 75, 79). While coronaviruses are 
commonly regarded as being highly species-specific, the recent emergence of SARS-CoV in 
humans has brought renewed awareness to the potential for cross-species virus transmission 
from animal reservoirs.  
 Perhaps the best-studied member of the Coronaviridae is the murine coronavirus known 
as mouse hepatitis virus (MHV). Despite its name, not all strains of MHV are hepatotropic, with 
individual isolates inducing respiratory, enteric, or neurologic disease alone or in combination with 
hepatitis (108). While enteric strains are typically responsible for MHV outbreaks in housed rodent 
colonies (33), the most frequently studied are the neurotropic strains due to their ability to induce 
acute encephalomyelitis with or without chronic demyelination. These neurotropic strains differ 
widely in terms of cellular tropism, spread throughout the central nervous system (CNS), host 
immune response, and disease outcome, making them useful for analysis of viral and host 
determinants of neurovirulence (108). 
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MURINE CORONAVIRUS STRUCTURE AND LIFECYCLE 
 The RNA genome of MHV is single-stranded, positive-sense, and approximately 31 kb in 
length (Fig. 1-1) (46, 50). The 5’ two thirds of the genome (ORF1a and ORF1b) encode the viral 
replicase as well as an assortment of enzymes and other nonstructural proteins, while the 3’ one 
third of the genome (ORFs 2-7) largely encodes the structural proteins of the virion. These 
structural proteins include the spike (S), small envelope (E), membrane (M), nucleocapsid (N), 
and, in some strains, hemagglutinin-esterase (HE) (Fig. 1-1). 
 
 
 
Figure 1-1. Genome organization and virion structure of MHV. A) Schematic of MHV 
genome. B) Schematic of MHV virion. L, leader; ORF1a/1b, replicase; structural genes/proteins: 
HE, hemagglutinin-esterase; S, spike; E, envelope; M, membrane; N, nucleocapsid; I, internal. 
ORFs 2a, 4, and 5a encode nonstructural proteins. 
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 Spike (S). The MHV spike plays an integral role in the viral lifecycle as it binds to the 
cellular receptor CEACAM1a and mediates membrane fusion and subsequent entry into a target 
cell. The spike is a type I membrane protein that is synthesized as a 180 kDa precursor protein, 
co-translationally glycosylated, and processed by a furin-like enzyme into two approximately 90 
kDa non-covalently-linked subunits, the amino-terminal S1 and the carboxyl-terminal S2 (Fig. 1-2) 
(21, 54). The spike glycoprotein is expressed on the virion membrane as a trimer in which the S1 
subunits form a globular head structure and the S2 subunits form a transmembrane stalk (Fig. 1-
1). Spike trimers project from the virion surface, forming the characteristic “corona” or halo-like 
appearance for which coronaviruses are named.  Considerable evidence has accumulated over 
the years showing that the MHV spike is the major determinant of viral tropism and pathogenicity. 
There are at least three domains within the spike that have been shown to influence pathogenic 
outcome: 1) the receptor binding domain (RBD) contained within the N-terminal 330 amino acids, 
2) the hypervariable region (HVR) within S1, and 3) the heptad repeat domains (HR1 and HR2) 
within S2 (Fig. 1-2). The role of spike in MHV pathogenesis will be detailed below. 
 
 
 
Figure 1-2. Structure of the JHM.SD spike glycoprotein. RBD, receptor binding domain; HVR, 
hypervariable region; HR, heptad repeat domain; TM, transmembrane domain; S510 and S598, 
H-2
b
-restricted T cell epitopes. Large arrowhead indicates cleavage site yielding S1 and S2 
subunits. Mutations/deletions found in selected neurotropic MHV strains are indicated below the 
structure.!
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 Small envelope (E) and membrane (M). In addition to spike, all coronaviruses encode 
two additional transmembrane proteins, E and M (Fig. 1-1). The coronavirus E protein is an 
integral membrane protein (119) that plays an important role in viral assembly (103). Surprisingly, 
E is not an essential protein; however, a recombinant MHV lacking E expression replicates very 
inefficiently, consistent with the important role of E in production of infectious virus (45). The M 
protein is the most abundant viral membrane protein and spans the membrane multiple times (1). 
M has been shown to interact with the N protein during viral assembly (70). Both E and M are 
targeted to membranes of the Golgi, where they likely participate in viral assembly and budding. 
 Nucleocapsid (N). The MHV N protein plays important structural roles by both 
complexing with genomic RNA to form the capsid (96) and interacting with the viral membrane 
protein (M) during virion assembly (Fig. 1-1) (35). N increases efficiency of transcription (11), 
significantly enhances recovery of infectious virus from cells transfected with genome-length 
synthetic RNA (30), and has been implicated to play a role in translation of viral mRNA (99).  
Furthermore, MHV N has been reported to associate with microtubules in a neuronal cell line in 
vitro (77), suggesting a possible role for N in virus trafficking and axonal transport. Recent 
evidence from our laboratory further demonstrates that the N protein is a determinant of MHV 
neurovirulence (13), though the mechanism remains unclear. Also encoded within the N gene is 
the internal (I) protein, a structural protein of unknown significance (20). 
 Hemagglutinin-esterase (HE). The nonessential HE glycoprotein forms a second, 
smaller spike on the envelope of some coronaviruses, including some MHV strains (Fig. 1-1) (40, 
92, 117, 118). The HE protein has sialic acid-binding and acetyl esterase (or receptor destroying) 
activities, both of which could potentially contribute to viral entry and/or release from the cell 
surface via interaction with sialic acid-containing moieties. While the viral HE glycoprotein is not 
essential for virulence in the CNS, isogenic viruses expressing full-length HE polypeptides or HE 
proteins with nonfunctional esterase activity are more virulent when inoculated intracranially into 
mice and spread more extensively than viruses expressing a truncated HE polypeptide (39). 
 Virus lifecycle. MHV binds to a target cell via interaction of the spike glycoprotein with its 
cellular receptor CEACAM1a (112). Receptor binding triggers a conformational change in the 
! 6 
spike that is believed to expose a fusion peptide that inserts into the host cell membrane and 
mediates fusion (4). MHV virions fuse either at the cell surface or from within endosomes, likely 
depending on target cell type and MHV strain (24, 41, 71). Genome replication and viral protein 
synthesis occur in the cytoplasm, and N proteins complex with copies of the viral genome; these 
capsids acquire their lipid envelopes and surface proteins by budding through internal 
membranes of the ER/Golgi, and the newly formed virions are released at the cell surface (15).  
 
MURINE CORONAVIRUS PATHOGENESIS 
 Two MHV strains commonly used to study coronavirus-induced CNS disease are the 
highly neurovirulent JHM strain and the more neuroattenuated but demyelinating A59 strain 
(Table 1-1). Neuroattenuated variants of JHM are also common. While highly neurovirulent 
strains, such as JHM.SD, cause severe and uniformly lethal encephalitis in naïve mice, more 
neuroattenuated strains, such as A59 and some JHM variants, induce a less severe 
encephalomyelitis followed by chronic demyelination (Fig. 1-3) (108). For this reason, MHV 
infection is commonly studied as a model for the human demyelinating disease multiple sclerosis. 
The JHM strain, named for Professor John Howard Mueller, was initially isolated by Cheever, 
Bailey, and colleagues in 1949 from the brain of a paralyzed mouse and shown to induce 
encephalitis with extensive destruction of myelin (2, 6). Dr. Leslie Weiner later serially passaged 
this virus multiple times through mouse brains (106, 107). Most JHM isolates used since, 
including those described below, were derived from this mouse-passaged virus. The A59 strain 
was isolated independently in 1961 from a mouse with leukemia (56).  
 CNS disease induced by neurotropic MHV strains can be loosely divided into two phases, 
acute encephalitis and chronic demyelinating disease (Fig. 1-3). Following intracranial or 
intranasal inoculation, mice develop a mild to severe encephalomyelitis, characterized by 
infiltration of a variety of inflammatory cells. Viral titers typically peak at day 5 post-infection and 
then begin to decline (52), with infectious virus becoming undetectable by approximately 2 weeks 
post-infection (63). Innate immune responses are apparent within the first few days of infection 
and then give way to adaptive immunity. CD8 T cells, which play a dominant role in controlling 
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virus replication, are most numerous in the brain at day 7 post-infection, coinciding with viral 
clearance (115). However, despite clearance of infectious virus, viral RNA persists long-term in 
the CNS and demyelination, largely immune-mediated, develops and peaks around 4 weeks 
post-infection (48, 49). A notable exception to this disease course is CNS infection with the highly 
neurovirulent JHM isolates, particularly JHM.SD, which grow to increasing titers and induce 
severe encephalitis that is lethal within the first week of infection (Fig. 1-3) (74). The degree of 
viral spread throughout the brain and spinal cord, tropism of virus for individual CNS cell types, 
and dissemination of virus to other organs is largely dependent on viral strain (Table 1-1). 
 
 
 
Figure 1-3. Kinetics of MHV-induced CNS disease. Kinetics of CNS disease after intracranial 
inoculation of A) demyelinating MHV strains like A59 or B) the highly neurovirulent JHM.SD 
strain. JHM.SD-infected mice succumb to acute CNS disease by 1 week post-infection. 
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RECEPTOR AND TROPISM 
 The primary cellular receptor for MHV has been identified as CEACAM1a (also referred 
to as mmCGM1, BGP1a, and CD66a) belonging to the carcinoembryonic antigen family of cell 
adhesion molecules within the immunoglobulin (Ig) superfamily (112, 113). CEACAM1a is a 
multifunctional protein shown to play diverse roles in a variety of cellular processes, including 
intercellular adhesion, tumor suppression, angiogenesis, and immune cell signaling (29, 44). The 
ceacam1 gene is highly conserved among mammalian species, and human CEACAM1 proteins 
serve as receptors for a variety of pathogens, including Neisseria species and Haemophilus 
influenzae. In the mouse, ceacam1 exists in two allelic forms, ceacam1a and ceacam1b, and the 
particular ceacam1 allele expressed largely determines susceptibility of individual mouse strains 
to MHV; mouse strains expressing ceacam1a, including C57BL/6 and BALB/c, are highly 
susceptible to MHV infection whereas strains homozygous for ceacam1b, such as SJL, are 
relatively resistant (17). 
 Ceacam1a transcripts typically undergo alternative splicing, giving rise to four distinct 
splice variants and protein isoforms in the mouse (Fig. 1-4). These murine CEACAM1a isoforms 
contain either 2 or 4 extracellular Ig-like domains linked by a transmembrane domain to either a 
short (10 amino acids) or long (73 amino acids) cytoplasmic tail (64, 65). Using recombinant 
CEACAM1a constructs with deletions within the extracellular domains, the site of MHV binding 
was shown to be within the N-terminal Ig-like domain, D1 (18). This N-terminal domain is present 
in all four murine CEACAM1a isoforms, thus all serve as functional MHV receptors. Interestingly, 
long-tailed CEACAM1a isoforms contain phosphorylatable tyrosine residues within 
immunoreceptor tyrosine-based inhibitory motifs (ITIM) that have been shown to participate in 
protein-protein interactions and downstream signaling cascades in a variety of cell types, 
including T cells (8) and dendritic cells (38). 
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Figure 1-4. Structural isoforms of the MHV receptor CEACAM1a. D, extracellular 
immunoglobulin-like domain; TM, transmembrane domain; L, long cytoplasmic tail; S, short 
cytoplasmic tail. 
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 While CEACAM1a is commonly regarded as the sole in vivo receptor for MHV, several 
lines of evidence suggest the presence of an alternative receptor or mechanism of viral infection. 
Despite the high predilection of some MHV strains for cells of the CNS, expression of 
CEACAM1a is relatively low in neural tissue compared to other MHV targets, such as liver and 
intestine (27). CEACAM1a is highly expressed on epithelial cells, endothelial cells, and cells of 
hematopoietic origin, including macrophages, B cells, and activated T cells (12, 27, 69). However, 
in the brain, only endothelial cells and microglia have been shown to express CEACAM1a protein 
(26, 84). Yet, perhaps paradoxically, many neurotropic MHV strains are able to infect a wide 
range of CNS cell types in addition to endothelial cells and microglia, including neurons, 
astrocytes, and oligodendrocytes. It has been suggested for the highly neurovirulent JHM cl-2 
strain that CEACAM1a-positive microglia serve as the initial target of infection and that virus 
subsequently spreads to other CNS cell types in a CEACAM1a-independent manner; a soluble 
receptor-resistant mutant of cl-2 known as srr7 (61) cannot spread without CEACAM1a and is 
thus restricted to microglia in mixed neural cultures (68). Curiously, strain A59, which has also 
been shown to depend on CEACAM1a for spread (101), infects a variety of CNS cell types in vivo 
in addition to microglia. These seemingly disparate results raise the question as to whether CNS 
cell types other than microglia express low levels of CEACAM1a that are simply not detected by 
routine methods or whether some neurotropic MHV strains may use an alternative mechanism to 
enter these cell types. 
 The generation of a knockout mouse deficient in ceacam1a (ceacam1a
-/-
) by targeted 
deletion of the exon encoding the N-terminal domain has made it possible to evaluate MHV 
infection in the absence of CEACAM1a (32). Interestingly, two neurotropic MHV strains, A59 and 
JHM.SD, differ in their ability to cause CNS disease in ceacam1a
-/-
 mice following intracranial 
inoculation. JHM.SD, a highly neurovirulent isolate previously shown to spread cell-to-cell in vitro 
in a CEACAM1a-independent manner, is able to cause lethal CNS disease in ceacam1a
-/-
 mice, 
albeit at considerably higher doses than are required in wild-type C57BL/6 mice, whereas doses 
as high as 1 million PFU of A59 do not cause CNS disease; the ability of JHM.SD to cause 
disease in these mice was mapped to the spike gene (32, 67). While this finding is intriguing, it is 
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unclear whether the inability of A59 to cause disease in ceacam1a
-/-
 mice is due to a lack of initial 
virus entry or a deficiency in cell-to-cell spread in the CNS in the absence of CEACAM1a. 
 Several alternative receptors have been identified and shown to mediate MHV infection in 
non-murine cells when overexpressed in vitro. An additional ceacam gene, ceacam2 (bgp2), is 
uniquely expressed in the mouse and can facilitate infection with A59, JHM, and the hepatotropic 
MHV-3 strain when transiently transfected into hamster cells, though much less efficiently than 
ceacam1a; ceacam2 mRNA was shown to be expressed in brain tissue (73). The alternative 
ceacam1b allele expressed by MHV-resistant mice can similarly mediate infection with A59 when 
overexpressed in vitro (17). While the relative efficiencies of these alternative receptors is 
unclear, the decreased infection efficiency compared to CEACAM1a is likely attributable to 
sequence differences within the MHV binding site in the N-terminal domain. Yet another putative 
receptor, psg16 (bCEA), belonging to the more distantly related pregnancy-specific glycoprotein 
family, was identified in the brain due to its weak homology with ceacam1a; curiously, psg16 is 
reported to function in vitro as a receptor for A59 but not JHM (7). It is unclear what CNS cell 
types express these alternative receptors and thus whether they are positioned to mediate the 
MHV infection observed in ceacam1a
-/-
 mice. It is possible that an alternative receptor used by 
MHV in the brain may be completely unrelated to CEACAM1a, making its identification more 
difficult. Furthermore, the possibility that a traditional receptor molecule is not required to trigger 
MHV fusion cannot be excluded as some MHV strains, like JHM.SD, are inherently more 
fusogenic or may have acquired unique mechanisms to spread to cells expressing low or no 
CEACAM1a. 
 
ROLE OF SPIKE IN VIRAL TROPISM AND SPREAD 
 It is not surprising that the spike, which interacts with the receptor CEACAM1a to mediate 
entry as well as cell-to-cell fusion, is crucial in determining the extent of viral spread within the 
CNS. Characterization of isogenic recombinant MHVs differing only in spike has definitively 
demonstrated the important role of spike in determining neurovirulence during infection in the 
mouse (36, 72, 82, 83). The replacement of the A59 spike gene with the spike of JHM.SD 
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(rA59/SJHM.SD) confers high neurovirulence on the resulting virus (72, 82). These studies have 
also demonstrated, perhaps unexpectedly, that a chimeric recombinant virus expressing the spike 
of the hepatotropic A59 within the background of the non-hepatotropic JHM.SD (rJHM.SD/SA59) 
cannot induce hepatitis (72). Thus, spike alone is unable to dictate organ tropism. 
 Mutations within the RBD have an influence on tropism and virulence. While two closely 
related JHM viruses, JHM.SD and JHM.IA, are both highly neurovirulent, the enhanced 
neurovirulence of JHM.SD can be mapped to a single amino acid difference within the RBD at 
residue 310 (Gly rather than Ser), as the introduction of a S310G substitution within the JHM.IA 
spike confers increased virulence on a recombinant JHM.IA. Furthermore, this Gly substitution at 
position 310 is associated with the ability to spread cell-to-cell in a CEACAM1a-independent 
manner (74). Characterization of viruses in which the RBDs of A59 and JHM.SD were exchanged 
further demonstrates that the ability to carry out CEACAM1a-independent spread requires both 
the RBD and the rest of the spike to be derived from JHM (101). Interestingly, a single amino acid 
substitution, Q159L, within the RBD eliminates the ability of A59 to infect the liver while having no 
measurable effect on neurovirulence (51, 52). 
 Among the many JHM isolates, high neurovirulence is correlated with the presence of a 
long hypervariable region (HVR) within S1 (Fig. 1-2). There are several JHM isolates with a 
similar long spike (Table 1-1), including MHV.SD (14, 74); JHM cl-2 (98), and JHM-DL (104). The 
extremely high neurovirulence of these viruses is believed to be due, at least in part, to their 
ability to induce cell-to-cell fusion and viral spread in the absence of the receptor CEACAM1a (14, 
22, 23). This lack of requirement for CEACAM1a is associated with a less stable association of 
S1 and S2 such that the conformational changes that lead to fusion are more easily triggered, 
even in the absence of CEACAM1a (22, 42). The important role of the HVR in neurovirulence is 
further supported by the observation that the neuroattenuated phenotypes of a group of 
monoclonal antibody escape variants of JHM.SD, including V5A13.1 (19), are associated with 
single site mutations and/or deletions within the HVR (14, 25, 81). Consistent with the comparison 
of different JHM spikes, the genome of the neuroattenuated A59 strain encodes a large deletion 
(52 amino acids) within the HVR. However, replacement of the HVR of A59 with that of JHM.SD 
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does not confer a highly neurovirulent phenotype to the virus (81), suggesting that cooperation of 
several regions of spike, including the long HVR, is likely required for the high neurovirulence 
conferred by the JHM.SD spike. 
 Single amino acid substitutions in the heptad repeat (HR) domains within S2 have been 
shown to have dramatic effects on pathogenesis as well (Fig. 1-2). This region of the spike 
undergoes conformational changes during the fusion process, and therefore it is not surprising 
that it plays a role in pathogenic phenotype. Amino acid substitutions at position 1114 within the 
heptad repeat 1 (HR1) of the JHM spike (L1114R/F) are particularly intriguing in that they have 
been reported in multiple studies and in association with several mutant phenotypes (Table 1-1). 
The spike protein of the OBLV60 mutant of JHM.SD, which is restricted in replication to the 
murine olfactory bulbs, contains three amino acid substitutions within HR1 that have been 
associated with the requirement for low pH to induce fusion. One of these substitutions alone, 
L1114R, is sufficient to confer neuroattenuation and restriction to the olfactory bulbs (24, 78, 
100). A L1114F substitution has also been identified in the spike of the 2.2-V-1 glial-tropic variant 
of JHM-DL (104) and in the spike of the highly attenuated soluble receptor-resistant mutant srr7 
derived from JHM cl-2 (88, 89). These substitutions are associated with an inability to induce 
CEACAM1a-independent cell-to-cell fusion as well as neuroattenuation (59, 60, 97). Interestingly, 
viruses expressing the JHM spike with a L1114F substitution have lost their tropism for neurons 
while the OBLV60 mutant, expressing a spike carrying the L1114R substitution, can readily infect 
neurons of the olfactory bulb in vivo. Thus, small changes within the HR domains, even different 
substitutions of the same residue, may result in alterations in spike/receptor interaction and 
subsequent virus entry and pathogenesis in vivo. 
 
IMMUNE REPSONSES TO MHV 
 Type I interferon. Type I interferon (IFN-!/") signaling is an important aspect of host 
defense during the early phases of MHV infection. This role is supported by several reports of the 
high mortality following MHV infection that were carried out in the absence of IFN signaling in 
type I interferon receptor deficient (IFNAR
-/-
) mice (5, 37, 87). IFNAR
-/-
 mice inoculated 
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intracranially with low doses of the neurotropic MHV strains A59 and JHM.SD show dramatically 
accelerated clinical signs and mortality compared with wild-type C57BL/6 mice. Furthermore, 
increased levels of infectious virus are detected in the brain and spinal cord (and in the case of 
A59, the liver) of infected IFNAR
-/-
 mice, as well as spread to other organs not usually affected, 
compared to wild-type mice (87).  
 Inflammatory cell infiltrate. A robust innate immune response involving chemokine 
secretion and migration of inflammatory cells into the CNS develops during the first few days 
following MHV inoculation. CNS infection with the highly neurovirulent JHM.SD strain, which is 
characterized by rapid spread of viral antigen throughout the brain, is accompanied by greater 
levels of infiltrating neutrophils and macrophages, as well as increased cellular destruction, 
compared to infection with the weakly neurovirulent A59 strain (36, 85, 86). Not surprisingly, the 
increased numbers of macrophages and neutrophils within the brains of JHM.SD-infected 
animals correlate with higher levels of macrophage- and neutrophil-recruiting chemokines, as well 
as prolonged expression of IFN-", whereas A59 infection is characterized predominantly by T cell 
infiltration into the brain consistent with higher levels of T cell-attracting chemokines (36, 85, 86, 
90). The MHV spike gene has been demonstrated to be a determinant of neurovirulence and to 
influence macrophage, but not T cell, infiltration into the brain (36, 82, 83, 86).  
 T cells in acute disease. Numerous studies of MHV infection in immunocompromised 
SCID, RAG-deficient, or sublethally irradiated wild-type mice have demonstrated that the host 
adaptive immune response plays a pivotal role in viral clearance (34, 62, 105, 116). Subsequent 
studies in mice lacking individual lymphocyte populations, either due to antibody depletion or 
genetic manipulation, combined with reconstitution experiments in mice lacking these 
lymphocytes more clearly delineated the roles of CD4 and CD8 T cells in viral control. While both 
CD4 and CD8 T cells are required for effective control of MHV infection in the CNS (114), CD8 T 
cells are most directly responsible for clearance of infectious virus. Following intracranial 
inoculation of a sublethal dose of neurotropic MHV, viral titers peak in the brain at day 5 post-
infection and then begin to decline, coincident with the accumulation of virus-specific CD8 T cells 
at the site of infection (115). The importance of CD8 T cells in control of MHV is further supported 
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by the increased susceptibility and delayed viral clearance observed in "2-microglobulin-deficient 
mice compared to wild-type control mice (47). Using a model in which C57BL/6 mice were 
infected with a recombinant A59 virus expressing the GP33 epitope of lymphocytic 
choriomeningitis virus (LCMV), it was shown that adoptive transfer of naïve, GP33-specific CD8 T 
cells results in lower viral titers and reduced antigen distribution in the brain (10). Further studies 
using this adoptive transfer system revealed that increasing the number of naïve, virus-specific 
CD8 T cells, either before infection or at early times post-infection, reduces viral replication and 
spread throughout the brain and spinal cord as well as demyelination compared to control mice; 
thus, enhancing the host CD8 T cell response is protective against A59-induced CNS disease 
(55). 
 To determine the kinetics of CD8 T cell activation and expansion, BALB/c mice were 
infected with the glial-tropic JHM variant 2.2-V-1 and virus-specific CD8 T cells were quantified at 
various times post-infection in the CNS and peripheral lymphoid organs. After intracranial 
inoculation, virus-specific CD8 T cells are first detected in the draining cervical lymph nodes 
(CLN) by day 3 post-infection, followed by further expansion in the spleen and ultimate 
accumulation in the brain, peaking at day 7 post-infection (58). These results indicate that the 
draining CLN are the initial site of CD8 T cell priming during neurotropic MHV infection. 
Interestingly, intracranial inoculation of the highly neurovirulent JHM.SD isolate has been shown 
to induce a weak antiviral CD8 T cell response in the brain compared to other neurotropic strains 
(36, 85); infectious virus is not cleared and mice typically succumb to CNS disease by day 7 post-
infection. Interestingly, studies of recombinant viruses in which the spike genes of A59 and 
JHM.SD were exchanged reveal that this differential T cell induction is not due to spike, as 
replacement of the A59 spike with that of JHM.SD (rA59/SJHM.SD) results in a virus that spreads 
extensively in the CNS like JHM.SD but induces a robust CD8 T cell response similar to A59. 
Furthermore, though rA59/SJHM.SD has an intracranial LD50 similar to JHM.SD, mice infected with 
rA59/SJHM.SD survive several days longer than those infected with JHM.SD, perhaps due, at least 
in part, to the effects of antiviral CD8 T cells (36, 82).  
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 Activated CD8 T cells possess numerous effector mechanisms that serve to clear 
pathogens from infected cells, and the particular mechanisms required for clearance of MHV 
appear to be specific to the infected cell type. In studies using perforin-deficient mice, clearance 
of two JHM variants, the moderately virulent JHM-DM isolate (93) and the neuroattenuated 2.2-V-
1 isolate, was delayed compared to wild-type control mice, suggesting that perforin-mediated 
cytolysis contributes to, but is not required for, clearance of MHV from the CNS; furthermore, 
JHM-infected perforin-deficient mice still developed encephalomyelitis and demyelination, 
indicating that these processes are independent of perforin activity (53). Interestingly, while CD8 
T cell-mediated cytolysis appears to be important for clearance of MHV from astrocytes and 
microglia (94), viral clearance from oligodendrocytes instead relies on IFN-# secretion, as 
indicated by persistence of the JHM variant 2.2-V-1 in oligodendrocytes of IFN-#-deficient mice 
(76). Though several neurotropic MHV strains infect large numbers of neurons in addition to glial 
cells, mechanisms of MHV control in this unique cell type are poorly understood. 
 While CD8 T cells play a direct role in viral clearance, CD4 T cells are also required for 
efficient control. In studies using the JHM-DM variant, transfer of activated virus-specific CD8 T 
cells into infected wild-type mice resulted in viral clearance, whereas cells transferred into CD4-
depleted mice are unable to effectively clear virus from the CNS (93). Furthermore, CD4 T cells 
are required for production of MHV-specific antibodies during infection with the JHM-DS variant 
(114). Recent studies in which IFN-#- and perforin-deficient mice were reconstituted with memory 
CD4 T cells competent in just one of these functions and challenged with the JHM variant 2.2-V-1 
suggest an additional, more direct role for CD4 T cells in viral clearance; while viral replication is 
initially controlled by both IFN-#- and perforin-deficient CD4 T cell populations, only those cells 
competent to express IFN-# are able to maintain prolonged control (95).  
 T cells in chronic disease. After clearance of an acute viral infection, most antiviral 
effector CD8 T cells are eliminated via apoptosis while a small subset continue to differentiate 
into a long-lived pool of resting memory cells; upon re-exposure to antigen, these memory CD8 T 
cells rapidly expand and reactive antiviral effector functions to protect the host against reinfection 
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(109). Using the lymphocytic choriomeningitis virus (LCMV) model of chronic infection, this 
pattern of differentiation from effector to memory CD8 T cell was shown to be significantly altered 
in the presence of ongoing viral replication; CD8 T cells present during chronic LCMV infection 
show a hierarchical loss of antiviral effector functions (functional exhaustion) and rely on 
continued viral antigen stimulation for maintenance in the host (91, 110, 111). Unlike chronic 
LCMV infection, MHV persists at lower levels and thus provides and interesting comparison to 
examine the effects of viral persistence on CD8 T cell function. 
 After clearance of infectious MHV, CD8 T cells in the CNS decrease in number but are 
not eliminated. Demyelination, largely immune-mediated, peaks at approximately four weeks 
post-infection and is accompanied by low levels of viral RNA that may persist in the CNS for the 
life of the mouse. A study comparing two glial-tropic JHM variants, one that persists and one that 
is cleared, showed that maintenance of CD4 and CD8 T cells within the infected CNS correlates 
with the continued presence of viral RNA, suggesting that viral persistence (as evidenced by 
detection of viral RNA) provides a signal that is necessary to maintain these lymphocyte 
populations within the CNS (57). Further studies using the glial-tropic JHM variant 2.2-V-1 
revealed that CD8 T cells maintained in the CNS after viral clearance display a loss of ex vivo 
cytolytic activity while maintaining the ability to secrete IFN-# (3). More recent studies indicate that 
CD8 T cells maintain expression of the inhibitory receptor programmed death 1 (PD-1) during 
persistence of the JHM variant 2.2-V-1 in the CNS, while expression of the PD-1 ligand B7-H1 is 
concurrently maintained on oligodendrocytes; the authors suggest that this PD-1/B7-H1 
interaction contributes to CD8 T cell dysfunction during persistence (80). Studies by Zhao et al. 
further reveal, using adoptive transfer techniques and bone marrow chimeras, that antiviral CD8 T 
cell populations are maintained during persistence in the CNS, at least in part, by recruitment of 
both antigen-experienced and naïve CD8 T cells from the periphery (120). While MHV 
persistence in the CNS appears to compromise CD8 T cell function during chronic disease, the 
relative effect of low level RNA persistence compared to high levels of persisting infectious virus 
on CD8 T cell function is unclear.  
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SUMMARY AND FOCUS 
 High neurovirulence of MHV is routinely associated with increased viral dissemination 
throughout the CNS, yet it is unclear how neurotropic strains of MHV infect and spread in CNS 
cell types reportedly expressing low to nonexistent levels of the receptor CEACAM1a. 
Furthermore, while virus-specific CD8 T cells are crucial for controlling MHV in the infected host, 
it is unknown how the JHM.SD strain of MHV avoids the induction of an antiviral CD8 T cell 
response during acute disease or how persistence of MHV impacts CD8 T cell differentiation 
during chronic disease. The following chapters discuss studies that were undertaken to elucidate 
mechanisms of viral infection/spread as well as the interaction of MHV with the host immune 
system to improve our understanding of how these determinants contribute to neurovirulence.   
 
VIRUS NOMENCLATURE 
 The nomenclature of recombinant viruses in our laboratory has evolved over the years, 
thus different names for the same recombinant virus are used in different chapters. RJHM and 
rJHM.SD refer to a recombinant version of the highly neurovirulent strain MHV-4. RA59 and rA59 
refer to a recombinant version of the less neurovirulent but demyelinating strain A59. SJHM/RA59 
and rA59/SJHM.SD refer to a chimeric recombinant A59 virus expressing the spike gene of JHM.SD. 
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CHAPTER 2 
 
Murine coronavirus receptors are differentially expressed in the central nervous system and play 
virus strain-dependent roles in neuronal spread 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been submitted to The Journal of Virology as the article “Murine coronavirus 
receptors are differentially expressed in the central nervous system and play virus strain-
dependent roles in neuronal spread” by S. J. Bender, J. M. Phillips, E. P. Scott, and S. R. Weiss. 
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ABSTRACT      
Coronavirus infection of the murine CNS provides a model to study viral encephalitis and 
demyelinating disease. While MHV-A59 causes mild encephalomyelitis and demyelination, the 
highly neurovirulent JHM.SD (MHV-4) causes fatal encephalitis with extensive neuronal spread of 
virus. The carcinoembryonic antigen family member CEACAM1a is the primary receptor for MHV, 
yet CEACAM1a expression is very low in the CNS and has been demonstrated on endothelial 
cells and microglia only despite infection of additional cell types in vivo. Therefore, ceacam1a 
mRNA expression was quantified in murine tissues and primary cells. Among CNS cell types, 
ceacam1a was most highly expressed in microglia, with decreasing levels in oligodendrocytes, 
astrocytes, and neurons.  Given low neuronal expression of ceacam1a, primary neurons from 
wild-type and ceacam1a-deficient mice were inoculated with MHV to determine the extent to 
which ceacam1a-independent infection might contribute to CNS infection. While both A59 and 
JHM.SD infected small numbers of ceacam1a-deficient neurons, only JHM.SD spread efficiently 
to adjacent cells in the absence of ceacam1a. Quantification of mRNA for ceacam1a-related 
genes ceacam2 and psg16 (bCEA), which encode proteins shown to serve inefficiently as MHV 
receptors when overexpressed in vitro, revealed low ceacam2 expression in microglia and 
oligodendrocytes and psg16 expression exclusively in neurons. Importantly, CEACAM2 mediated 
infection when expressed in human 293T cells while PSG16 receptor activity was not detectable. 
Thus, CEACAM2 on endothelial cells, microglia, and/or oligodendrocytes may facilitate initial 
infection in the absence of ceacam1a but is unlikely responsible for CEACAM1a-independent 
neuronal spread of JHM.SD. 
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INTRODUCTION 
 Murine coronavirus (mouse hepatitis virus, MHV) is a member of the Coronaviridae family 
of large, enveloped, RNA viruses. Central nervous system (CNS) infection with neurotropic 
strains of MHV provides a model for studying acute virus-induced neurological disease with or 
without chronic demyelination. These neurotropic strains differ widely in terms of tropism, spread, 
host response, and disease outcome, making them useful for identifying viral and host 
determinants of neurovirulence (58). Two strains commonly used to study coronavirus-induced 
CNS disease are the highly neurovirulent JHM.SD (formerly called MHV-4) strain and the more 
neuroattenuated and hepatotropic A59 strain (3, 28). Following intracranial (i.c.) or intranasal (i.n.) 
inoculation, JHM.SD causes severe and uniformly lethal encephalitis, whereas A59 induces a 
less severe encephalomyelitis followed by chronic demyelination (58). The extreme 
neurovirulence of JHM.SD largely maps to the spike glycoprotein, as a recombinant A59 virus 
expressing the JHM.SD spike (rA59/SJHM.SD) shows increased virulence and viral dissemination 
throughout the brain compared to parental A59 (43, 44). Viral genes other than spike also 
contribute to neurovirulence (7, 23) 
 MHV binds to a target cell via interaction of the viral spike glycoprotein with a cellular 
receptor. This binding leads to a conformational change in spike that allows the virion membrane 
to fuse with the host cell membrane. Subsequent viral spread can occur via release of new virions 
from the infected cell and/or syncytium formation mediated by viral spikes expressed on the cell 
surface. The receptor for MHV is the murine carcinoembryonic antigen family member 
CEACAM1a (also referred to as mmCGM1, BGP1a, CD66a) (60). In the mouse, the ceacam1 
gene exists in two allelic forms, ceacam1a and ceacam1b, and the ceacam1 alleles expressed 
largely determine mouse susceptibility to MHV. Mouse strains expressing ceacam1a (such as 
C57BL/6, BALB/c and C3H) are highly susceptible while strains homozygous for ceacam1b (such 
as SJL) are resistant to infection (9). Ceacam1a transcripts are alternatively spliced, yielding four 
distinct variants in the mouse. These splice variants encode either two or four extracellular 
immunoglobulin-like (Ig-like) domains linked by a transmembrane domain to a short (10 amino 
acids) or long (73 amino acids) cytoplasmic tail (33, 34). The MHV binding site resides within the 
! 36 
N-terminal Ig-like domain, D1 (10). This domain is present in all four isoforms of CEACAM1a and 
thus all serve as functional receptors for MHV (9). 
 While CEACAM1a is commonly regarded as the sole in vivo receptor for MHV, several 
lines of evidence suggest the presence of an alternative receptor and/or mechanism of viral 
infection/spread. Curiously, despite the high predilection of neurotropic MHV strains for the CNS, 
CEACAM1a expression is relatively low in neural tissue compared to other MHV targets such as 
the liver and intestine (17). While CEACAM1a is highly expressed on epithelial cells, endothelial 
cells, and cells of hematopoietic origin (6, 17, 37), CNS expression of CEACAM1a has only been 
demonstrated on endothelial cells by immunohistochemistry (16) and on microglia by flow 
cytometry (46). Yet, both A59 and JHM.SD infect multiple CNS cell types, with neurons being the 
predominant cell type infected (11, 35, 44). This apparent paradox raises the question of whether 
resident CNS cell types such as neurons, astrocytes, and oligodendrocytes express low levels of 
CEACAM1a that are simply not detected by routine methods or whether some MHV strains use 
an alternative mechanism to enter these cell types. 
 Additionally, in vitro studies reveal that the highly neurovirulent JHM.SD strain can spread 
efficiently from CEACAM1a-positive cells to cells lacking murine CEACAM1a (15, 38, 41, 54). 
Similar in vitro studies using primary mixed neural cultures demonstrated that the closely related 
JHM cl-2 variant spreads to adjacent neural cells in the presence of CEACAM1a-blocking 
antibodies (36). This “receptor-independent spread” phenomenon should more accurately be 
referred to as “CEACAM1a-independent spread” since the process may or may not require an 
alternative receptor. The generation of a knockout mouse deficient in ceacam1a (ceacam1a
-/-
) 
further facilitates analysis of CEACAM1a-independent spread both in vivo and in vitro. 
Interestingly, both JHM.SD and the chimeric rA59/SJHM.SD induce lethal CNS disease in 
ceacam1a
-/-
 mice, albeit at higher doses compared to wild-type mice, while doses of A59 as high 
as 1 million PFU i.c. are insufficient to cause disease (21, 35). While this finding is intriguing, it is 
unclear whether A59 fails to cause disease in ceacam1a
-/-
 mice due to a lack of virus entry, 
deficiency in cell-to-cell spread in the absence of CEACAM1a, or inability to achieve a high 
enough viral dose to initiate infection. 
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 Notably, two ceacam1a-related genes expressed in the mouse brain encode proteins that 
serve inefficiently as MHV receptors when overexpressed in vitro. The more closely related 
ceacam2 (bgp2) gene is uniquely expressed in the mouse and facilitates infection with both A59 
and JHM when transiently transfected in hamster cells (40). Additionally, the more distantly 
related psg16 (bCEA) gene, belonging to the CEA-related pregnancy-specific glycoprotein family, 
is reported to function as a receptor for A59 but not JHM when transfected in monkey cells (4). It 
is unclear how these alternative receptors compare in terms of receptor functionality, and the 
cellular expression patterns of these receptor genes have not been explored. Therefore, in the 
current study we aimed to evaluate expression of ceacam1a and related genes in murine tissues 
and CNS cell types and to investigate the role of these receptor genes in neuronal infection and 
spread. 
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MATERIALS AND METHODS 
Mice. Virus-free C57BL/6 mice were purchased from the National Cancer Institute (Frederick, 
MD). Ceacam1a-deficient (ceacam1a
-/-
) mice on a C57BL/6 background were provided by Nicole 
Beauchemin (McGill University) (21). Mice were housed and bred at the University of 
Pennsylvania in accordance with Institutional Animal Care and Use Committee guidelines. 
Viruses and inoculations. Recombinant A59 (rA59) (previously referred to as RA59, SA59R13, 
wtR13), recombinant JHM.SD (rJHM.SD) (previously referred to as RJHM and derived from the 
MHV-4 isolate of JHM), and a chimeric recombinant expressing the JHM.SD spike in the A59 
background (rA59/SJHM.SD) (previously referred to as SJHM/RA59 or S4R22) have been described 
(39, 43, 44). Recombinant viruses of the same genotypes, only expressing enhanced green 
fluorescent protein (EGFP) in place of gene 4 (29, 49), were used to monitor infection in primary 
cells. Viruses were propagated in murine 17Cl1 fibroblasts and titrated by standard plaque assay 
on murine L2 fibroblasts. To remove cell fragments from the virus preparations, filtered virus 
stocks were prepared by passage through a 0.22 µm filter apparatus and retitrated after filtration. 
For intracranial (i.c.) inoculations, 4-week-old mice were anesthetized with isoflurane and 50 PFU 
of virus diluted in 30 µL PBS containing 0.75% BSA was injected into the left cerebral 
hemisphere. Mock infections were performed with lysate from 17Cl1 fibroblasts. 
Immunofluorescence. For identification of infected cell types, brains were perfused with PBS, 
fixed in 10% phosphate-buffered formalin, embedded in paraffin, and sagittally sectioned. 
Sections were deparaffinized and rehydrated, treated with Antigen Unmasking Solution (Vector 
Labs), blocked with 1.5% normal goat serum, and dual immunolabeled with a mouse monoclonal 
antibody (1.16.1) directed against the MHV nucleocapsid protein (a gift from Julian Leibowitz, 
Texas A&M University) and a rabbit polyclonal antibody directed against either glial fibrillary 
acidic protein (GFAP) for astrocytes (Dako USA), Iba1 for microglia (Wako Pure Chemical 
Industries), OLIG2 for oligodendrocytes (Millipore), or microtubule-associated protein 2 (MAP2) 
for neurons (a gift from Virginia Lee, University of Pennsylvania). Primary antibodies were 
detected with goat-anti-mouse and goat-anti-rabbit Alexa Fluors 488 and 594 (Invitrogen). 
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Cultured cells were fixed in PBS containing 4% paraformaldehyde (Electron Microscopy 
Sciences), blocked with 1.5% normal goat serum, and immunolabeled as above with the 
exception of microglia, which were labeled with rat monoclonal anti-CD11b (Abcam) and goat-
anti-rat Alexa Fluor 594 (Invitrogen). Fluorescence was visualized with a Nikon Eclipse TE2000-U 
microscope and images were acquired using SPOT Imaging Software (Diagnostic Instruments). 
Primary hepatocyte cultures. Primary hepatocytes were prepared from Avertin-anesthetized 8-
week-old mice by in situ perfusion and digestion with Liver Perfusion Medium and Liver Digestion 
Medium (Invitrogen), respectively, followed by mechanical disruption through nylon mesh and 
centrifugation through 45% Percoll. Hepatocytes were seeded onto BioCoat collagen I-coated 
plates (BD Biosciences) and cultured overnight in RPMI 1640 medium containing 10% FBS. 
Primary glial cultures. Mixed glial cells were prepared from the cortices of P1-3 neonates by 
mechanical disruption through nylon mesh and cultured in DMEM containing 10% FBS, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 ng/mL streptomycin for 5-14 days. Mixed glial cultures 
were enriched for either astrocytes or microglia based on differential adhesion to tissue culture 
plastic as previously described (1). Briefly, microglia were detached from the astrocyte monolayer 
by brief gentle shaking of the culture flasks. Cells in the supernatant were collected by 
centrifugation and seeded onto tissue culture plastic. After 30 min., medium was replaced to 
remove non-adherent cells from microglia cultures. Microglia cultures were routinely !98% pure 
as determined by positive immunostaining for CD11b and negative staining for MAP2, GFAP, and 
OLIG2. Astrocyte monolayers were shaken at 200 RPM for 45 min. to remove loosely adherent 
cells. Remaining cells were detached with trypsin/EDTA and the resulting suspension was placed 
in tissue cultures flasks at room temperature for 30 min. to allow adherence of microglia to the 
plastic. This step was repeated, and the remaining astrocyte suspension was seeded onto tissue 
culture plastic. Astrocyte cultures were routinely 90-95% pure as determined by positive 
immunostaining for GFAP and negative staining for MAP2, CD11b, and OLIG2. Oligodendrocytes 
were prepared from minced forebrains of P1-3 neonates by trypsin/DNase digestion and cultured 
in DMEM containing 10% FBS, 1X non-essential amino acids solution (Invitrogen), 2 mM L-
glutamine, 100 U/mL penicillin, and 100 ng/mL streptomycin as previously described (12). After 
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24 hours, culture medium was replaced with neurobasal medium containing B-27 supplement, 10 
ng/mL bovine FGF basic (R&D Systems), 2 ng/mL recombinant human PDGF (R&D Systems), 
and 1 ng/mL recombinant human NT-3 (PeproTech Inc.). After 7 days, oligodendrocytes were 
removed from underlying astrocytes by gentle rinsing and seeded onto poly-D-lysine-coated 
tissue culture plates. Oligodendrocyte cultures were routinely 90-95% pure as determined by 
positive immunostaining for OLIG2 and negative immunostaining for MAP2, CD11b, and GFAP. 
Primary neuronal cultures. Hippocampal neurons were prepared from E15-16 mouse embryos 
by trypsin digestion and mechanical disruption with a heat-polished Pasteur pipette, seeded onto 
poly-L-lysine-coated coverslips or tissue culture plates, and cultured in neurobasal medium 
containing B-27 supplement (Invitrogen), 100 U/mL penicillin, 100 ng/mL streptomycin, 2 mM L-
glutamine, and 4 µg/mL glutamate for 4 days in the absence of an astrocyte feeder layer as 
previously described (2, 42, 45). Cortical neurons prepared from E18 mouse embryos were 
provided by Marc Dichter (University of Pennsylvania) (8, 50). Neuron cultures of both types were 
routinely 95-98% pure as determined by positive immunostaining for MAP2 and negative 
immunostaining for CD11b, GFAP, and OLIG2. After 4 days in vitro, neuron cultures were 
inoculated with virus diluted in neurobasal medium for 1 hour at 37°C, washed, and cultured an 
additional 24-72 hours in neurobasal medium. To quantify extracellular virus, neuron 
supernatants were collected at various times post-infection and stored at -80°C until titration. 
Fresh neurobasal medium was added to the remaining cells and intracellular virus was released 
by repeated freeze/thaw cycles at -80°C. Infectious virus was titrated by plaque assay on L2 
fibroblast monolayers. 
Cell lines. Murine DBT astrocytoma cells, 17Cl1 fibroblasts, and L2 fibroblasts were cultured in 
DMEM supplemented with 10% FBS, 10 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin, 
100 ng/mL streptomycin, and 2.5 µg/mL amphotericin B. Human 293T cells were cultured in high 
glucose DMEM containing 10% FBS, 100 U/mL penicillin, and 100 ng/mL streptomycin.  
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Quantitative RT-PCR. RNA was isolated from liver, brain, and spinal cord tissue by 
homogenization in TRIzol Reagent (Invitrogen) followed by phenol/chloroform extraction and 
purification with an RNeasy Mini Kit (Qiagen) as previously described (47). RNA was isolated 
from cultured cells using an RNeasy Mini Kit according to manufacturer’s instructions. Tissue and 
cellular RNA was DNase-treated using a Turbo DNA-free Kit (Ambion) and quantitative PCR 
reactions without reverse transcriptase were performed to ensure adequate removal of genomic 
DNA. For cDNA synthesis, 350 ng RNA was combined with 0.5 mM dNTP mix (Invitrogen) and 50 
ng random hexamers (Invitrogen) in a total volume of 13 µL, heated to 65°C in a PCR 
thermocycler for 3 minutes, and cooled to room temperature. 1X First Strand Buffer (Invitrogen), 5 
mM DTT (Invitrogen), 200 U SuperScript III Reverse Transcriptase (Invitrogen), and nuclease-
free water were added for a final reaction volume of 20 µL and the mixture was heated to 50°C 
for 60 minutes followed by 70°C for 15 minutes. cDNA was stored at -20°C until use. Quantitative 
PCR was performed in duplicate using 2 µL cDNA, 12.5 µL iQ SYBR Green Supermix (Bio-Rad), 
and 0.4 µM forward and reverse primers (listed in Table 2-1) in a total volume of 25 µL in an iQ5 
iCycler (Bio-Rad). For copy number determination, cycle threshold (CT) values were compared to 
a plasmid standard curve run in parallel for each target. Copy numbers are expressed as target 
cDNA copies per million cDNA copies of mouse beta-actin (actb). For relative expression 
compared to mock-infected samples, CT values were normalized to actb levels resulting in a "CT 
value ("CT = CT target – CT actb). ""CT values were then calculated (""CT = "CT infected – "CT mock) 
and results are expressed as fold change over mock-infected samples (2#""
C
T). 
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Plasmids. pLXSN-BgpC (CEACAM1a-2S) and pLXSN-BgpD (CEACAM1a-4L) used for 
ceacam1a splice variant standard curves were provided by Nicole Beauchemin (McGill 
University). pCMV-SPORT6-CEACAM1, pCMV-SPORT6-CEACAM2, pCMV-SPORT6-PSG16, 
and pCMV-SPORT6-ACTB (mouse beta-actin, partial clone) were purchased from Open 
Biosystems (Thermo Scientific). 
Transfections. To compare MHV receptor activity, human 293T cells were seeded in a 12-well 
plate at 1.5 $ 10
5
 cells per well and transfected with 0.4 µg pCMV-SPORT6-CEACAM1, pCMV-
SPORT6-CEACAM2, or pCMV-SPORT6-PSG16 plus 0.6 µg empty vector (1 µg total DNA) using 
6 µL FuGENE 6 Transfection Reagent (Roche Applied Science) in 100 µL serum-free DMEM. A 
control plasmid encoding GFP was used in parallel to assess transfection efficiency. At 36 hours 
post-transfection, cells were inoculated with 3 $ 10
5 
PFU of virus diluted in DMEM containing 2% 
FBS for 1 hour at 37°C. At 8 hours post-infection, cells were fixed in 4% paraformaldehyde and 
immunolabeled for MHV nucleocapsid protein as described above. Cell nuclei were labeled with 
DAPI, and percent infection was determined as the percentage of DAPI-positive cells per field 
that also stained positively for MHV nucleocapsid.  
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RESULTS  
rA59 and rJHM.SD infect multiple CNS cell types in vivo but predominantly infect neurons. 
To determine what CNS cell types are infected at early times after intracranial (i.c.) inoculation, 4-
week-old C57BL/6 mice were inoculated i.c. with 50 PFU of rA59 or rJHM.SD. At days 3 and 5 
post-infection (p.i.), infected mice were euthanized and brains were fixed for 
immunofluorescence. By day 3, MHV antigen was readily detected in GFAP-positive astrocytes, 
Iba1-positive microglia, and MAP2-positive neurons (Fig. 2-1A, white arrowheads) as well as 
occasional OLIG2-positive oligodendrocytes (data not shown). By day 5, large patches of MHV-
infected neurons were evident in both rA59- and rJHM.SD-infected brains (Fig. 2-1B), consistent 
with previous data that neurons are the predominant cell type infected by these strains (11, 35, 
44). Importantly, while rA59 and rJHM.SD both infect large numbers of neurons, rJHM.SD is more 
extensively distributed throughout the brain than rA59, which remains more focal (23). 
 
! 45 
 
 
 
Figure 2-1. MHV infection of CNS cell types. C57BL/6 mice inoculated i.c. with 50 PFU of rA59 
or rJHM.SD were sacrificed at days A) 3 and B) 5 post-infection. Formalin-fixed, paraffin-
embedded tissues were sectioned and dual immunolabeled for GFAP, Iba1, or MAP2 (red) and 
MHV nucleocapsid protein (green). Arrowheads indicate double positive cells. 400X 
magnification. Data are representative of two independent experiments.  
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Ceacam1a mRNA is expressed in murine tissues, primary cells, and cell lines. Since rA59 
and rJHM.SD infect multiple cell types not yet shown to express CEACAM1a protein by routine 
methods, a quantitative RT-PCR (qRT-PCR) approach was taken to assess expression of 
ceacam1a mRNA in murine tissues, primary CNS cells, and cell lines. Primers were designed to 
amplify a region of the N-terminal Ig-like domain. This domain contains the site of MHV spike 
binding and is present in all four known ceacam1a splice variants, thus allowing amplification of 
total ceacam1a mRNA. Results are expressed as cDNA copies of ceacam1a per million cDNA 
copies of actb. To determine if mRNA expression data parallels known CEACAM1a protein 
expression data, RNA isolated from liver, brain, and spinal cord of 4-week-old C57BL/6 mice was 
subjected to qRT-PCR analysis for total ceacam1a mRNA using the primer set listed in Table 2-1. 
Consistent with published data that the liver expresses more CEACAM1a protein than the brain 
(17, 60), ceacam1a mRNA levels in the liver were approximately 10- to 100-fold higher than both 
brain and spinal cord in wild-type (WT) mice (Fig. 2-2A). To ensure specificity of these primers, 
qRT-PCR analysis was performed on RNA from ceacam1a
-/-
 (KO) mouse tissues. As expected, 
no product was amplified from ceacam1a
-/-
 RNA (Fig. 2-2A), confirming the specificity of the 
assay.  
 To evaluate which CNS cell types express ceacam1a, enriched primary cell cultures were 
generated from WT mice as described in Materials and Methods. RNA isolated from these cell 
cultures was then subjected to qRT-PCR analysis for total ceacam1a expression. Primary 
hepatocytes and microglia, two cell types known to express CEACAM1a protein (17, 46), were 
used as positive controls. As expected, both hepatocytes and microglia were positive for 
ceacam1a expression, with hepatocytes expressing approximately 10-fold higher levels than 
microglia (Fig. 2-2B). Interestingly, ceacam1a expression was readily detected in both astrocyte 
and oligodendrocyte cultures, albeit to lower levels than microglia (Fig. 2-2B). While ceacam1a 
expression was also detected in cortical and hippocampal neuron cultures, these expression 
levels were extremely low (Fig. 2-2B). Importantly, since primary cell cultures are enriched but not 
entirely pure, immunofluorescent labeling was performed as described in Materials and Methods 
to identify contaminating cell types in the individual cultures. Microglia cultures were routinely 
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!98% pure, with rare astrocyte and oligodendrocyte contamination (data not shown). Astrocyte 
cultures were routinely 90-95% pure, with contaminating microglia and rare oligodendrocytes 
(data not shown). Oligodendrocyte cultures were routinely 90-95% pure, with contaminating 
astrocytes and rare microglia (data not shown). Neuron cultures were routinely 95-98% pure, with 
contaminating astrocytes, oligodendrocytes, and rare microglia (data not shown). It is important to 
consider these low levels of contaminating cells when interpreting the qRT-PCR results obtained 
from primary cell cultures. 
 Murine DBT, 17Cl1, and L2 cell lines are routinely used for propagation and/or titration of 
MHV. DBT cells are derived from astrocytoma tissue in CDF1 mice (22), whereas 17Cl1 and L2 
fibroblasts are derived from the BALB/c 3T3 cell line and C3H/An L929 cell line, respectively (51). 
Given the different mouse strains of origin as well as ongoing propagation in tissue culture, it was 
important to characterize the levels of ceacam1a expression in these cell lines. To this end, RNA 
isolated from DBT, 17Cl1, and L2 cells was subjected to qRT-PCR analysis for total ceacam1a 
expression. As expected, ceacam1a mRNA was readily detected in all three cell lines (Fig. 2-2C), 
consistent with their permissiveness to MHV infection in vitro. Furthermore, all cell lines examined 
showed similar levels of ceacam1a expression (Fig. 2-2C). 
 WT mice exhibit age-dependent differences in susceptibility to CNS infection with some 
neurotropic strains of MHV, including rA59. Since ceacam1a expression is developmentally 
regulated (20), it was of interest to determine if ceacam1a mRNA levels in the CNS changed 
during adulthood. To this end, RNA was isolated from liver and brain tissue of WT mice aged 2 to 
14 weeks. This age range encompasses the different subsets of weanling and adult mice typically 
used for MHV studies. Interestingly, ceacam1a expression levels were relatively stable in both the 
liver and brain at all ages observed (Fig. 2-2D). 
 Previous flow cytometric studies demonstrated that CEACAM1a expression is 
downregulated on microglia during acute infection of BALB/c mice with the J2.2-V-1 variant of 
JHM; this downregulation, largely mediated by CD4 T cells, is restored following viral control (46). 
To determine if ceacam1a expression was altered in the whole brain (including brain-resident 
cells not easily observed by flow cytometry), C57BL/6 mice were inoculated i.c. with 50 PFU of 
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rA59 or rJHM.SD and RNA was isolated on days 1-5 post-infection. Within this period of acute 
infection, ceacam1a expression levels were unchanged compared to mock-infected brains (Fig. 
2-2E). Importantly, these ceacam1a expression levels remained constant despite robust levels of 
virus replication, as demonstrated by qRT-PCR for nucleocapsid messenger RNA (mRNA7) (Fig. 
2-2F). 
 
 
 
Figure 2-2. Ceacam1a mRNA expression in murine tissues, primary cells, and cell lines. 
RNA isolated from A) 4-week-old C57BL/6 mouse tissues, B) primary cell cultures, C) cell lines, 
D) 2-14-week-old C57BL/6 mouse tissues, and E-F) C57BL/6 mouse brains inoculated i.c. with 
50 PFU of rA59 or rJHM.SD were analyzed by qRT-PCR for expression of total ceacam1a mRNA 
(A-E) or MHV mRNA7 (F). Results are expressed as cDNA copies of ceacam1a per million cDNA 
copies of actb (A-D) or fold change over mock (E-F). Error bars represent standard error of the 
mean (n=3). Data are representative of two or more independent experiments. LIV, liver; BR, 
brain; SC, spinal cord; WT, wild-type; KO, ceacam1a
-/-
; HEP, hepatocyte; MIC, microglia; AST, 
astrocyte; OLI, oligodendrocyte; CN, cortical neuron; HN, hippocampal neuron. 
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Ceacam1a splice variant mRNAs are differentially expressed in murine tissues and 
primary cells. To more fully characterize the expression patterns of ceacam1a in CNS tissues 
and cell types, primer sets were designed to detect ceacam1a splice variants expressing 2 versus 
4 Ig-like domains (2D vs. 4D) and short versus long cytoplasmic tails (S vs. L). Primer sets are 
listed in Table 2-1, and a schematic depicting primer amplification sites is shown in Fig. 2-3A. 
While traditional RT-PCR has been used to distinguish all four splice variants based on product 
size alone, these assays are complicated by differences in amplification efficiency for shorter 
versus longer splice variants. While the qRT-PCR assay described here does not allow for 
distinction of each individual splice variant (2S, 2L, 4S, 4L), it does allow for more careful 
quantification of 2D versus 4D species and S versus L species. As shown in Fig. 2-3A, 2D 
primers amplify a region at the splice junction between D1 and D4 whereas 4D primers amplify a 
region at the junction of D3 and D4. Similarly, S primers amplify the region where exon 7 has 
been removed by splicing whereas L primers encompass a portion of exon 7 (Fig. 2-3A). 
Plasmids encoding ceacam1a-2S (BgpC) and ceacam1a-4L (BgpD) were used to construct 
standard curves for copy number determination by qRT-PCR. 
 Using these primer sets, the tissue and cellular RNA described for Fig. 2-2 was analyzed 
by qRT-PCR to compare splice variant expression. As shown in Fig. 2-3B, 4D variants 
predominated over 2D in the liver whereas 2D and 4D variants were more uniformly expressed in 
CNS tissues. Interestingly, while primary hepatocytes mirror the 4D>2D expression observed in 
the liver, most primary CNS cell types also expressed 4D variants to greater levels than 2D (Fig. 
2-3C). This difference in brain expression versus primary cells may reflect the contribution of an 
additional cell type in vivo, such as endothelial cells, not analyzed in the primary cell panel. A 
notable exception in the primary cell panel was the oligodendrocyte cultures, which expressed 
slightly more 2D than 4D species (Fig. 2-3C). This unique ratio of 2D to 4D variants supports the 
idea that oligodendrocytes themselves express ceacam1a and that the total ceacam1a 
expression shown in Fig. 2-2B is not entirely due to contaminating cells. Cell line expression of 
ceacam1a isoforms also differed slightly, with DBT cells expressing relatively equal levels of 2D 
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and 4D variants while 17Cl1 and L2 fibroblasts expressed higher levels of 4D species compared 
to 2D (Fig. 2-3D). 
 Since most functional differences in terms of cell signaling and tumor suppression that 
have been described for CEACAM1a are due to the length of the cytoplasmic tail (18, 27), tissue 
and cellular RNA was analyzed for expression of ceacam1a mRNA species encoding S versus L 
cytoplasmic tails. Interestingly, liver exhibited relatively even expression of S and L variants while 
L predominated over S in the CNS (Fig. 2-3E). In terms of S versus L tails, the primary cells 
analyzed mirrored the expression seen in the tissues from which they were derived (Fig. 2-3F). 
Expression in all three cell lines showed a similar pattern as well, with L species predominating 
slightly over S (Fig. 2-3G).  
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Figure 2-3. Ceacam1a splice variant expression in murine tissues, primary cells, and cell 
lines. A) Schematic representing ceacam1a splice variants. B-G) RNA isolated from 4-week-old 
C57BL/6 mouse tissues (B and E), primary cell cultures (C and F), and cell lines (D and G) were 
analyzed by qRT-PCR for ceacam1a expression of 2 versus 4 Ig-like domains (B-D) or short 
versus long cytoplasmic tails (E-G). Results are expressed as cDNA copies of ceacam1a per 
million cDNA copies of actb. Error bars represent standard error of the mean (n=3). *, P % 0.05; 
**, P % 0.005 as determined by paired t-tests. Data are representative of two independent 
experiments. 2D, two extracellular Ig-like domains; 4D, four extracellular Ig-like domains; S, short 
cytoplasmic tail due to exclusion of exon 7; L, long cytoplasmic tail due to inclusion of exon 7. 
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rJHM.SD spreads in wild-type neuron cultures despite low levels of infectious virus. To 
assess the ability of rA59 and rJHM.SD to infect and spread among neurons, hippocampal 
neuron cultures were generated from embryonic C57BL/6 mice and inoculated with approximately 
1 PFU/cell of filtered rA59, rJHM.SD, or a chimeric recombinant A59 virus expressing the 
JHM.SD spike (rA59/SJHM.SD); virus stocks were filtered prior to neuronal inoculations to remove 
residual cell debris. Recombinant versions of these viruses expressing EGFP were used in 
parallel to monitor infection over time and revealed widespread infection with all virus strains by 
72 hours post-infection (data not shown). Therefore, cells were fixed at 72 hours post-infection 
and immunolabeled for MAP2 and MHV nucleocapsid protein as described in Materials and 
Methods. As expected, all three viruses were able to infect and spread in cultured neurons, as 
evidenced by co-localization of MAP2 and MHV antigen (Fig. 2-4A); however, foci of rJHM.SD- 
and rA59/SJHM.SD-infected neurons were typically larger than foci of rA59-infected neurons, 
consistent with previous results (44). To investigate whether spread in neuron cultures was 
occurring cell-to-cell or via virus release, cell lysates and culture supernatants were collected at 
24, 48, and 72 hours post-infection and infectious virus was titrated by standard plaque assay on 
L2 cell monolayers. Interestingly, while rA59 replicated to relatively high titers within cells, 
rJHM.SD and the chimeric rA59/SJHM.SD titers were approximately 10- to 100-fold lower than rA59 
titers at all three timepoints (Fig. 2-4B). Virus release from infected neuron cultures paralleled the 
intracellular differences, with extracellular rA59 titers exceeding rJHM.SD titers by up to 1000-fold 
by 72 hours post-infection (Fig. 2-4C). Thus, both rJHM.SD and rA59/SJHM.SD spread well in wild-
type neurons despite relatively low levels of virus replication and release, suggesting that cell-to-
cell spread is likely to be the major route of rJHM.SD dissemination in neurons.  
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Figure 2-4. MHV infection and replication in wild-type neuron cultures. Hippocampal 
neurons generated from C57BL/6 mice were inoculated with 1 PFU/cell of rA59, rA59/SJHM.SD, or 
rJHM.SD. A) Cells were fixed at 72 hours post-infection and dual immunolabeled for MHV 
nucleocapsid protein (green) and MAP2 (red). 200X magnification. B) Cell lysates and C) culture 
supernatants were collected at 24, 48, and 72 hours post-infection and infectious virus was 
titrated by standard plaque assay on L2 cell monolayers. Error bars represent standard error of 
the mean (n=3), dotted line indicates limit of detection. Data are representative of two or more 
independent experiments. 
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rJHM.SD spreads extensively in ceacam1a
-/-
 neurons. To determine if MHV entry and spread 
in neurons was dependent on the receptor CEACAM1a, hippocampal neurons were generated 
from embryonic ceacam1a
-/-
 mice and inoculated with approximately 1 PFU/cell of filtered rA59, 
rJHM.SD, or the chimeric rA59/SJHM.SD. Recombinant versions of these viruses expressing EGFP 
were again used in parallel to monitor the spread of infection (data not shown). Cells were fixed at 
72 hours post-infection and immunolabeled for MAP2 and MHV nucleocapsid protein as in Fig. 2-
4. Surprisingly, all three viruses were able to infect ceacam1a
-/-
 neurons, as evidenced by co-
localization of MAP2 and MHV antigen (Fig. 2-5). However, foci of infected cells were much more 
rare (typically 1-3 foci per coverslip) for all virus strains in ceacam1a
-/-
 neuron cultures compared 
to the numerous coalescing foci of infected cells observed in wild-type neuron cultures (data not 
shown). Thus, virus infection of neuron cultures was much less efficient in the absence of 
ceacam1a. Strikingly, though all viruses were able to enter individual cells in the ceacam1a
-/-
 
neuron cultures, only rJHM.SD and rA59/SJHM.SD spread efficiently to adjacent cells (Fig. 2-5). By 
72 hours post-infection, rA59 remained localized to one or two ceacam1a
-/-
 neurons while viruses 
expressing the JHM.SD spike spread similarly in ceacam1a
-/-
 and wild-type cultures (Fig. 2-4A 
and 5). Notably, similar differences in spread were observed in blocking experiments in which 
wild-type neurons were first infected with rA59 or rJHM.SD and then treated with CEACAM1a-
blocking antibody (data not shown). Thus, while MHV entry in neural cells appears largely 
dependent on ceacam1a expression, only rA59 appears to require ceacam1a expression for 
efficient cell-to-cell neuronal spread. This finding is consistent with previous studies showing that 
ceacam1a
-/-
 mice are susceptible to infection with viruses expressing the JHM.SD spike but 
resistant to rA59 infection (35). 
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Figure 2-5. MHV infection in ceacam1a
-/-
 neuron cultures. Hippocampal neurons generated 
from ceacam1a
-/-
 mice were inoculated with 1 PFU/cell of rA59, rA59/SJHM.SD, or rJHM.SD. Cells 
were fixed at 72 hours post-infection and dual immunolabeled for MHV nucleocapsid protein 
(green) and MAP2 (red). 200X magnification. Data are representative of two or more independent 
experiments. 
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Ceacam2 mRNA is expressed at low levels in the murine liver and CNS. To determine if an 
alternative CEACAM1a-related receptor might be positioned to mediate viral infection/spread in 
ceacam1a
-/-
 mice and neuron cultures, primers were designed to amplify the N-terminal Ig-like or 
equivalent domain of ceacam2 and psg16 (bCEA), two ceacam1a-related genes that encode 
proteins that serve inefficiently as MHV receptors when overexpressed in vitro (4, 40). Primer 
sequences are shown in Table 2-1. Using the tissue and cellular RNA described for Fig. 2-2, 
qRT-PCR was performed to detect expression of ceacam2, the most closely related gene to 
ceacam1a in the mouse. Results are expressed as cDNA copies of ceacam2 per million cDNA 
copies of actb. As shown in Fig. 2-6A, ceacam2 mRNA is expressed to similarly low levels in both 
liver and CNS tissue of wild-type (WT) mice. Notably, CNS expression of ceacam2 was relatively 
unchanged in the absence of ceacam1a (KO) while liver expression was slightly increased 
compared to WT (Fig. 2-6A); however, only one set of KO tissues (n=3) was available for qRT-
PCR analysis. Interestingly, despite detectable levels of ceacam2 mRNA in both liver and CNS 
tissue, low to no expression of ceacam2 was observed in the primary cell types studied, with only 
microglia and oligodendrocyte cultures showing consistent low-level expression (Fig. 2-6B). Thus, 
other resident cell types, such as endothelial cells, likely contribute to the ceacam2 expression 
observed in liver and CNS tissue. Interestingly, when cell lines were observed, ceacam2 
expression was detectable in L2 and to a lesser extent DBT but not 17Cl1 cells (Fig. 2-6C). As 
with ceacam1a, ceacam2 expression remained relatively constant from 2-14 weeks of age (Fig. 
2-6D) and was not markedly affected by MHV infection (Fig. 2-6E). 
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Figure 2-6. Ceacam2 mRNA expression in murine tissues, primary cells, and cell lines. 
RNA isolated from A) 4-week-old C57BL/6 mouse tissues, B) primary cell cultures, C) cell lines, 
D) 2-14-week-old C57BL/6 mouse tissues, and E) C57BL/6 mouse brains inoculated i.c. with 50 
PFU of rA59 or rJHM.SD were analyzed by qRT-PCR for expression of ceacam2 mRNA. Results 
are expressed as cDNA copies of ceacam2 per million cDNA copies of actb (A-D) or fold change 
over mock (E). Error bars represent standard error of the mean, n=3. Data are representative of 
two or more independent experiments. 
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Psg16 (bCEA) mRNA is expressed in the murine CNS and primary neurons. Using the tissue 
and cellular RNA described for Fig. 2-2, qRT-PCR was performed to detect expression of psg16 
(bCEA), a more distantly related gene to ceacam1a described solely in the murine CNS (4). 
Results are expressed as cDNA copies of psg16 per million cDNA copies of actb. Consistent with 
the previously published data (4), psg16 expression was readily detected in the brain and spinal 
cord of both WT and KO mice while expression was negligible in the liver (Fig. 2-7A). 
Interestingly, when RNA from primary cells was examined, psg16 expression was detected 
exclusively in neurons (Fig. 2-7B). DBT, 17Cl1, and L2 cell lines were all negative for psg16 
expression (Fig. 2-7C). As with ceacam1a and ceacam2, psg16 expression remained constant in 
the murine CNS from 2-14 weeks of age (Fig. 2-7D) and was not significantly affected by MHV 
infection (Fig. 2-7E). The neuronal localization of psg16 expression suggested PSG16 might 
substitute for CEACAM1a to facilitate MHV infection in neurons. Therefore, functionality of this 
receptor was investigated. 
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Figure 2-7. Psg16 (bCEA) mRNA expression in murine tissues, primary cells, and cell lines. 
RNA isolated from A) 4-week-old C57BL/6 mouse tissues, B) primary cell cultures, C) cell lines, 
D) 2-14-week-old C57BL/6 mouse tissues, and E) C57BL/6 mouse brains inoculated i.c. with 50 
PFU rA59 or rJHM.SD were analyzed by qRT-PCR for expression of psg16 mRNA. Results are 
expressed as cDNA copies of psg16 per million cDNA copies of actb (A-D) or fold change over 
mock (E). Error bars represent standard error of the mean (n=3). Data are representative of two 
or more independent experiments. 
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CEACAM2 mediates MHV entry in human 293T cells. While CEACAM2 and PSG16 are both 
known to mediate inefficient MHV infection when overexpressed in vitro (4, 40), their functionality 
as MHV receptors has not been directly compared. Furthermore, PSG16 reportedly serves as a 
receptor for A59 but not JHM (4). To evaluate receptor activity, human 293T cells were 
transfected with equal amounts of plasmid DNA encoding CEACAM1a, CEACAM2, or PSG16 
using FuGENE 6 Transfection Reagent as described in Materials and Methods. At 36 hours post-
transfection, cells were inoculated with approximately 1 PFU/cell of rA59 or rJHM.SD and fixed at 
8 hours post-infection for immunofluorescent detection of MHV antigen; this timepoint was 
selected to allow approximately one round of MHV infection. Parallel transfection with a plasmid 
encoding GFP was performed to assess transfection efficiency (Fig. 2-8C). Quantification of MHV 
infection is shown in Fig. 2-8B. As expected, CEACAM1a mediated robust infection with both 
rA59 and rJHM.SD, whereas CEACAM2 was much less efficient at mediating entry (Fig. 2-8A 
and 2-8B). Importantly, no MHV antigen staining was observed in mock-infected cells or in cells 
transfected with vector alone (Fig. 2-8A). Furthermore, transfection of higher amounts of receptor 
cDNA did not increase infection rates but did, particularly in the case of CEACAM1a, cause cells 
to cluster together (data not shown). Interestingly, PSG16 did not mediate infection with either 
rA59 or rJHM.SD in this assay (Fig. 2-8A), suggesting inefficient expression levels or a complete 
lack of cell surface expression and/or lack of receptor functionality.  
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Figure 2-8. MHV infection of 293T cells transfected with receptor. Human 293T cells were 
transfected with expression plasmids encoding CEACAM1a, CEACAM2, PSG16, or empty vector 
using FuGENE 6 Transfection Reagent. A) Cells were infected at 36 hours post-transfection with 
approximately 1 PFU/cell of rA59 or rJHM.SD, fixed at 8 hours post-infection, and immunolabeled 
for MHV nucleocapsid protein. B) Quantification of infected cells. Error bars represent standard 
error of the mean (n=3). C) GFP transfection control indicating transfection efficiency. 200X 
magnification. Data are representative of two or more independent experiments. 
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DISCUSSION      
 MHV utilizes murine CEACAM1a proteins as entry receptors, yet CEACAM1a expression 
in the CNS is remarkably low compared to expression levels in other MHV targets such as the 
liver (17, 60). Furthermore, in the brain, only endothelial cells and microglia have been shown to 
express CEACAM1a (17, 46). Thus, it was unclear how neurotropic strains of MHV infect 
additional CNS cell types in vivo, such as astrocytes, oligodendrocytes, and particularly neurons 
(Fig. 2-1). One possibility is that these cell types express low levels of CEACAM1a that are not 
detectable by routine methods and/or that CEACAM1a is sublocalized, such as at the neuronal 
synapse, such that antibodies cannot access it. Using immunohistochemical amplification 
techniques such as Tyramide Signal Amplification (PerkinElmer) designed for detection of low-
level protein targets, we were unable to demonstrate CEACAM1a expression on neurons or glia, 
including microglia (data not shown). Thus, to avoid the potential caveats of antibody-based 
techniques, we instead used qRT-PCR to assess expression of ceacam1a mRNA in enriched 
CNS cell cultures. Importantly, our qRT-PCR data for ceacam1a expression corresponded with 
published protein data for the liver and brain (17, 60), with liver expressing significantly higher 
levels of ceacam1a than the brain in our assays (Fig. 2-2A). Furthermore, expression levels in the 
brain and liver remained stable in mice 2-14 weeks of age (Fig. 2-2D), suggesting that age-
related differences in susceptibility to MHV are not due to differences in ceacam1a expression. 
As expected, ceacam1a mRNA expression was highest in primary hepatocytes and microglia 
(Fig. 2-2B), the two cell types in this panel known to express CEACAM1a protein (17, 46). 
Interestingly, decreasing levels of ceacam1a expression were also detected in oligodendrocyte, 
astrocyte, and neuron cultures (Fig. 2-2B). However, when interpreting this data, it is important to 
consider the level of cellular contaminants in these enriched cultures. Astrocyte cultures were 90-
95% pure, with microglia being the primary contaminant; thus, it is difficult to distinguish low-level 
ceacam1a expression in astrocytes from higher-level expression by contaminating microglia. 
Expression of ceacam1a in neuron cultures was quite low and may also be due to low-level 
microglia contamination. However, the striking difference in neuronal spread observed in WT and 
KO cultures infected with rA59 suggests to us that neurons express CEACAM1a, though possibly 
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at very low levels. Interestingly, ceacam1a expression was readily detectable in oligodendrocyte 
cultures; these cultures were 90-95% pure, with astrocytes being the primary contaminant. 
Furthermore, the ratio of 2D to 4D splice variants in oligodendrocyte cultures was inverted 
compared to the ratio in microglia (Fig. 2-3C). Thus, the ceacam1a expression detected in these 
cultures is unlikely to be due entirely to contaminating microglia. Future studies aim to purify glial 
cells from the adult CNS and isolate RNA from these purified cell populations as described by 
Malone et al. (30) in order to reduce the complication of contaminating cells and to investigate 
ceacam1a expression in cells directly ex vivo. 
 CEACAM1a is a multifunctional protein involved in a variety of cellular processes 
including intercellular adhesion, tumor suppression, angiogenesis, and immune cell signaling (18, 
27). Many of these signaling and regulatory functions are specific to long-tailed CEACAM1a 
isoforms, which contain phosphorylatable tyrosine residues within an immunoreceptor tyrosine-
based inhibitory motif (ITIM). These residues have been shown to participate in protein-protein 
interactions and downstream signaling cascades in a variety of cell types, including T cells (5) 
and dendritic cells (24). Furthermore, the balance of short (S) to long (L) isoforms in a particular 
cell likely contributes to signaling outcome (18). Thus, from the standpoint of host cell signaling, it 
was of interest to evaluate expression patterns of individual ceacam1a splice forms, particularly 
those encoding S versus L tails. In our studies, L splice variants predominated over S in the brain 
while the two were more balanced in liver, and this trend was recapitulated in primary CNS cell 
types (Fig. 2-3E and 2-3F). Thus, it is tempting to speculate that MHV binding to long-tailed 
CEACAM1a isoforms may trigger or modulate intracellular signaling pathways in neural cells in 
ways that are not yet appreciated, and CEACAM1a-dependent versus CEACAM1a-independent 
mechanisms of infection/spread could lead to different signaling outcomes in an infected cell. 
Future studies aim to investigate CEACAM1a signaling during MHV infection. While expression of 
2D versus 4D splice variants in the CNS was more balanced than liver (Fig. 2-3B), both microglia 
and astrocyte cultures expressed significantly higher levels of the 4D variants (Fig. 2-3C). 
However, since 2D and 4D isoforms both mediate MHV entry, the functional significance of this 
difference, if any, in unknown.  
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 If neurons, astrocytes, and/or oligodendrocytes are indeed CEACAM1a-negative, MHV 
might use an alternative receptor to enter these cells; such a receptor would likely be less 
functional than CEACAM1a and/or more limited in its availability given the reduced susceptibility 
of ceacam1a
-/-
 mice to CNS infection with MHV. Two ceacam1a-related genes, ceacam2 and 
psg16 (bCEA), are expressed in the brain and encode proteins reported to act as MHV entry 
receptors when overexpressed in vitro (4, 40). However, it was unclear what cell types express 
these alternative receptors in the CNS. To address this question, qRT-PCR was again used to 
quantify expression of ceacam2 and psg16 in primary CNS-derived cells. Interestingly, ceacam2 
mRNA levels in these cell types were quite low despite more readily detectable levels in whole 
brain (Fig. 2-6A and 2-6B). While microglia and oligodendrocyte cultures were the most highly 
positive, it is difficult to know if such expression levels are sufficient to encode functional levels of 
receptor on the cell surface. Furthermore, other cell types not examined, such as endothelial 
cells, likely contribute to the overall expression levels observed in CNS tissue (Fig. 2-6A). 
Consistent with previous reports (4), psg16 expression was indeed observed in the CNS; 
strikingly, this expression was detected in cortical and hippocampal neuron cultures only (Fig. 2-
7B).  To our knowledge, this is the first report of a pregnancy-specific glycoprotein family member 
expressed in cultured neurons, though the role of PSG16 in these cells remains unclear.  
 To directly compare the ability of these alternative receptors to mediate MHV entry, we 
transfected cDNA clones of CEACAM1a, CEACAM2, and PSG16 into human 293T cells (not 
normally infected by MHV), allowed time for protein expression to occur, and then inoculated with 
rA59 or rJHM.SD. Consistent with previous reports, CEACAM2 mediated infection with both 
strains but was considerably less efficient than CEACAM1a (Fig. 2-8A and 2-8B). The lower 
efficiency of CEACAM2 compared to CEACAM1a is likely due to structural differences at the site 
of MHV binding, though differences in receptor density and surface distribution could also 
contribute. While PSG16 is reported to be a receptor for A59 but not JHM (4), no infection of 
PSG16-transfected cells was observed for either rA59 or rJHM.SD in our assay (Fig. 2-8A and 2-
8B). However, we could not confirm that PSG16 was actually expressed on the 293T cell surface. 
Computer algorithms were also unable to identify a transmembrane region or membrane anchor 
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in the sequence, nor could they identify a traditional secretory signal. To address the issue of 
surface expression, PSG16 was artificially linked to either a transmembrane domain or a GPI 
anchor, expressed in 293T cells, and inoculated with virus. Curiously, even when PSG16 was 
successfully targeted to the cell surface, no infection was observed with rA59 or rJHM.SD (Judith 
Phillips, unpublished data). Notably, when CEACAM1a was attached to the membrane via a GPI 
anchor MHV infection was indeed observed (Judith Phillips, unpublished data), indicating that the 
extracellular Ig-like domains of CEACAM1a are sufficient to mediate MHV entry when attached to 
the cell membrane in the absence of a transmembrane domain and cytoplasmic tail. It is possible 
that PSG16 is normally expressed in conjunction with another protein or membrane entity in the 
mouse and that this entity is lacking in human 293T cells. Interestingly, the placental members of 
the PSG family are largely secretory proteins, several of which have immunomodulatory functions 
(19, 59). Thus, it is intriguing to imagine that PSG16 expressed by neurons might be released 
under certain conditions to provide a signal to neighboring cells. Since primary neurons did not 
express ceacam2 (Fig. 2-6) and the product of psg16 appears to be nonfunctional (Fig. 2-8), it 
remains unclear how MHV initially enters ceacam1a
-/-
 neurons (Fig. 2-5). It is possible that an 
alternative PSG16 isoform or PSG16 in association with another surface protein specific to 
neurons may mediate infection in this cell type, though previous studies suggest this mechanism 
would only function for A59 entry (4). It is also possible that neurons express another, thus far 
unidentified, receptor that can mediate inefficient MHV entry in this cell type. Furthermore, 
rJHM.SD could enter a non-neuronal cell type first (perhaps via CEACAM2) and subsequently 
spread to neurons via a CEACAM1a-independent mechanism, as has been described in vitro. 
 Finally, neurotropic strains of MHV may have evolved a novel mechanism to spread to 
and between specialized CNS cell types, particularly neurons. Using mixed neural cultures, 
Nakagaki et al. (36) demonstrated that the highly neurovirulent JHM cl-2 isolate spreads to non-
microglial cells in the presence of CEACAM1a antibody blockade; in contrast, a soluble receptor 
resistant mutant of cl-2 known as srr7 remains localized to microglia when CEACAM1a is 
blocked. From these experiments, it was proposed that initial CNS infection with MHV occurs via 
entry into CEACAM1a-expressing microglia and that spread to additional CNS cell types requires 
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the capacity for CEACAM1a-independent spread. While microglia may indeed represent an early 
site of MHV replication in the CNS, this model is insufficient to explain the diverse cellular tropism 
of rA59 (Fig. 2-1), particularly since rA59 requires CEACAM1a for efficient cell-to-cell spread in 
vitro (56). Further, while in vitro studies indicate that both rA59 and rJHM.SD require CEACAM1a 
for initial entry (15, 54), this does not seem to be the case in vivo as rJHM.SD can infect cells in 
the CNS of ceacam1a
-/-
 mice (35). These results suggest that more than one mechanism may be 
involved during infection of ceacam1a
-/-
 animals: 1) initial entry in the absence of CEACAM1a and 
2) cell-to-cell spread in the absence of CEACAM1a (which may or may not be the same as 
CEACAM1a-independent spread observed in vitro). Thus, the inability of rA59 to cause CNS 
disease in ceacam1a
-/-
 mice could be the result of its dependence on CEACAM1a for cell entry 
and/or cell-to-cell spread. These possibilities are difficult to distinguish in whole brain, thus we 
devised an in vitro system using primary cells derived from wild-type C57BL/6 and ceacam1a
-/-
 
mice to address these questions.  
 While most CNS cell types can be infected by MHV in vivo, neurons are the predominant 
cell type infected by rA59 and rJHM.SD (Fig. 2-1) (11, 44). For this reason, primary neurons were 
the cell type of choice to model infection in vivo. We first aimed to compare infection and 
replication of rA59, rJHM.SD, and the chimeric rA59/SJHM.SD in wildtype (WT) neurons versus 
ceacam1a
-/-
 (KO) cells. When WT neurons were inoculated with MHV, foci of infected cells were 
readily detected throughout the coverslip (Fig. 2-4A). Parallel infections using EGFP-expressing 
viruses revealed that these foci increased in size from 24-72 hours postinfection (data not 
shown), presumably due to cell-to-cell spread. Viral titration of culture supernatants and cell 
lysates at 24, 48, and 72 hours post-infection revealed that rA59 infection resulted in higher levels 
of infectious virus, both inside and outside the cell, compared to both rJHM.SD and rA59/SJHM.SD 
(Fig. 2-4B and 2-4C). Thus, as in the brain (23, 43), widespread neuronal infection with viruses 
expressing the rJHM.SD spike occurs in the absence of high levels of infectious virus. It should 
be noted, however, that the JHM.SD spike is inherently less stable than that of A59 and may 
inactivate more rapidly following release from an infected cell (13, 26, 52). Thus, it is possible that 
some extracellular virus was no longer infectious at the time of sampling due to spontaneous 
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inactivation. However, this is less likely to be the case intracellularly, where rJHM.SD titers were 
also lower than rA59 (Fig. 2-4B).  
 Given that rA59 and rJHM.SD both infect and spread well in WT neurons (Fig. 2-4A), we 
next asked whether these strains could infect neuron cultures generated from ceacam1a
-/-
 (KO) 
mice. Surprisingly, occasional foci of infected cells (typically 1-3 per coverslip) were observed for 
both strains as well as with the chimeric rA59/SJHM.SD virus (Fig. 2-5). This result was initially 
surprising given previous reports that CEACAM1a antibody blockade prevents MHV infection in 
mixed neural cultures (36). However, given the low incidence of infection seen in ceacam1a
-/-
 
neurons, it is possible that the phenomenon was not appreciated in these blocking experiments or 
attributed to incomplete antibody blockade. Importantly, the results in Fig. 2-5 are consistent with 
previous data that JHM.SD successfully infects the CNS of ceacam1a
-/-
 mice (35). Notably, as 
infection proceeded from 24-72 hours post-infection, differences in spread became apparent, with 
rA59 remaining localized to individual cells while rJHM.SD and rA59/SJHM.SD spread extensively, 
generating foci of infected cell that were indistinguishable from infected foci in WT neurons (Fig. 
2-5). Further, while efficient cell-to-cell spread in KO neuron cultures largely maps to the JHM.SD 
spike (Fig. 2-5), variability in the extent of spread by rA59/SJHM.SD in these cultures suggests viral 
genes other than spike may also contribute to the neuronal spread of rJHM.SD (data not shown). 
Interestingly, when microglia cultures derived from ceacam1a
-/-
 mice were infected by rJHM.SD, 
large foci of infected cells were not observed and cell-to-cell spread was limited to just a few cells 
(data not shown). Thus, the ability of rJHM.SD to spread in the absence of CEACAM1a may be 
specifically enhanced in neurons compared to other CNS cell types. Additional viral surface 
proteins, such as hemagglutinin-esterase (HE), or the internal viral nucleocapsid (N) protein, 
which shares homology with the microtubule binding protein tau (42), may contribute in unique 
ways to enhance neuronal spread of MHV, though such activity may not be limited to the 
rJHM.SD virus (7, 25). 
 Based on these data, we propose a model for ceacam1a
-/-
 mouse infection in which both 
rA59 and rJHM.SD can enter occasional CNS cells lacking ceacam1a expression; this initial entry 
may occur via CEACAM2 on endothelial cells, microglia, and/or oligodendrocytes, via an 
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alternative form of PSG16 that has not yet been described, and/or via another as-yet-unidentified 
alternative receptor that can facilitate virus entry, albeit inefficiently. Once initial entry has 
occurred, a CEACAM1a-independent mechanism allows viruses expressing the JHM.SD spike to 
spread cell-to-cell. Thus, rA59 remains restricted to individual cells and does not produce 
detectable CNS infection while rJHM.SD and rA59/SJHM.SD spread efficiently to adjacent cells and 
ultimately lead to fatal neurological disease. While the precise mechanism of CEACAM1a-
independent spread remains unclear, one possibility is that an alternative receptor can interact 
with rJHM.SD but not rA59; differences between the JHM.SD and A59 spikes could likely allow 
for differences in receptor utilization by these strains. Another possibility is that the less stable 
association of the S1 and S2 subunits of the JHM.SD spike allows conformational changes 
leading to fusion to be more easily triggered even in the absence of a traditional receptor, as has 
been proposed for spread among tissue culture cells lacking CEACAM1a expression (14, 26). 
Finally, JHM.SD may have developed a way to spread across the neuronal synapse; such 
mechanisms of transsynaptic spread have been described for other neurotropic viruses. In 
support of this idea, low levels of infectious rJHM.SD are detected extracellularly despite 
widespread distribution of viral antigen in neurons in vitro. 
 Several amino acid residues within the JHM.SD spike have been identified in relation to 
CEACAM1a-independent spread or lack thereof. For example, introduction of a S310G 
substitution within the spike of JHM.IA (a CEACAM1a-dependent virus) confers increased 
virulence and the ability to spread cell-to-cell in the absence of CEACAM1a in vitro (41). Such a 
mutation could contribute to any of the aforementioned mechanisms of spread. Additionally, a 
L1114F substitution within the spike of the J2.2-V-1 glial-tropic variant of JHM-DL (57) and in the 
spike of the highly attenuated srr7 mutant of JHM cl-2 (48) is associated with an inability to induce 
CEACAM1a-independent fusion in mixed glial cultures (31, 32, 53); these viruses are 
neuroattenuated compared to their parental strains, further indicating the contribution of 
CEACAM1a-independent spread to enhanced neurovirulence. Viruses such as J2.2-V-1 with the 
L1114F substitution in spike are primarily glial-tropic and rarely infect neurons in vivo. However, a 
similar variant with a L1114R substitution, despite being CEACAM1a-dependent, infects neurons 
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of the olfactory bulb (55). Thus, different amino acid residues at the same position in spike have 
unique effects on neurotropism.   
 It remains unclear how neurotropic strains of MHV spread to CNS cell types expressing 
low to nonexistent levels of CEACAM1a, particularly neurons, and how viruses that use the same 
entry receptor can exhibit such varied cellular tropisms. However, the ability of rJHM.SD to 
spread in the absence of CEACAM1a likely contributes to neurovirulence by increasing viral 
dissemination throughout the CNS. Future studies using the ceacam1a
-/-
 mouse and primary cell 
models combined with the variety of neurotropic MHV strains differing in tropism and CEACAM1a 
dependence will aim to address the mechanism of CEACAM1a-independent spread in neural 
cells and the contribution of this process to neurovirulence. 
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CHAPTER 3 
 
Priming of CD8 T cells during central nervous system infection with a murine coronavirus is strain 
dependent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter appeared as the published article “Priming of CD8+ T cells during central nervous 
system infection with a murine coronavirus is strain dependent” by K. C. MacNamara,* S. J. 
Bender,* M. M. Chua, R. Watson, and S. R. Weiss. Journal of Virology, 82: 6150-6160 (2008). 
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ABSTRACT 
Virus-specific CD8+ T cells are critical for protection against neurotropic coronaviruses; however, 
CNS infection with the recombinant JHM (RJHM) strain of mouse hepatitis virus (MHV) elicits a 
weak CD8+ T cell response in the brain and causes lethal encephalomyelitis. An adoptive 
transfer model was used to elucidate the kinetics of CD8+ T cell priming during CNS infection 
with RJHM as well as two MHV strains that induce a robust CD8+ T cell response (RA59 and 
SJHM/RA59, a recombinant A59 virus expressing the JHM spike). While RA59 and SJHM/RA59 
infections resulted in CD8+ T cell priming within the first 2 days post-infection, RJHM infection did 
not lead to proliferation of naïve CD8+ T cells. While all three viruses replicated efficiently in the 
brain, only RA59 and SJHM/RA59 replicated to appreciable levels in the cervical lymph nodes 
(CLN), the site of T cell priming during acute CNS infection. RJHM was unable to suppress the 
CD8+ T cell response elicited by RA59 in mice simultaneously infected with both strains, 
suggesting RJHM does not cause generalized immunosuppression. RJHM was also unable to 
elicit a secondary CD8+ T cell response in the brain following peripheral immunization against a 
viral epitope. Notably, the weak CD8+ T cell response elicited by RJHM was unique to CNS 
infection, as peripheral inoculation induced a robust CD8+ T cell response in the spleen. These 
findings suggest that RJHM fails to prime a robust CD8+ T cell response during CNS infection 
due to inaccessibility of viral antigen in the brain and/or limited availability of viral antigen in the 
CLN. 
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INTRODUCTION 
 Members of the Coronaviridae family infect a wide range of mammalian species including 
humans and induce mild to severe disease of the respiratory tract, gastrointestinal tract, and 
central nervous system (CNS). Mouse hepatitis virus (MHV) infection provides a useful model to 
study acute and chronic CNS disease and specifically the process of demyelination, the hallmark 
of the human disease multiple sclerosis. Different strains of MHV induce disease with varying 
degrees of severity. For example, CNS infection with the recombinant wild-type A59 (RA59) strain 
causes acute encephalitis during the first week of infection; a strong CD8+ T cell response is 
observed in the brain coinciding with viral clearance. However, despite clearance of infectious 
RA59 virus, demyelination develops, peaking at approximately four weeks post-infection (p.i.) (17, 
20). In contrast, infection with the recombinant wild-type JHM (RJHM) strain (derived from the 
JHM isolate referred to as MHV-4 or JHM.SD (7, 28)) causes severe encephalomyelitis; virus is 
not cleared and mice typically succumb to disease by the end of the first week of infection. 
Furthermore, RJHM infection of the CNS elicits a very weak virus-specific CD8+ T cell response 
in the brain (7, 20, 34). However, we have only examined the most virulent strain of JHM. It 
should be noted that there are other strains of JHM that have deletions and mutations within the 
spike glycoprotein, rendering them less virulent and sometimes resulting in a change in cell 
tropism. The ability of neurotropic strains of MHV to replicate within cells of the CNS and cause 
disease of varying degrees is ideal for allowing the dissection of both viral and host determinants 
of neuropathogenesis. 
 The spike glycoprotein of MHV is a major determinant of neurovirulence (32). It controls 
virus tropism and spread as it both binds the cellular receptor and induces fusion with target cells. 
In addition, it encodes neutralizing antibody epitopes and the H-2
b
-restricted CD8+ T cell epitopes 
recognized in C57BL/6 (B6) mice. The A59 spike differs from the JHM spike in that it contains a 
deletion of 52 amino acids within the hypervariable region (HVR). The HVR has been well 
documented to tolerate mutation but with attenuating effects on virulence (5, 7). RA59 and RJHM 
both encode an H-2K
b
 epitope at position S598-605 (S598); however, due to the deletion, the 
A59 spike lacks the immunodominant H-2D
b
 epitope at position S510-519 (S510). We previously 
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selected isogenic recombinant viruses that express the JHM spike with all other genes derived 
from the A59 strain of MHV (SJHM/RA59). The isogenic SJHM/RA59 has a similar fifty percent 
lethal dose (LD50) to RJHM, demonstrating that the JHM spike is sufficient to generate a highly 
neurovirulent phenotype and increased ability to spread within the CNS (32, 33). However, 
SJHM/RA59-infected mice exhibit slower kinetics of death compared to RJHM-infected mice, and 
notably, unlike RJHM, the chimeric SJHM/RA59 virus induces a strong CD8+ T cell response in 
the brain (14, 34). 
 In addition to spike, there is increasing evidence that other viral genes play an important 
role in pathogenesis. We (14, 21) and others (34, 35) have noted that the low CD8+ T cell 
response observed during RJHM infection is not dependent on spike since the SJHM/RA59 
recombinant induces a robust virus-specific CD8+ T cell response. The difference in CD8+ T cell 
response elicited by SJHM/RA59 and RJHM may explain why SJHM/RA59 kills mice more slowly 
than RJHM. Furthermore, the reverse chimeric recombinant virus expressing the A59 spike in the 
JHM background (SA59/RJHM) is unable to replicate in the liver despite the fact that it expresses 
the spike from the hepatotropic RA59 strain (27), suggesting that background genes play a 
significant role in viral tropism. 
 It is well established that virus-specific CD8+ T cells play a protective role against MHV 
and are essential for clearance of infectious virus from the CNS (6, 20, 40, 41). The effector 
mechanisms exerted by activated, virus-specific CD8+ T cells include the ability to secrete 
cytokines as well as the ability to lyse target cells. Interferon gamma (IFN-!) expression is 
essential for clearance of MHV from the brain (3, 22, 29), and perforin-mediated lysis of infected 
cells also appears to play a role in viral clearance (6, 31). In contrast to infection with RA59 or the 
relatively neuroattenuated glial-tropic strains of JHM, CNS infection with the highly neurovirulent 
RJHM strain results in very low numbers of activated, virus-specific CD8+ T cells in the spleen 
and brain (14, 34). Furthermore, RJHM infection induces a different expression profile of 
cytokines and chemokines in the brains of infected mice compared to infection with RA59 (34, 35, 
38). One dramatic difference is that RA59 infection results in a robust IFN-! response whereas 
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RJHM infection results in higher, sustained levels of IFN-" (34). These observations prompted us 
to address the following questions: 1) Does RJHM elicit a CD8+ T cell response in the brain 
following intranasal inoculation, a route that requires more virus and results in slower infection 
compared to intracranial inoculation? 2) What are the kinetics of CD8+ T cell priming during CNS 
infections with RA59, SJHM/RA59, and RJHM? 3) Is CNS infection with RJHM generally 
immunosuppressive? 4) Do RA59, SJHM/RA59, and RJHM replicate efficiently in the draining 
cervical lymph nodes? 5) Can RJHM elicit a secondary CD8+ T cell response in the brain 
following peripheral immunization against a viral epitope? 6) Is the low CD8+ T cell response 
elicited during RJHM infection an inherent characteristic of the viral strain or specific to RJHM 
infection of the CNS? Our results suggest that RJHM fails to prime a CD8+ T cell response 
specifically during infection of the CNS without causing generalized immunosuppression, and this 
lack of priming correlates with a low level of RJHM replication in the draining cervical lymph 
nodes, the site of CD8+ T cell priming during acute CNS infection.  
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MATERIALS AND METHODS 
Mice and viruses. Four- to five-week-old male mice were used in all experiments. C57BL/6 (B6) 
and B6-LY5.2/Cr (CD45.1+) mice were obtained from the National Cancer Institute (Frederick, 
MD). P14 mice (CD45.2+) (4) were bred at the University of Pennsylvania. Recombinant MHV 
strains A59 (RA59), JHM (RJHM), and a chimeric virus expressing the JHM spike in the A59 
background (SJHM/RA59, originally referred to as S4R22) were selected by targeted 
recombination as described elsewhere (20, 32). Recombinant A59 and SJHM/RA59 expressing 
enhanced green fluorescent protein (EGFP) in the place of nonessential gene 4 (referred to as 
RA59-gfp and SJHM/RA59-gfp, respectively) were selected by targeted recombination as 
previously described (37). RJHM-gfp was selected using similar techniques. Selection of RA59-
gfp expressing the H-2
b
-restricted gp33 epitope of lymphocytic choriomeningitis virus (LCMV) as 
an N-terminal fusion protein to EGFP in place of gene 4 (referred to as RA59-gfp/gp33) is 
described in detail elsewhere (6). RJHM and SJHM/RA59 expressing the gfp/gp33 fusion were 
selected similarly via targeted recombination. 
Inoculation of mice. For intracranial (i.c.) inoculations, mice were anesthetized with isoflurane 
and virus was injected into the left cerebral hemisphere in a total volume of 30 µL phosphate-
buffered saline (PBS) containing 0.75% bovine serum albumin (BSA). For intranasal (i.n.) 
inoculations, virus was applied directly to the nostrils of a slightly anesthetized mouse in a total 
volume of 20 µL PBS containing 0.75% BSA. For intraperitoneal (i.p.) inoculations, virus was 
injected in a total volume of 100 µL PBS containing 0.75% BSA. Doses for individual experiments 
are indicated in the figure legends. 
Isolation of mononuclear cells. Mononuclear cells were prepared from the brain as previously 
described (6, 30). Brains from 4-6 animals were pooled per group. Briefly, animals were perfused 
with 10 mL PBS. Brains were placed in ice-cold RPMI 1640 medium containing 10% fetal bovine 
serum (FBS) and homogenized through a nylon mesh bag (pore diameter 64 µm) using a syringe 
plunger. Cells were passed through a 30% Percoll gradient and then through a cell strainer (pore 
diameter 70 µm). The cell suspension was layered atop a 2 mL cushion of Lympholyte-M 
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(Cedarlane Laboratories) and viable cells were removed from the interface, washed, and 
counted. Mononuclear cells were prepared from the spleen as previously described (6); this 
method was also used to isolate cells from the cervical lymph nodes (CLN). Briefly, tissues were 
homogenized through a nylon mesh bag (pore diameter 64 µm) in RPMI 1640 medium containing 
1% FBS. Red blood cells were lysed with 0.83% NH4Cl, and the remaining cells were washed 
and counted. 
Intracellular cytokine staining and flow cytometry. Intracellular IFN-! production was assayed 
in response to specific peptide stimulation as previously described (26, 33). Briefly, 1 # 10
6
 brain- 
or spleen-derived mononuclear cells were cultured with 10 units human recombinant IL-2 and 1 
µL/mL Brefeldin A (Golgiplug; BD Biosciences) in the presence or absence of 1 µg/mL peptide in 
a total volume of 200 µL RPMI 1640 medium supplemented with 5% FBS for 5 hours at 37°C. 
Cells were stained for surface expression of CD4, CD8, and/or CD45.2 using fluorescently 
conjugated monoclonal antibodies (BD Pharmingen). Cells were then fixed and permeabilized 
using the Cytofix/Cytoperm kit (BD Biosciences) and stained with a FITC-conjugated monoclonal 
rat anti-mouse IFN-! antibody (BD Pharmingen). Cells were fixed in 2% paraformaldehyde and 
analyzed using a FACScan or FACSCalibur flow cytometer (Becton Dickinson). Total cell 
numbers per mouse were determined by multiplying the fraction of live cells positive for a given 
marker by the total number of live cells isolated per organ.  
CFSE staining of spleen-derived mononuclear cells for adoptive transfer. Mononuclear cells 
were prepared from the spleens of P14 mice as described above. Cells were incubated with 5 µM 
CFSE for 10 minutes with periodic agitation. Staining was quenched by the addition of an equal 
volume of FBS and cells were washed three times with PBS. Cells were then counted and 
resuspended in PBS for adoptive transfer into B6 mice. 2 # 10
7
 cells were injected intravenously 
(i.v.) into the lateral tail vein in a total volume of 0.5 mL PBS. 
Mononuclear cell proliferation analysis. Mononuclear cells were isolated from the spleen or 
CLN as described above. Since CFSE labeling was performed on different days, it is important to 
note that the peak fluorescence intensity is not always the same; only those transfers performed 
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on the same day can be compared. The proliferative index (PI), the average number of divisions 
undergone by the divided population, was determined using FlowJo software (Tree Star, Inc.). 
Virus replication in mice. To measure in vivo virus replication, mice were sacrificed and 
perfused with 10 mL PBS. Brains and/or CLN were placed in 1-3 mL gel saline, an isotonic saline 
solution containing 0.167% gelatin, weighed, and stored frozen at -80°C. Tissues were 
subsequently homogenized and standard plaque assays were performed on murine L2 fibroblast 
monolayers (13). Neutralization assays were performed using monoclonal antibodies raised 
against either the JHM spike (J7.2 and J7.18) or the A59 spike (A2.1); these antibodies were a 
kind gift from John Fleming (University of Wisconsin, Madison). 
Listeria immunization. Recombinant Listeria monocytogenes (rLm) strains expressing the H-2
b
-
restricted gp33-41 epitope (KAVYNFATC; referred to as gp33) or the H-2
d
-restricted np118-126 
epitope (RPQASGVYM; referred to as np118) from LCMV were engineered as previously 
described (36, 39). Both epitopes are expressed as fusion proteins with dihydrofolate reductase. 
Strain XFL703 expresses the gp33 epitope and will be referred to as rLm-gp33. Strain XFL303 
expresses the np118 epitope and will be referred to as rLm-np118. Mice were inoculated i.p. with 
10
4
 CFU of rLm in 0.5 mL PBS, rested for three weeks, and then challenged i.c. with gp33-
expressing strains of MHV. 
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RESULTS 
RJHM elicits a weak virus-specific CD8+ T cell response in the brain. Intracranial (i.c.) 
inoculation of RJHM results in severe encephalitis with high numbers of innate immune cells, 
including macrophages and neutrophils, being recruited into the brain parenchyma early during 
infection. However, the recruitment of T cells into the brain, both total and virus-specific CD8+ T 
cells, is extremely low (14, 34). One possibility that could account for the low CD8+ T cell 
response in the brain following i.c. RJHM inoculation is that RJHM infection causes extensive 
tissue changes (more than observed with SJHM/RA59) that prevent proper immune cell 
trafficking into or out of the brain. To address this issue, mice were inoculated with virus via the 
intranasal (i.n.) route, which results in slightly slower spread of virus within the brain and less 
tissue destruction during the first week of infection compared to i.c. inoculation. Mice inoculated 
i.n. do not succumb to the disease until after the first week of infection, thus allowing us to 
examine the antiviral T cell response before massive tissue destruction occurs. It is important to 
note that the LD50 for RJHM when administered i.n. is approximately 2 log10 higher than when 
administered i.c. In this experiment, all mice inoculated by the i.n. route survived the first seven 
days of infection. However, similar to i.c. inoculation, i.n. infection with RJHM elicited a very weak 
CD8+ T cell response in the brain (Fig. 3-1). This result was in contrast to infection with the 
chimeric SJHM/RA59 strain of MHV, which induced a robust CD8+ T cell response to both H-2
b
-
restricted viral epitopes, S510 and S598 (Fig. 3-1). While the total number of cells isolated per 
brain from RJHM- and SJHM/RA59-infected mice varied by only 2-fold (6.4 # 10
5
 versus 1.3 # 
10
6
, respectively), the total number of CD8+ T cells isolated from RJHM-infected brains was 
nearly 50-fold lower compared to SJHM/RA59-infected brains (5.3 # 10
3
 versus 2.6 # 10
5
) (Fig. 3-
1). Total epitope-specific cells per brain were also significantly lower following RJHM infection 
compared to SJHM/RA59 (Fig. 3-1). Thus, RJHM infection of the CNS elicits a weak CD8+ T cell 
response in the brain following either i.c. or i.n. inoculation. Furthermore, this weak response is 
not solely dependent upon the JHM spike. This difference in CD8+ T cell response between 
RJHM and SJHM/RA59 following i.n. inoculation is similar to what we have previously reported 
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for i.c. inoculation (14), demonstrating that the minimal CD8+ T cell response observed following 
i.c. inoculation of RJHM is unlikely due to the rapid spread of virus and massive tissue destruction 
in the brain before a T cell response can be elicited. 
  
Figure 3-1. Intranasal inoculation of RJHM elicits a weak CD8+ T cell response in the brain. 
Brain lymphocytes harvested on day 7 p.i. from mice inoculated i.n. with 10
4
 PFU SJHM/RA59 or 
10
3
 PFU RJHM were stimulated with S510 or S598 peptides and then stained for intracellular 
IFN-! to evaluate the virus-specific CD8+ T cell response. The number in the upper right quadrant 
of each plot represents the percentage of CD8+ T cells that are epitope-specific as determined by 
IFN-! production. Data represent cells pooled from the brains of 4-6 animals per group and are 
representative of two independent experiments. The average numbers of live cells and CD8+ T 
cells harvested per brain are located above each column. 
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Kinetics of CD8+ T cell priming during CNS infection with MHV is strain-dependent. To 
assess the protective or pathogenic effects of virus-specific CD8+ T cells during the course of 
MHV disease, we previously developed an adoptive transfer system in which we could modulate 
the level of epitope-specific CD8+ T cells in vivo. This system utilized recombinant MHV strains 
expressing the gp33 epitope of LCMV and the transfer of gp33-specific CD8+ T cells from P14 
transgenic mice. We previously observed that adoptive transfer of P14 splenocytes during the 
first 2 days p.i. with RA59-gfp/gp33 can protect against disease; however, transfer on days 3 or 5 
p.i. neither protects nor enhances disease (20). Further analysis revealed that the P14 cells do 
not accumulate at the site of infection, the brain, when transferred at these later times; this result 
is in contrast to the dramatic accumulation of P14 cells within the brain when transferred early or 
prior to infection (20). We next aimed to determine the kinetics of CD8+ T cell priming and, 
importantly, whether CD8+ T cell priming was occurring during CNS infection with RJHM. 
Increasing the number of precursor cells by adoptive transfer allowed us to visualize CD8+ T cell 
expansion and proliferation, and cell proliferation was used as an indicator of CD8+ T cell 
priming. In this experiment, mice were inoculated with 10
4
 PFU of RA59, SJHM/RA59, or RJHM 
expressing gfp/gp33. The gfp/gp33-expressing viruses are attenuated relative to their respective 
parental viruses, thus allowing inoculation of higher doses. On days 1, 2, or 3 p.i., P14 
splenocytes were labeled with CFSE and transferred into the infected mice. At 3 days post-
transfer, cells were isolated from the spleen and cervical lymph nodes (CLN) and examined for 
CFSE dilution as an indicator of cell proliferation. Cells expressing low amounts of CFSE 
(CFSE
lo
) represent the divided population. 
 To analyze proliferation of the transferred P14 cells (CD45.2+), we used CD45.1+ mice 
as transfer recipients, thus allowing us to identify CD8+CD45.2+ cells as the transferred cells. 
The results of this experiment are shown in Fig. 3-2. As expected, the transferred cells did not 
proliferate and remained CFSE
hi
 in uninfected and RA59-gfp-infected animals (data not shown). 
During RA59-gfp/gp33 infection, when cells were transferred on day 1 p.i. and examined 3 days 
later, we observed that a significant number of the transferred CD8+CD45.2+ cells underwent 
several rounds of division in both the CLN and the spleen as indicated by dilution of CFSE (Fig. 
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3-2A). However, transfers performed on day 2 p.i. or later showed significantly lower percentages 
of proliferated cells, indicating that CD8+ T cells are primed within the first 2 days of RA59-
gfp/gp33 infection. Importantly, the absence of proliferating cells in the animals receiving transfer 
on day 3 p.i. was not due to their presence in another location, as we have already shown that 
transferred cells are not present in the brains of these recipients (20). Similarly, infection with the 
chimeric gp33-expressing virus SJHM/RA59-gfp/gp33 resulted in early and robust CD8+ T cell 
priming (Fig. 3-2B), consistent with the observation that this virus induces a strong CD8+ T cell 
response (Fig. 3-1). 
 In sharp contrast, infection with RJHM-gfp/gp33 resulted in a dramatically different 
proliferation profile. Interestingly, little to no proliferation was observed in the populations of cells 
transferred on days 1, 2, or 3 p.i. (Fig. 3-2C). Thus, priming of naïve, virus-specific CD8+ T cells 
is greatly reduced during RJHM-gfp/gp33 infection compared to both RA59-gfp/gp33 and 
SJHM/RA59-gfp/gp33 infections. Importantly, this reduced response was not due to a lack of 
gp33 expression during infection with RJHM-gfp/gp33 as sequencing of RNA from infected cells 
confirmed the presence of an intact gp33 sequence. Furthermore, EGFP, which is fused to the 
carboxyl terminus of the gp33 epitope, continued to be expressed for at least three days p.i. in 
mice (data not shown). 
       Reports indicate that CD8+ T cells are not infected by MHV in vivo (9); however, to confirm 
that donor CD8+CD45.2+ cells were not infected with the EGFP-expressing recombinant viruses 
(and thus contributing to the population of CFSE
lo
 cells), we harvested cells from the spleen and 
CLN of RA59-gfp/gp33- and RA59-gfp-infected animals that either did not receive adoptive 
transfer or received adoptive transfer of unlabeled P14 cells. As expected, these cells were 
negative for fluorescence in the FL1 channel (data not shown). Additionally, the experiments in 
Fig. 3-2 were repeated using an alternative dye, PKH26, that fluoresces in the FL2 channel to 
confirm that the divided CFSE
lo
 population did not include MHV-infected CD8+CD45.2+ cells 
(data not shown).  
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Figure 3-2. Kinetics of naïve CD8+ T cell priming. CD45.1+ mice inoculated i.c. with 10
4
 PFU 
gfp/gp33-expressing virus received adoptive transfer of CFSE-labeled P14 cells on days 1, 2, or 3 
p.i. Histograms represent transferred CD8+CD45.2+ T cells. The number in the upper left of each 
histogram indicates the percentage of transferred cells that have divided; in parentheses below is 
the proliferative index, which represents the average number of cell divisions that have occurred 
in the dividing population. Panels represent proliferation of transferred cells in mice infected with 
A) RA59-gfp/gp33, B) SJHM/RA59-gfp/gp33, or C) RJHM-gfp/gp33. The numbers to the left of 
each row indicate the days p.i. when cells were transferred/harvested. Each histogram represents 
data collected from a single mouse and is representative of the entire group (n=3). Data are 
representative of two independent experiments. 
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RJHM is not generally immunosuppressive. The induction of cytokines and chemokines in the 
brain has been shown to differ among different strains of MHV (34, 38). Based on these findings, 
we next investigated whether the RJHM-induced cytokine response could suppress the 
development of a virus-specific CD8+ T cell response to RA59. To determine which strain of MHV 
dominates the adaptive response, the weak CD8+ T cell inducer RJHM or the robust CD8+ T cell 
inducer RA59, we inoculated mice with both viral strains simultaneously and analyzed the CD8+ 
T cell response in the brain at day 7 p.i. (Fig. 3-3). 
 The RA59 strain of MHV expresses only the subdominant S598 epitope, whereas RJHM 
expresses both S598 and the immunodominant S510 epitope. While similar numbers of 
mononuclear cells were isolated per brain from mice infected with either RA59 or RJHM (9.3 # 
10
5
 versus 9.4 # 10
5
, respectively), the total number of CD8+ T cells per brain was approximately 
25-fold less in the RJHM-infected animals (1.6 # 10
5
 versus 6.6 # 10
3
) (Fig. 3-3). Furthermore, the 
S598-specific CD8+ T cells accounted for approximately 5% of the CD8+ T cells in RA59-infected 
mice, whereas RJHM infection resulted in minimal levels of S510- and S598-specific CD8+ T 
cells (Fig. 3-3). In contrast to infection with RJHM alone, co-infection with RA59 and RJHM 
resulted in significant recruitment of CD8+ T cells into the brain. While co-infected mice exhibited 
a robust response (similar to RA59 infection in both percentage and total number) to S598, the 
epitope expressed by both RA59 and RJHM, there was no appreciable response to the 
immunodominant S510 epitope expressed only by RJHM (Fig. 3-3). Thus, under these 
conditions, the ability of RA59 to elicit a robust, virus-specific CD8+ T cell response was dominant 
over the low CD8+ T cell response induced by RJHM. Importantly, the striking observation that 
co-infection did not result in an S510-specific CD8+ T cell response in the brain suggests that 
RJHM is unable to elicit a robust CD8+ T cell response even in the presence of immune 
mediators governing an adaptive immune response to RA59. 
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Figure 3-3. RJHM inoculation does not suppress the CD8+ T cell response elicited by 
RA59. Mice were inoculated i.c. with either 500 PFU RA59, 10 PFU RJHM, or both 500 PFU 
RA59 and 10 PFU RJHM; these doses represent approximately one LD50 of RJHM and less than 
one LD50 of RA59. Brain lymphocytes harvested on day 7 p.i. were stimulated with peptide and 
stained as in Fig. 3-1. The number in the upper right quadrant of each plot represents the 
percentage of CD8+ T cells that are epitope-specific as determined by IFN-! production. Data 
represent cells pooled from the brains of 4-6 animals per group and are representative of two 
independent experiments. The average numbers of live cells and CD8+ T cells harvested per 
brain are located above each column. 
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In addition to analyzing the virus-specific CD8+ T cell response in the brain, we also 
monitored survival in the co-infected mice. As shown in Fig. 3-4A, the majority of mice co-infected 
with RA59 and RJHM survived the infection, and those that died did so with slower kinetics 
compared to mice infected with RJHM alone, suggesting that some component of the host 
response elicited by RA59 is protective even in the context of infection with the destructive and 
highly lethal RJHM strain. To ensure that both viruses were indeed present within the brain and 
that preferential replication and spread of RA59 was not responsible for the RA59-like immune 
response, tissue homogenates were titrated for the presence of both RA59 and RJHM (Fig. 3-
4B). At day 4 p.i., which is close to the peak of virus replication in vivo, brains and CLN were 
harvested from co-infected mice. The CLN were evaluated to determine if both RA59- and RJHM-
infected cells were present at the site where CD8+ T cell priming is thought to occur during acute 
MHV infection of the CNS. 
 At day 4 p.i., viral titers in the brains of RA59-infected mice were significantly higher than 
titers in RJHM-infected brains (Fig. 3-4B). Interestingly, RA59 also replicated to relatively high 
titers in the CLN whereas RJHM titers were below the limit of detection (Fig. 3-4B). Titers 
observed in co-infected mice appeared to mirror the titers observed in mice infected with RA59 or 
RJHM alone (Fig. 3-4B). However, to confirm that both RA59 and RJHM were indeed replicating 
in the brains of co-infected animals, a neutralization assay was performed in which brain 
homogenates from co-infected animals were incubated with monoclonal antibodies specific for 
either the A59 spike (A2.1) or the JHM spike (J7.2 and J7.18) prior to performing standard plaque 
assays. This allowed selective detection of either RA59 or RJHM. While both RA59 and RJHM 
were present in the brains of co-infected animals, only RA59 replicated to measurable titers within 
the CLN (Fig. 3-4C). This difference in RA59 and RJHM replication in the draining CLN correlates 
with the difference in CD8+ T cell priming observed during these infections.  
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Figure 3-4. Survival and virus replication in co-infected mice. Mice were inoculated i.c. as 
described in Fig. 3-3. A) The survival of infected mice was monitored in 10 mice per group. Mice 
co-infected with RA59 and RJHM (open circles) displayed an intermediate survival phenotype 
compared to RJHM-infected mice (black squares) and RA59-infected mice (black diamonds). B) 
Virus replication in the brains and CLN of mice infected with RA59 (A; white bar), RJHM (J; black 
bar), or co-infected with RA59 and RJHM (C; gray bar) was examined in tissues harvested on day 
4 p.i. Tissue homogenates were titrated on L2 fibroblasts. Bars represent mean viral titers (3 mice 
per group), and error bars represent the standard error of the mean. C) Brain and CLN 
homogenates from co-infected animals were used in a neutralization assay using mAb specific for 
either the A59 spike (A2.1) or the JHM spike (J7.2 and J7.18). Tissue homogenates were 
incubated with a 1:10 dilution of anti-JHM Ab ($-J; white bar), anti-A59 Ab ($-A; black bar), or no 
Ab (N; gray bar) for one hour prior to performing standard plaque assays. (The CLN from all 
RJHM-infected mice had titers below the limit of detection.) 
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RJHM replicates poorly in the CLN compared to RA59 and SJHM/RA59. The difference in 
viral titers in the CLN of RA59- and RJHM-infected mice at day 4 p.i. (Fig. 3-4C) suggested that 
the poor CD8+ T cell priming during RJHM infection could be due, at least in part, to the absence 
of infectious virus in the CLN, the site of priming during acute MHV infection of the CNS.  Thus, 
we further compared the replication of RA59, SJHM/RA59, and RJHM in the draining CLN to 
determine if RJHM replicates in the CLN at early times post-infection when priming is thought to 
occur. Mice were infected with 50 PFU of RA59, SJHM/RA59, or RJHM, and infectious virus was 
titrated from brain and CLN homogenates on days 1-5 p.i. While all three viruses replicated 
efficiently in the brain during the course of five days p.i. (Fig. 3-5A), only RA59 and SJHM/RA59 
replicated to appreciable titers in the CLN during this time while RJHM replicated to only a 
minimal extent (Fig. 3-5B). Thus, the ability of these strains to prime an effective CD8+ T 
response correlates with the presence of infectious virus in the draining CLN. Interestingly, RJHM 
replication in the brain was lower than RA59 and SJHM/RA59 during the first two days p.i. (Fig. 3-
5A), the time during which priming occurs (Fig. 3-2). These data suggest that the minimal CD8+ T 
cell priming observed during RJHM infection of the CNS may be due to a lack of RJHM antigen in 
the CLN, the site of T cell priming during acute CNS infection. 
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Figure 3-5. RJHM replicates inefficiently in the draining cervical lymph nodes (CLN). Mice 
were inoculated with 50 PFU RA59 (white bars), SJHM/RA59 (gray bars), or RJHM (black bars). 
A) Brains and B) CLN were removed on days 1-5 p.i. and tissue homogenates were titrated on L2 
fibroblasts to assess viral replication. Bars represent mean viral titers (5 mice per group), and 
error bars represent the standard error of the mean. (Individual tissues with no measurable titer 
were assigned a log10 value of zero.) Data are representative of two independent experiments. 
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RJHM elicits a weak secondary CD8+ T cell response in the brain after immunization 
against a viral epitope. To further investigate the mechanism by which RJHM fails to elicit a 
robust CD8+ T cell response in the brain, we next asked whether RJHM infection could elicit a 
strong secondary response in the brain following peripheral immunization against a single viral 
epitope. Since the S510- and S598-specific CD8+ T cell responses differ for RA59 and RJHM, we 
instead utilized the gp33 epitope and the gfp/gp33-expressing MHV strains for this experiment. 
Immunization was performed using two recombinant Listeria monocytogenes (rLm) strains 
engineered to express either the gp33 epitope (expressed by recombinant gfp/gp33-expressing 
MHV strains) or the non-specific np118 epitope of LCMV (not expressed by these MHV strains). 
Mice were inoculated i.p. with 10
4
 CFU of rLm-gp33 or rLm-np118, rested for three weeks, and 
then challenged i.c. with approximately one LD50 of either RA59-gfp/gp33 or RJHM-gfp/gp33. 
Since a secondary immune response typically occurs more rapidly than a primary response, mice 
were sacrificed at day 5 p.i. and brain lymphocytes were analyzed to assess the magnitude of the 
CD8+ T cell response. While the average number of live cells per brain varied less than 2-fold 
among all groups, striking differences were observed in the number of CD8+ T cells per brain 
(Fig. 3-6A and 3-6B). While RA59-gfp/gp33-infected mice immunized with non-specific Listeria 
yielded approximately 9.66 # 10
4
 CD8+ T cells per brain at 5 days p.i. (representing 
approximately 8.09% of the live cells recovered), those mice immunized with rLm-gp33 showed a 
significantly greater response (3.51 # 10
5
 CD8+ T cells per brain,
 
representing approximately 
29.61% of live cells) (Fig. 3-6A). In sharp contrast, mice infected with RJHM-gfp/gp33 showed 
little to no difference in CD8+ T cell response following immunization with rLm-gp33 compared to 
non-specific Listeria (approximately 2.87% vs. 2.25% CD8+ T cells, respectively) (Fig. 3-6B). 
Importantly, the secondary CD8+ T cell response elicited by RJHM-gfp/gp33 following rLm-gp33 
immunization was significantly reduced compared to the secondary response elicited by RA59-
gfp/gp33, both in total number and percentage (2.87% vs. 29.61% CD8+ T cells, respectively) 
(Fig. 3-6A and 3-6B). Since the percentage of CD8+ T cells specific for gp33 was similar in all 
cases, the absolute number of gp33-specific CD8+ T cells elicited during the secondary response 
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to RJHM-gfp/gp33 was no greater than the response in mice immunized with non-specific Listeria 
and was significantly lower than the secondary response to RA59-gfp/gp33 (Fig. 3-6A and 3-6B). 
Thus, while RA59-gfp/gp33 induced a robust secondary response in the brain following peripheral 
immunization against a viral epitope, RJHM-gfp/gp33 was deficient in this ability.  
To verify that the lack of CD8+ T cell response in RJHM-gfp/gp33 infected mice following 
peripheral immunization was not due to poor replication of RJHM-gfp/gp33 in the brain, tissue 
homogenates from infected mice were titrated at day 5 p.i. As shown in Fig. 3-6C, RJHM-
gfp/gp33 replicated to higher titers than RA59-gfp/gp33 in the brains of infected mice, 
demonstrating that the poor secondary CD8+ T cell response to RJHM-gfp/gp33 is not due to 
poor viral replication in the brain. Furthermore, immunization with rLm-gp33 did not reduce the 
amount of replication in the brains of RJHM-gfp/gp33-infected mice compared to rLm-np118-
immunized mice (Fig. 3-6C); this is not surprising given the very small numbers of gp33-specific 
CD8+ T cells infiltrating the brain (Fig. 3-6B). There was, however, an approximately ten-fold 
reduction in RA59-gfp/gp33 titers (P = 0.04) when mice were immunized with rLm-gp33 
compared to rLm-np118, similar to what we have previously observed (6).  
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Figure 3-6. RJHM fails to elicit a robust secondary response in the brain following 
peripheral immunization against a viral epitope. Mice were inoculated with 10
4
 CFU rLm-
np118 or rLm-gp33 i.p., rested for 3 weeks, and then challenged i.c. with A) 10
5
 PFU RA59-
gfp/gp33 or B) 10
3
 PFU RJHM-gfp/gp33. Brain lymphocytes were harvested on day 5 p.i., 
stimulated with gp33 peptide, and stained as in Fig. 3-1. The number in the upper right quadrant 
of each plot represents the percentage of CD8+ T cells that are epitope-specific as determined by 
IFN-! production. Data represent cells pooled from the brains of 4-6 animals per group and are 
representative of three similar experiments. The average numbers of live cells and CD8+ T cells 
harvested per brain are located above each column. C) Virus replication in the brain was 
examined on day 5 p.i. Tissue homogenates were titrated on L2 fibroblasts. Bars represent mean 
viral titers (3 mice per group), and error bars represent the standard error of the mean (*P = 
0.04). 
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RJHM elicits a robust CD8+ T cell response in the spleen following peripheral inoculation. 
Since CNS infection with RJHM elicits a weak virus-specific CD8+ T cell response in the brain, 
we next aimed to determine if this feature was inherent to the virus or a unique characteristic of 
CNS infection. To address this issue, mice were inoculated with RA59, SJHM/RA59, or RJHM via 
the intraperitoneal (i.p.) route. Spleen lymphocytes were analyzed on day 8 p.i. (the peak of the 
CD8+ T cell response following this route of inoculation) to assess the magnitude of the 
response. As expected, i.p. inoculation with RA59 elicited a robust CD8+ T cell response to S598 
in the spleen (Fig. 3-7A). Interestingly, both SJHM/RA59 and RJHM elicited a robust response to 
epitopes S510 and S598 following i.p. inoculation (Fig. 3-7A). Total numbers of viable 
splenocytes per mouse as well as CD8+ T cells per spleen were not statistically different for any 
of the viruses examined (Fig. 3-7B). Similarly, no statistical difference was observed in total 
numbers of S510-specific (SJHM/RA59 and RJHM only) and S598-specific CD8+ T cells 
harvested per spleen (Fig. 3-7B). Thus, the RJHM strain of MHV induces a robust virus-specific 
CD8+ T cell response when inoculated i.p. This result is in sharp contrast to the response 
observed following CNS infection. 
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Figure 3-7. Intraperitoneal inoculation of RJHM elicits a robust CD8+ T cell response in the 
spleen. A) Spleen lymphocytes harvested on day 8 p.i. from mice inoculated i.p. with 10
4
 PFU 
RA59, SJHM/RA59, or RJHM were stimulated with peptide and stained as in Fig. 3-1. The 
number in the upper right quadrant of each plot represents the percentage of CD8+ T cells that 
are epitope-specific as determined by IFN-! production. Each column represents cells harvested 
from one individual mouse and is representative of the entire group (n=4). B) Total numbers of 
live cells, CD8+ T cells, and S510- and S598-specific CD8+ T cells per spleen were compared for 
each virus. Bars indicate the mean value for each group (n=4), and error bars represent the 
standard error of the mean. All P values were > 0.10, as determined by one-way analysis of 
variance. Data are representative of two independent experiments. 
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DISCUSSION 
 The presence of CD8+ T cells in the CNS during infection with neurotropic strains of 
MHV has been implicated in both protection and pathogenesis. While virus-specific CD8+ T cells 
likely contribute to the pathogenesis of demyelination through the secretion of macrophage-
recruiting cytokines (34), their role in protection and clearance of infectious virus appear to 
outweigh their detrimental effects. This protective role is illustrated by the remarkable 
susceptibility of "2-microglobulin-deficient mice to infection with RA59 (10). Furthermore, we 
speculate that the lethality of the highly neurovirulent RJHM strain of MHV may be due, at least in 
part, to the poor CD8+ T cell response elicited by this virus after i.c. (14) or i.n. inoculation (Fig. 3-
1). A similarly low CD8+ T cell response has been reported with MHV-4, a closely related JHM 
isolate (34). The data presented here suggest that during CNS infection RJHM is largely able to 
avoid CD8+ T cell priming and that this ability leads to the poor CD8+ T cell response observed in 
the brains of RJHM-infected mice. Importantly, this finding appears to be unique to CNS infection 
with RJHM, as i.p. inoculation resulted in a robust virus-specific CD8+ T cell response in the 
spleen (Fig. 3-7). Furthermore, the poor CD8+ T cell response during CNS infection with RJHM 
does not appear to be a function of disease severity as illustrated by i.n. infection (Fig. 3-1) and 
co-infection (Fig. 3-3), both of which were less severe than i.c. infection with RJHM alone. In 
addition, a chimeric recombinant expressing the A59 spike within the background of RJHM 
causes a very mild infection and still fails to induce a CD8+ T cell response (14). The poor CD8+ 
T cell response during CNS infection with RJHM also appears to be independent of viral dose as 
very high doses of RJHM-gfp/gp33 were used in the priming experiments (Fig. 3-2) and since 
doses as low as 20 PFU of RA59 i.c. induce a robust CD8+ T cell response in the brain (14).  
Since minimal priming of virus-specific CD8+ T cells was observed in RJHM-infected 
mice (Fig. 3-2), we further investigated whether activated CD8+ T cells transferred into RJHM-
gfp/gp33-infected mice could traffic to the infected CNS and protect against neurological disease. 
To this end, P14 splenocytes were transferred into B6 mice and activated in vivo with rLm-gp33. 
Activated P14 cells were then transferred to naïve B6 mice, and these recipients were infected 
with RA59-gfp/gp33 or RJHM-gfp/gp33. Analysis of brain lymphocytes on day 7 p.i. demonstrated 
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that activated P14 cells trafficked efficiently to the brains of RA59-gfp/gp33-infected mice while 
only small numbers of activated cells were present in the brains of RJHM-gfp/gp33-infected mice 
(data not shown). Furthermore, those RJHM-gfp/gp33-infected mice that received adoptive 
transfer of activated cells showed similar clinical signs and mortality as controls not receiving 
transfer (data not shown). While transfer of activated virus-specific CD8+ T cells was unable to 
protect mice from RJHM-induced neurological disease, such experiments are complicated by the 
low levels of T cell recruiting cytokines expressed in the brain following RJHM infection compared 
to RA59 infection (34, 38). Thus, RJHM may avoid the induction of a CD8+ T cell response in the 
brain due to both an inefficiency of priming and an inability to recruit activated cells to the CNS.  
Many studies have demonstrated that a robust adaptive immune response can be 
mounted to antigens expressed in the brain. While antigen presentation during some chronic 
infections can occur within the brain itself (24), the ability to recruit an adaptive immune response 
during acute CNS infection relies on antigen presentation in the draining CLN (15, 23, 25). 
Soluble antigen injected directly into the brains of mice reach the CLN within minutes to hours 
(11, 19). The development and migration of a protective CD8+ T cell response has been 
examined for several CNS infections and likely depends on the pathogenic organism. Mice 
infected with an attenuated variant of JHM (J2.2-V-1) that primarily infects glial cells were used to 
characterize the trafficking of CD8+ T cells into the CNS during acute infection (23). Interestingly, 
in contrast to the highly neurovirulent RJHM strain used in our studies, J2.2-V-1 induces a robust 
antiviral CD8+ T cell response. Similar to what we observe with RA59, CNS infection with J2.2-V-
1 results in a high percentage of virus-specific CD8+ T cells in the brain during the acute stage of 
disease. Using tetramers specific for the immunodominant S510 epitope, it was determined that 
the initial expansion of CD8+ T cells occurs in the CLN, followed by further expansion of virus-
specific CD8+ T cells in the spleen and eventual accumulation in the brain (23). In this model, 
only highly activated CD8+ T cells are evident in the brain. The data from our T cell priming 
experiments are in agreement with this finding, as only CFSE-negative P14 cells were detected in 
the brains of infected mice (data not shown).  
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 In a mouse model using ocular herpes simplex virus-1 (HSV-1) infection and the adoptive 
transfer of epitope-specific CD8+ T cells, the site of T cell priming was determined to be the 
submandibular lymph node (16). Interestingly, however, when cells are transferred one day prior 
to HSV-1 infection, proliferation cannot be detected until day 5 p.i.; these kinetics are delayed 
compared to what we observed during infection with RA59-gfp/gp33 (Fig. 3-2A) and raise the 
question as to what factors contribute to the kinetics of T cell priming. Important factors likely 
include the tropism of the infectious organism, the kinetics of infection, the route of inoculation, 
and the potential interactions of the infectious organism with antigen presenting cells (APC). Each 
of these factors may influence antigen distribution and availability, the rate at which APC 
encounter antigen and thus the length of time it takes them to interact with naïve CD8+ T cells, 
and/or the capacity of APC to present antigen and provide appropriate co-stimulation. The poor 
CD8+ T cell priming observed during acute infection with RJHM-gfp/gp33 compared to infection 
with RA59-gfp/gp33 (Fig. 3-2), the lack of response to S510 in mice co-infected with RA59 and 
RJHM (Fig. 3-3), and the inability of RJHM to elicit a robust secondary response in the brain (Fig. 
3-6) together suggest an inefficiency of RJHM antigen presentation that could potentially be due 
to viral effects on the APC and/or inaccessibility of RJHM antigen.  
 The data presented here support the hypothesis that the poor CD8+ T cell priming 
observed during RJHM infection of the CNS likely results from an inaccessibility of RJHM antigen 
to APC in the CLN rather than a direct effect on APC function. The data in Fig. 3-2 and Fig. 3-5 
show that the ability to prime a CD8+ T cell response correlates with viral replication in the CLN 
during the first 2 days p.i. when antigen presentation is taking place. RJHM replicates very poorly 
in the CLN compared with RA59 and SJHM/RA59 while all three viruses replicate to high titers in 
the brain. Furthermore, RJHM induces a robust CD8+ T cell response when inoculated i.p. (Fig. 
3-7). While little is known about the site of replication or the site of T cell priming following i.p. 
inoculation with MHV, dendritic cells (DC) are believed to be the relevant APC following this route 
of inoculation (43), thus arguing against an interaction of RJHM with DC that prevents priming. 
Furthermore, we compared the phenotype of DC present in the CLN of mice infected with RA59 
and RJHM on days 1-3 p.i. and were unable to detect any differences in DC activation despite an 
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increase in CD11c+ cells in the CLN of both RA59- and RJHM-infected mice (data not shown); 
this increase in CD11c+ cells was similar to that reported for CNS infection with an attenuated 
variant of JHM (J2.2-V-1) (42). Nevertheless, we cannot exclude the possibility that there may be 
other phenotypic or functional differences between DC from RA59- and RJHM-infected mice that 
could contribute to the differences in T cell priming. Finally, the observation that co-infected mice 
mount a robust CD8+ T cell response to RA59 even in the presence of RJHM infection (Fig. 3-3) 
indicates that RJHM is not generally immunosuppressive; thus, RJHM does not appear to alter 
the cytokine milieu in the brain or CLN in a way that compromises antigen presentation. 
We further speculate that a lack of antigen availability to APC in the CLN may be linked 
to the cellular tropism of RJHM. The highly neurovirulent RJHM strain of MHV disseminates 
widely in neurons throughout the brain (8), in contrast to RA59 and neuroattenuated JHM variants 
that infect a significant number of glial cells and induce a robust CD8+ T cell response. Indeed, 
we have observed that RJHM spreads more extensively than RA59 in primary neuronal cells in 
vitro (data not shown). Infected neurons are less likely to lyse and release viral antigen than other 
CNS cell types due to their ability to prevent apoptosis (reviewed in (2)), and cell-mediated lysis 
of infected neurons is limited by their low surface expression of MHC class I molecules. Thus, 
mechanisms that preserve neuronal integrity in the face of viral infection may limit the availability 
of RJHM antigen to be taken up and presented by APC via cross-presentation pathways. 
Furthermore, MHV may drain directly from the CNS to the CLN via lymphatics (1) where virus is 
then able to infect APC in the LN. It was recently shown that, following peripheral infection, both 
vaccinia virus and VSV rapidly reach the draining lymph nodes via lymphatics and infect DC, 
which then present antigen to T cells (12). While infectious RJHM is present in the brains of 
infected mice (Fig. 3-5 and 3-6), titers are comparatively low at early times p.i. when T cell 
priming takes place (Fig. 3-5). If RJHM is indeed highly neuronal, it may be highly cell associated 
as primary neurons infected in vitro produce less infectious virus than other CNS cell types (18, 
33). In contrast, RA59 replication in CNS cell types such as microglia/macrophages and 
astrocytes as well as its measurable replication in the draining CLN (Fig. 3-4 and 3-5) likely yields 
higher levels of viral antigen that can be processed for presentation by APC. Ongoing studies aim 
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to quantify the relative cellular tropisms of RA59 and RJHM, particularly at early times p.i. when T 
cell priming occurs. 
 The data presented here demonstrate that closely related neurotropic strains of MHV 
have a differential ability to induce a CD8+ T cell response during CNS infection. We suggest that 
the decreased ability of RJHM to induce a CD8+ T cell response in the brain leads to a lack of 
viral clearance and thus contributes to the high neurovirulence of RJHM compared to RA59. 
Notably, this feature appears to be unique to RJHM infection of the CNS, as i.p. inoculation of 
RJHM induces a robust CD8+ T cell response in the periphery. The precise mechanism by which 
RJHM avoids the induction of a protective antiviral CD8+ T cell response during CNS infection is 
an area of ongoing research. 
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CHAPTER 4 
 
Severity of CD8 T cell dysfunction during chronic viral infection in the brain and liver correlates 
with level of viral persistence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in preparation for submission to The Journal of Immunology as the article 
“Severity of CD8 T cell dysfunction during chronic viral infection in the brain and liver correlates 
with level of viral persistence” by S. J. Bender,* H. Shin,* S. D. Blackburn, K. C. MacNamara, S. 
R. Weiss, and E. J. Wherry. 
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ABSTRACT  
Clearance of acute viral infections typically results in the generation of highly functional memory 
CD8 T cells that provide long-lived protective immunity. However, during chronic viral infections, 
the differentiation of effector CD8 T cells into protective memory cells is altered, leading to 
progressive stages of T cell dysfunction. We, and others, have demonstrated in confined systems 
that the stage of CD8 T cell exhaustion correlates with viral load; however, this prediction has 
never been tested in a system comparing CD8 T cell responses to unrelated viruses expressing a 
common epitope. Here, we report a model system that allows direct comparison of acute LCMV 
Armstrong infection that is completely cleared, chronic LCMV clone 13 infection with high levels 
of viral replication, as well as infection with a murine coronavirus (MHV) characterized by low 
levels of persisting viral RNA accompanied by demyelination in the CNS. Importantly, since this 
recombinant MHV expresses the GP33 epitope of LCMV (MHV-GP33), we can directly compare 
antiviral CD8 T cell responses to these unrelated viruses via this shared epitope. Given the 
intermediate level of MHV persistence compared to acute versus chronic LCMV infection, we 
predict, and show data to support, that CD8 T cells maintained in the brain during MHV-GP33 
persistence are 1) functionally intermediate compared to cells maintained in the brains of 
Armstrong- or clone 13-infected mice and 2) less functional than CD8 T cells present in the liver, 
an organ where virus is cleared and MHV-GP33 does not persist. 
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INTRODUCTION 
 During an acute viral infection, naïve virus-specific CD8 T cells become activated and 
expand to form an antiviral effector CD8 T cell pool that functions to clear virus from the host. 
This clearance is largely mediated by antiviral cytokines, including IFN! and TNF", as well as 
cytotoxic molecules, such as perforin and granzymes, that cooperate to lyse infected target cells. 
As viral titers decline and viral antigen (Ag) is cleared, the majority of these antiviral effector T 
cells die by apoptosis while a subset of cells persists and continues to differentiate, forming a 
population of long-lived memory CD8 T cells. Optimal memory CD8 T cells are typically 
characterized by long-term self-renewal in the absence of Ag, mediated by IL-7 and IL-15, as well 
as rapid reactivation of effector functions and robust expansion following re-exposure to Ag (14, 
29, 37). Together, this set of properties allows memory CD8 T cells to confer long-term protective 
immunity. However, this pattern of CD8 T cell differentiation is markedly altered during viral 
persistence. 
 We have previously addressed the differentiation of CD8 T cells during viral persistence 
using the lymphocytic choriomeningitis virus (LCMV) model of chronic infection. Infection of mice 
with LCMV, an arenavirus, is commonly used to study antiviral T cell responses following acute 
versus chronic infection because different strains of this virus can be rapidly cleared or result in 
persisting infection. In adult mice, the Armstrong (Arm) strain of LCMV causes an acute infection 
that is successfully cleared by the host within 8-10 days post-infection (p.i.). Following viral 
clearance, a subset of virus-specific CD8 T cells differentiates into a population of highly 
functional memory cells that provide long-term protective immunity in the absence of viral Ag. In 
contrast, the clone 13 (Cl-13) strain of LCMV establishes a chronic infection in adult mice 
characterized by approximately 2 months of viremia, after which time viral replication is controlled 
in tissues such as the spleen and liver while high levels of infectious virus persist long-term in 
organs such as the kidney and brain (1, 22, 38). The virus-specific CD8 T cells present during 
chronic Cl-13 infection show signs of severe T cell dysfunction that lead to poor pathogen control. 
This loss of effector functions occurs in a hierarchical manner, with IL-2 production and cytolytic 
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functions disappearing first, followed by TNF" and then IFN! production (39). This functional 
impairment also correlates with increased expression of PD-1 on exhausted CD8 T cells (2). 
Furthermore, these CD8 T cells require the presence of viral Ag for maintenance during chronic 
infection rather than using IL-7 and IL-15 for homeostatic proliferation (31, 38). 
 Until now, comparative studies of CD8 T cell dysfunction during chronic infection have 
been limited to cross-virus comparisons of T cell responses to dissimilar epitopes or infections 
with an individual virus where viral loads are varied. We now describe a model system that allows 
direct comparison of CD8 T cell responses to a common epitope expressed by unrelated viruses 
with inherently different levels of persistence. Importantly, this system can be used to test our 
working model about the relationship between the level of virus persistence and the stages of T 
cell exhaustion during chronic viral disease. Using acute Arm and chronic Cl-13 infection as our 
standards, we have expanded our comparison to include persisting infection with a recombinant 
murine coronavirus (mouse hepatitis virus, MHV) expressing the GP33 epitope of LCMV (MHV-
GP33). In weanling mice, intracranial (i.c.) inoculation of MHV strain A59 results in acute infection 
in the liver and central nervous system (CNS). Viral titers peak by day 5 p.i., after which time 
infectious virus is cleared (24). Despite clearance of infectious virus, MHV RNA persists in the 
CNS long-term and demyelination, largely immune-mediated, develops and peaks around 4 
weeks p.i. (23). Previous studies assessing the protective capacity of GP33-specific CD8 T cell 
against MHV-GP33-induced demyelination showed that increasing the numbers of virus-specific 
T cells during acute infection correlates with decreased severity of demyelination; these virus-
specific CD8 T cells were maintained in the brain for at least one month following clearance of 
infectious virus (21). However, little is known about the differentiation state of these cells, how the 
amount of MHV persistence in different tissues impacts the functional quality or exhaustion of 
CD8 T cells responding to MHV infection, or how these cells compare to CD8 T cells responding 
to cleared versus other persisting infections.  
 Given the intermediate level of MHV persistence in the brain compared to cleared Arm 
and chronic Cl-13 infection, our model predicts an intermediate level of CD8 T cell dysfunction 
during persistent MHV-GP33 infection. Furthermore, the differences in MHV infection in the brain 
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versus liver (persisting infection versus viral clearance) would suggest that virus-specific CD8 T 
cells in the liver during late stages of infection will be more highly functional than cells in the brain, 
where viral RNA persists. Thus, using this model system, we can now begin to make direct 
comparisons regarding pattern and extent of virus persistence on the overall quality of antiviral 
CD8 T cells responding to an individual epitope that were not possible in previous systems. 
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MATERIALS AND METHODS 
Animals and viruses. Four- to six-week-old male C57BL/6 mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME) or National Cancer Institute (Frederick, MD). P14 
transgenic mice bearing a TCR specific for the GP33-41 (GP33) epitope of LCMV (27) were 
maintained on a Ly5.1
+
 background at The Wistar Institute. To generate P14 chimeras, small 
numbers (5-7.5#10
4
 for Arm and MHV-GP33 infections, 2-5#10
3 
for Cl-13) of naïve P14 CD8 T 
cells (Ly5.1
+
) were adoptively transferred i.v. to congenic C57BL/6 mice (Ly5.2
+
). P14 chimeras 
were subsequently inoculated with 2#10
5
 PFUs of LCMV Armstrong (Arm) i.p., 2#10
6
 PFUs 
LCMV clone-13 (Cl-13) i.v., or intracranially (i.c.) with 1#10
4
 PFUs of recombinant MHV strain 
A59 expressing the GP33 epitope fused to enhanced green fluorescent protein in place of 
nonessential gene 4 (MHV-GP33) (previously referred to as RA59-gfp/gp33) (4) as described (1, 
20, 39). Viruses were grown and titrated by plaque assay as previously described (1, 6). All mice 
were used in accordance with Institutional Animal Care and Use Committee guidelines. 
Quantitative RT-PCR. RNA was isolated from MHV-GP33-infected tissues by homogenization in 
TRIzol reagent (Invitrogen) followed by phenol/chloroform extraction and purification using an 
RNeasy Kit (Qiagen) then DNase treated using a Turbo DNA-free Kit (Ambion) as previously 
described (30). Quantitative PCR was performed in the absence of reverse transcriptase to 
ensure adequate removal of genomic DNA. For cDNA synthesis, 1 µg RNA was combined with 
0.5 mM dNTP mix and 50 ng random hexamers (Invitrogen) in a total volume of 13 µL, heated to 
65°C for 3 minutes, and cooled to room temperature. 1X First Strand Buffer, 5 mM DTT, and 200 
U SuperScript III Reverse Transcriptase (Invitrogen) were added for a final reaction volume of 20 
µL and the mixture was heated to 50°C for 60 minutes followed by 70°C for 15 minutes. 
Quantitative PCR reactions were performed in duplicate in an iQ5 iCycler (Bio-Rad) using 2 µL 
cDNA, 12.5 µL iQ SYBR Green Supermix (Bio-Rad), and 0.4 µM forward and reverse primers in a 
total volume of 25 µL. MHV genome primers (forward 5’-ATGGCGTCTACATTAACACGAC-3’, 
reverse 5’-TTACCTTGTGGGCTCCGGTA-3’) amplified a conserved region of ORF1b. MHV 
GP33 primers (forward 5’-GACGATGGCCGTGTTGGTCCT-3’, reverse 5’-
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GGTGGCGACCGGTGGATCCGG-3’) amplified a region of gene 4 containing the GP33 
sequence. Mouse beta-actin primers (forward 5’-CAGATGTGGATCAGCAAGCAGGA-3’, reverse 
5’-CGCAGCTCAGTAACAGTCCGCCTA-3’) were used as a normalization control. Cycle 
threshold (CT) values for MHV genome and GP33 were normalized to mouse beta-actin levels, 
resulting in $CT values [$CT = CT(target) – CT(beta-actin)]. $$CT values were then calculated [$$CT = 
$CT(infected) – $CT(mock)] and results are expressed as fold change over mock-infected tissues       
(2
-$$C
T). 
Lymphocyte isolation and flow cytometry. Lymphocyte isolation from lymphoid and 
nonlymphoid tissues, surface staining, and intracellular cytokine staining (ICS) were performed as 
previously described (2, 38, 39). Briefly, lymphocytes were isolated from spleen by mechanical 
disruption through nylon mesh followed by lysis of RBCs. Lymphocytes were isolated from liver 
by mechanical disruption through nylon mesh and separation on a 44/56% Percoll gradient, 
followed by lysis of RBCs. Lymphocytes were isolated from brain by mechanical disruption 
through nylon mesh and separation on a 35/70% Percoll gradient. PBMCs were isolated from 
blood using Histopaque 1083 (Sigma). Data in Fig. 4-2 and 4-3 represent lymphocytes pooled 
from multiple animals. Data in Fig. 4-4 represent lymphocytes isolated from individual animals. All 
antibodies were purchased from Biolegend except for CD127, TNF", IL-2 (eBioscience), and 
granzyme B (Caltag). LIVE/DEAD dead-cell stain was purchased from Invitrogen. MHC class I 
tetramers of H-2D
b
 complexed with GP33 peptide were made and used as previously described 
(39). All flow cytometry data were acquired on an LSRII flow cytometer (BD Biosciences) and 
analyzed with FlowJo software (Treestar).  
Adoptive transfers and bacterial challenge. Approximately 30 days after viral infection, donor 
lymphocytes from LCMV- or MHV-GP33-infected brain, liver, or spleen were adoptively 
transferred i.v. to C57BL/6 recipient mice. In each individual experiment, identical numbers of 
D
b
GP33 tetramer
+
 CD8 T cells were adoptively transferred to each recipient mouse. Recipient 
mice were subsequently challenged i.v. with recombinant Listeria monocytogenes strain XFL203 
expressing the GP33 epitope of LCMV (LM-GP33) (11) and T cells were analyzed at 5-7 days p.i. 
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RESULTS 
LCMV Cl-13 and MHV-GP33 are chronic viral infections. To investigate the impact of different 
types of viral persistence on the quality of antiviral CD8 T cells, we utilized two strains of LCMV, 
Arm and Cl-13, and a recombinant MHV expressing the GP33 epitope (MHV-GP33) (4). Arm 
causes acute infection in adult mice that is completely cleared within 8-10 days post infection 
(p.i.) (1, 16, 39), whereas Cl-13 establishes chronic infection with viremia lasting approximately 2 
months p.i. (1, 39). MHV persistence, characterized by the maintenance of viral RNA in the brain 
but not in the liver (18, 19), is intermediate compared to Arm and Cl-13 and thus provides an 
important comparison in terms of CD8 T cell quality and viral load. To facilitate our T cell 
analyses, adult C57BL/6 mice received adoptive transfer of 5#104 naïve P14 CD8 T cells prior to 
virus infection (referred to here as P14 chimeras). Therefore, we first aimed to confirm the 
persistence of MHV-GP33 in this model. 
To evaluate viral persistence, P14 chimeras were inoculated i.c. with 1#10
4
 PFUs of 
MHV-GP33 and sacrificed on days 3, 14, 21, and 28 p.i. Spleen, liver, and brain tissue were 
divided in half to provide paired samples for virus titration and RNA analysis. Standard plaque 
assays were performed to quantify infectious virus in tissue homogenates. As shown in Fig. 4-1A, 
infectious MHV-GP33 was recovered from both liver and brain on day 3 p.i. By day 14 p.i., 
infectious virus was eliminated from the liver and had declined to relatively low titers in the brain 
(Fig. 4-1A). As expected, no infectious virus was detected in any of the organs at days 21 and 28 
p.i. (Fig. 4-1A). Though wild-type MHV has been shown to replicate at low levels in the spleen 
(17), no infectious virus was detected in spleens of P14 chimeras infected with MHV-GP33 at the 
times shown (Fig. 4-1A). Since viral RNA typically persists in the brain following clearance of 
infectious virus, we next performed quantitative RT-PCR (qRT-PCR) to evaluate levels of MHV 
genome and the genome region encoding GP33. Using primers designed to a conserved region 
of the MHV replicase gene, viral genome was detected in both liver and brain at day 3 p.i. (Fig. 4-
1B). By day 14 p.i., viral genome levels remained elevated in the brain but were no longer 
detectable in the liver (Fig. 4-1B). Despite a gradual decline, genomic RNA remained detectable 
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in the brain by day 28 p.i. In contrast, viral genome levels in the liver were no longer detectable 
(Fig. 4-1B). We have previously shown that GP33 epitope immunization prior to MHV-GP33 
infection provides high selective pressure that results in mutation and/or deletion of the viral 
GP33 epitope during the acute stage of infection (4); similar results were observed when large 
numbers of P14 CD8 T cells (2#10
7
/mouse) were adoptively transferred prior to viral infection. To 
determine if the GP33 region of the genome remained intact during the course of MHV-GP33 
infection in our system, we designed qRT-PCR primers to amplify the region of gene 4 
surrounding the GP33 sequence. As shown in Fig. 4-1B, the pattern of GP33 expression 
paralleled that of MHV genome. While nucleotide sequencing of these qRT-PCR products 
revealed an intact consensus sequence (data not shown), we cannot exclude the possibility of 
point mutations in the GP33 RNA sequence. However, agarose gel electrophoresis of the qRT-
PCR products revealed no significant changes in product size (data not shown), indicating that no 
gross deletions had occurred in the region encoding the GP33 epitope.  
For comparison, we evaluated the replication of Cl-13 in the spleen, liver, and brain at 
early and late times p.i. by plaque assay of tissue homogenates. Wild-type mice were inoculated 
with LCMV Cl-13 and sacrificed on days 8 and 42 p.i. As expected, infectious Cl-13 was detected 
at high levels in all three tissues both early and late after infection (Fig. 4-1C). Notably, Cl-13 
titers in the brain were considerably higher than titers in the liver at this late timepoint (Fig. 4-1C). 
In contrast, LCMV Arm is rapidly cleared from all tissues tested by day 8 p.i. (Fig. 4-1D); while 
viral RNA might be detectable for a short time after day 8 (25), there is no evidence for long-term 
persistence of LCMV Arm viral RNA (16). These data confirm that MHV-GP33 and Cl-13 
establish vastly different levels of persistence in the mouse. Thus, we now have a model system 
with which to compare virus-specific CD8 T cell responses to different viruses exhibiting high, 
low, or no viral persistence and to evaluate the impact of viral persistence on CD8 T cell 
responses in different tissues. 
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Figure 4-1. MHV-GP33 and LCMV Cl-13 are chronic viral infections. A) 5#10
5
 naïve T cells 
from Ly5.1
+
 P14 Tg mice were adoptively transferred to congenic naïve recipients. Recipients 
were then infected with MHV-GP33. Viral titers were measured in multiple tissues by plaque 
assay of tissue homogenates at the indicated days p.i. (n=3-5). B) Quantitative RT-PCR for total 
viral genome and GP33 in liver and brain during MHV-GP33 infection. C-D) Naïve mice were 
infected with Cl-13 (C) or Arm (D). Viral titers in multiple tissues were determined by plaque 
assay at the indicated days p.i. (n=7-8).  
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CD8 T cell phenotype correlates with level of viral persistence. To assess the effect of virus 
persistence on CD8 T cell differentiation, we next examined the differentiation state of virus-
specific CD8 T cells at 30 days p.i. This timepoint was chosen to allow comparison of CD8 T cells 
in mice that had fully cleared Arm infection, mice chronically infected with Cl-13, and mice that 
had cleared infectious MHV-GP33 but had persisting viral RNA in the brain (Fig. 4-1). As shown 
in Fig. 4-2A, D
b
GP33 tetramer
+
 CD8 T cells were detected in spleen, liver, and brain of virus-
infected P14 chimeras. As expected, these cells were predominantly CD44
Hi
, indicative of prior 
activation (Fig. 4-2A). The frequency of tetramer
+
 CD8 T cells in the brain following Arm and 
MHV-GP33 infection was similar at approximately 40% of total CD8 T cells (Fig. 4-2A). In 
contrast, however, the frequency of D
b
GP33-specific CD8 T cells in the spleen and liver of MHV-
GP33-infected mice was substantially lower than for Arm-immune mice (Fig. 4-2A). The 
frequency of D
b
GP33-specific CD8 T cells in the brains of Cl-13-infected mice was slightly lower 
than in Arm- or MHV-GP33-infected mice, while the frequencies of D
b
GP33-specific cells in the 
spleen and liver of Cl-13 infected mice were intermediate between Arm- and MHV-GP33-infected 
mice.  Some of the differences in virus-specific CD8 T cell frequencies between Cl-13- versus 
Arm- or MHV-GP33-infected mice could reflect the lower number of P14 CD8 T cells initially 
transferred.  In contrast, the MHV-GP33- and Arm-infected mice received the same number of 
naïve P14 cells, suggesting different dynamics and tissue distribution of the virus-specific CD8 T 
cell responses (for cells responding to the same epitope) following these infections. The number 
of virus-specific CD8 T cells in the spleens of MHV-GP33-infected mice was relatively low 
compared to other tissues.  In all cases, however, a substantial number of virus-specific CD8 T 
cells were present in the brain and liver, allowing qualitative comparisons of antiviral CD8 T cells 
generated during these different infections.   
 To begin to investigate the activation and differentiation state of virus-specific CD8 T cells 
following LCMV Arm, Cl-13, or MHV-GP33 infection, we first examined expression of CD69, an 
early activation marker that is highly expressed on virus-specific CD8 T cells in the brain at late 
times p.i. with other neurotropic viruses such as dengue virus, influenza virus, and the MHV 
variant J2.2-V-1 (3, 7, 33). As shown in Fig. 4-2B, tetramer
+
 CD8 T cells isolated from the liver of 
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Arm- and MHV-GP33-infected mice were predominantly negative for CD69 expression while most 
tetramer
+
 cells in Cl-13 liver expressed low levels of CD69. In contrast, tetramer
+
 CD8 T cells 
isolated from the MHV-GP33-infected brain more closely resembled cells isolated from Cl-13-
animals rather than Arm-immune mice, with the majority of tetramer
+
 cells in both persisting 
infections expressing high levels of CD69 while the Arm-immune CD8 T cells were largely CD69
Lo
 
(Fig. 4-2B). These data correlate with the level of MHV-GP33 and Cl-13 persistence in these 
organs; in the liver where infectious MHV-GP33 and viral RNA are cleared, MHV-GP33-primed 
CD8 T cells more closely resemble Arm-immune cells whereas in the brain where viral RNA 
persists CD8 T cells appear more like cells in Cl-13-infected brain, even though the level of MHV-
GP33 versus Cl-13 persistence in the brain is different.  It should be noted that CD69 expression 
could reflect persisting antigen stimulation but also might indicate ongoing inflammation at the site 
of viral persistence (41). Also, the consequence of expressing CD69 on virus-specific CD8 T cells 
in the brain, for example inhibition of S1P1-mediated egress (32), could have important 
implications.  
The transition of CD8 T cells from effector to memory cells is typically associated with 
alterations in cell surface molecule expression. We next evaluated surface expression of killer cell 
lectin-like receptor G1 (KLRG1), CD127, and CD62L on virus-specific CD8 T cells in the liver and 
brain on day 30 p.i.  High expression of KLRG1 and low CD127 has been demonstrated on short-
lived effector cells during resolution of LCMV Arm infection (10). Conversely, high level 
expression of CD127, the homeostatic cytokine IL-7 receptor alpha (IL-7R") chain, and low 
KLRG1 is associated with memory precursor CD8 T cells that have the capacity to differentiate 
into long-lived memory CD8 T cells (9, 13, 28). The lymphoid homing molecule L-selectin 
(CD62L) is also upregulated as CD8 T cells transition from effector to memory (8).  During Cl-13 
infection, in contrast, virus-specific CD8 T cells remain CD127
Lo 
and CD62L
Lo
 long-term, but also, 
despite exhibiting some characteristics of terminal differentiation, these cells do not express 
KLRG1 (35). As with CD69 expression, D
b
GP33 tetramer
+
 CD8 T cells isolated from MHV-GP33-
infected liver were phenotypically similar to cells isolated from LCMV Arm-immune liver with 
regards to KLRG1, CD127, and CD62L expression (Fig. 4-2C). Approximately 39% of the 
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tetramer
+
 cells in Arm- and MHV-GP33-infected liver were KLRG1
+
 compared to only 7% in Cl-
13-infected liver (Fig. 4-2C). Strikingly, nearly 70% of the tetramer
+
 cells in Arm- and MHV-GP33-
infected liver expressed CD127 compared to only 39% in Cl-13-infected liver and the overall MFI 
was substantially lower during Cl-13 infection (Fig. 4-2C). Furthermore, roughly 10% of the 
tetramer
+
 cells in Arm- and MHV-GP33-infected liver had upregulated CD62L on the cell surface 
whereas only 2% were CD62L
+
 in Cl-13-infected liver (Fig. 4-2C). 
Interestingly, a different pattern of surface expression was observed in MHV-GP33-
infected brain compared to liver (Fig. 4-2C and 4-2D). While over 55% of the tetramer
+
 cells in 
LCMV Arm-immune brain were KLRG1
+
, only 1-4% of the tetramer
+
 cells were positive for 
KLRG1 in Cl-13- and MHV-GP33-infected brain (Fig. 4-2D). Similar results were observed for 
CD62L, with 2-4% of tetramer
+
 cells being positive in Cl-13- and MHV-GP33-infected brain 
compared to over 7% in Arm-immune brain (Fig. 4-2D). Curiously, the majority of the tetramer
+
 
cells in MHV-GP33-infected brain expressed high levels of CD127 similar to cells isolated from 
Arm-immune brain (Fig. 4-2D). This intermediate surface phenotype of cells in MHV-GP33-
infected brain compared to tissues infected with Arm and Cl-13 correlates with the intermediate 
level of viral persistence and inflammation/demyelination present during this stage of MHV-GP33 
infection. 
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Figure 4-2. Antigen-specific CD8 T cells responding to MHV-GP33 or LCMV infection follow 
distinct differentiation pathways. 5#10
5
 naive CD8 T cells from Ly5.1
+
 P14 Tg mice were 
adoptively transferred to congenic naïve recipients. Recipients were infected with LCMV Arm, Cl-
13, or MHV-GP33. Data represent pooled cells isolated from the indicated tissues at 30 days p.i. 
A) Frequency of donor antigen-specific CD8 T cells in multiple tissues during MHV-GP33 or 
LCMV infection. Frequencies of D
b
GP33-specific CD8 T cells were measured in the indicated 
tissues at 30 days p.i. All plots are gated on total CD8 T cells. Numbers in plots show the 
percentage of total CD8 T cells that are D
b
GP33
+
. B) CD69 expression on donor antigen-specific 
CD8 T cells during MHV-GP33 or LCMV infection. CD69 expression on D
b
GP33-specific CD8 T 
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cells isolated from the indicated tissues at 30 days p.i. was quantified. All plots are gated on total 
CD8 T cells. Numbers in plots show the percentage of D
b
GP33-specific CD8 T cells that are 
CD69
+
. C-D) Phenotype of antigen-specific CD8 T cells during MHV-GP33 or LCMV infection. 
Expression of indicated markers was measured on cells isolated from the liver (C) or brain (D) at 
30 days p.i. Plots are gated on total CD8 T cells. Numbers in each plot indicate the percentage of 
D
b
GP33-specific CD8 T cells that are positive for each indicated marker. For all panels, plots are 
representative of 5 independent experiments. 
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CD8 T cell functionality is slightly impaired during MHV-GP33 persistence. A prediction from 
models about T cell exhaustion during chronic viral infections is that the level of viral and/or 
antigen persistence impacts the severity of T cell dysfunction; that is, the hierarchical stages of 
exhaustion get progressively worse as viral and/or antigen burden increases.  However, these 
models are based largely on examining T cells responding to different viral loads for the same 
infection or by comparing responses to different epitopes during different viral infections.  Using 
the MHV-GP33 versus LCMV Arm and Cl-13 system outlined here, we next examined whether 
the differences in memory CD8 T cell differentiation and phenotype also corresponded to different 
functional properties or stages of exhaustion.  Typically, during T cell exhaustion, functional 
properties are lost in a hierarchical manner as viral/antigen load increases, with the ability to 
secrete IL-2 lost early followed successively by defects in efficient cytoxicity, robust proliferative 
capacity and TNF" production, and, finally, compromised production of IFN! and chemokines 
such a MIP1-" or -% (39).  An increase in expression of the inhibitory receptor PD-1, and other 
inhibitory receptors, is also associated with increasing severity of exhaustion (5).  Therefore, we 
evaluated expression of these cytokines, as well as granzyme B and PD-1, in CD8 T cells from 
the liver following
 
GP33 peptide stimulation. As shown in Fig. 4-3A and 4-3B, the majority of IFN!
+
 
cells in liver of Arm-immune mice also expressed TNF" whereas most IFN!
+
 cells from Cl-13-
infected mice failed to produce TNF".  CD8 T cells in the MHV-GP33-infected liver, though 
intermediate with respect to IFN!/TNF" co-production, more closely resembled cells from Arm-
immune mice (Fig. 4-3A and 4-3B). A similar pattern was observed in the brain, with GP33-
specific CD8 T cells from MHV-GP33-infected mice being intermediate between GP33-specific 
cells from Arm- or Cl-13-infected brain; however, cells in MHV-GP33-infected brain were more 
similar to cells in Arm-immune brain than to CD8 T cells present during Cl-13 infection.  In terms 
of IL-2 expression, the percentage of IFN!
+
 cells in MHV-GP33-infected tissues that were also 
positive for IL-2 was again intermediate between Arm and Cl-13 (Fig. 4-3A and 4-3B), suggesting 
a partial loss of function during MHV-GP33 persistence. Thus, as with cell phenotype, MHV-GP33 
was again intermediate between Arm and Cl-13 in terms of cytokine production by GP33-specific 
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CD8 T cells, further supporting our model that viral persistence contributes to CD8 T cell 
dysfunction during chronic infection. 
We also evaluated intracellular levels of granzyme B in D
b
GP33 tetramer
+
 cells from liver 
and brain. As CD8 T cells differentiate from effector cells to resting memory cells, they 
downregulate expression of cytotoxic molecules including granzyme B (12). However, during 
chronic LCMV infection, granzyme B expression is sustained, though killing in some assays (e.g. 
51
Cr-release) is compromised in some settings. As expected, the lowest percentages of tetramer
+
 
cells that were positive for granzyme B (approximately 39%) were observed in the liver and brain 
of Arm-immune mice (Fig. 4-3D). Consistent with ongoing viral replication, a larger percentage of 
tetramer
+
 cells in Cl-13-infected liver and brain (52-57%) expressed granzyme B (Fig. 4-3D). 
Interestingly, while granzyme B expression in MHV-GP33-infected liver cells was similar to cells 
from Arm-immune liver, over 85% of the tetramer
+
 cells from MHV-GP33-infected brain continued 
to express granzyme B (Fig. 4-3D). The elevated granzyme B levels in cells from MHV-GP33-
infected brain even compared to CD8 T cells in Cl-13-infected brain could suggest additional 
defects in degranulation, resulting in retention of granzyme B within the cell. Thus, CD8 T cells 
retained in the brain during MHV-GP33 persistence appear more similar to the dysfunctional cells 
present during chronic Cl-13 infection, lending additional support to the proposed link between 
virus persistence and T cell dysfunction.  
Given the important role for inhibitory receptors during persisting viral infections (2, 5), we 
next assessed expression of PD-1 on the D
b
GP33 tetramer
+
 cells. Previous studies show high 
levels of PD-1 on the surface of exhausted CD8 T cells during chronic LCMV Cl-13 infection 
compared to functional memory cells present in Arm-immune mice (2). As expected, the mean 
fluorescence intensity (MFI) of PD-1 on tetramer
+
 cells from Cl-13-infected liver and brain was 
significantly higher (>100-fold) compared to cells from Arm-immune mice (Fig. 4-3E). 
Interestingly, D
b
GP33
+
 CD8 T cells from MHV-GP33-infected liver expressed a similar amount of 
PD-1 compared to D
b
GP33
+
 CD8 T cells from the livers of Arm-immune mice.  In contrast, the 
PD-1 MFI of D
b
GP33
+
 CD8 T cells in the brains of MHV-GP33-infected mice was increased 
approximately 5-fold compared to the D
b
GP33
+
 CD8 T cells from Arm-immune animals (Fig. 4-
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3E).  This PD-1 expression profile is consistent with the modest functional defects illustrated 
above.  Notably, the MHV-GP33-primed D
b
GP33-specific CD8 T cells are largely functional, and 
any modest compromise of their functional capacity has only been revealed through direct 
comparison to CD8 T cells responding to the same epitope following LCMV Arm infection, further 
emphasizing the utility of this model for identifying subtle alterations in T cell quality. 
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Figure 4-3.  Antigen-specific CD8 T cells do not become exhausted during chronic MHV-
GP33 infection. 5#10
5
 naïve splenocytes from Ly5.1
+
 P14 Tg mice were adoptively transferred to 
congenic naïve recipients.  Recipients were infected with LCMV Arm, Cl-13, or MHV-GP33. Data 
represent pooled cells isolated from the indicated tissues at 30 days p.i. A-B) Cytokine production 
by antigen-specific CD8 T cells.  Cells isolated from the liver (A) or brain (B) at 30 days p.i. were 
stimulated with GP33 peptide for 5 hours. Plots are gated on total CD8 T cells. Numbers in plots 
show the percentage of IFN!
+
 CD8 T cells that co-produce the second indicated cytokine. Data 
are representative of 3 independent experiments. C) Cytokine production by antigen-specific CD8 
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T cells.  Graphs show co-production of IFN! and TNF" (top) or IFN! and IL-2 (bottom) after 
stimulation with GP33 peptide.  Data are representative of 3 independent experiments.  D) 
Cytotoxicity of antigen-specific CD8 T cells.  Granzyme B expression was measured in D
b
GP33-
specific CD8 T cells isolated from the indicated tissues at 30 days p.i. Plots are gated on total 
CD8 T cells.  Numbers in plots show the percentage of D
b
GP33-specific CD8 T cells that are 
granzyme B
Hi
. E) Inhibitory receptor expression on antigen-specific CD8 T cells.  Amount of PD-1 
expression on D
b
GP33-specific CD8 T cells isolated from the indicated tissues was measured at 
30 days p.i.  Data are representative of 5 independent experiments.  
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Antigen-specific CD8 T cells isolated during chronic MHV-GP33 infection proliferate in 
response to pathogen rechallenge. The data in Fig. 4-2 and 4-3 suggest that GP33-specific 
CD8 T cells isolated from the liver and brain at day 30 p.i. with MHV-GP33 are intermediate in 
phenotype and function compared to cells present during Arm and Cl-13 infections, though they 
appear to fall toward the Arm end of the spectrum in terms of low viral persistence and high 
functional capacity. Furthermore, cells isolated from the brains of MHV-GP33-infected mice 
appear slightly more impaired than cells isolated from the liver of the same mice, consistent with 
viral RNA and inflammation in the brain tissue. We therefore wanted to compare GP33-specific 
CD8 T cells from the different infections and different tissues in terms of their ability to mount a 
recall response upon challenge infection. As outlined in Fig. 4-4A, P14 chimeras were infected 
with LCMV Arm, Cl-13, or MHV-GP33. At day 30 p.i., donor lymphocytes were harvested from 
spleen, liver, and brain, the number of D
b
GP33-specific CD8 T cells was normalized, and 1#10
4
 
Ly5.1
+
 D
b
GP33 tetramer
+
 CD8 T cells were adoptively transferred i.v. to naïve Ly5.2
+
 C57BL/6 
recipients. Recipient mice were subsequently challenged i.v. with Listeria monocytogenes 
expressing the GP33 epitope (LM-GP33) (11). At day 7 post-challenge, lymphocytes were 
isolated from the spleen, liver, and peripheral blood of the challenged recipients and analyzed by 
flow cytometry for quantification of total cells. As expected, donor GP33-specific CD8 T cells 
isolated from the spleen of Arm-immune mice at day 30 p.i. proliferated to high levels when 
challenged with LM-GP33, with donor GP33-specific
 
cells comprising roughly 1.6% of total CD8 T 
cells in the recipient liver (Fig. 4-4B). In sharp contrast, donor GP33-specific
 
CD8 T cells isolated 
from Cl-13-infected spleen only constituted 0.04% of total CD8 T cells in the recipient liver (Fig. 4-
4B). Interestingly, comparison of MHV-GP33 donor cells again revealed intermediate results, with 
MHV-GP33 donor cells comprising a greater percentage of total CD8 T cells in the recipient liver 
than Cl-13 donor cells regardless of whether the MHV-GP33- and Cl-13-derived D
b
GP33-specific 
CD8 T cells were from the liver or brain (Fig. 4-4B).   However, the D
b
GP33
+
 CD8 T cells from 
brain and liver of MHV-GP33-infected mice did not expand as well as the D
b
GP33-specific CD8 T 
cells from the spleen of Arm-immune mice.  It is possible that some of the differences between 
MHV-GP33- and Arm-derived D
b
GP33-specific CD8 T cells reflect differences between CD8 T 
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cells from the liver versus spleen, but Arm-immune CD8 T cells from the liver and spleen have 
relatively modest differences in phenotype and function at day 30 p.i. (data not shown). 
 To more rigorously assess donor cell proliferation in response to LM-GP33 challenge, the 
absolute number of responding P14 cells from MHV-GP33-infected mice was quantified in the 
recipient spleen and liver and normalized to the number of responding P14 cells from Arm-
immune spleen. As shown in Fig. 4-4C, donor GP33-specific
 
CD8 T cells isolated from MHV-
GP33-infected liver and brain proliferated to similar levels in both compartments examined. Thus, 
GP33-specific CD8 T cells maintained during MHV-GP33 persistence retain the ability to 
proliferate in response to Ag re-exposure but are slightly impaired compared to cells from Arm-
immune mice. Taken together, our data fit well with our working model that the amount of viral 
persistence dictates the severity of CD8 T cell dysfunction during chronic infection. Thus, MHV-
GP33, which persists at a low level in the brain but not in the liver, has only a modest impact on 
the overall functionality of antiviral CD8 T cells and would thus be positioned closer to Arm than to 
Cl-13 on a spectrum of persistence as well as CD8 T cell impairment. 
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Figure 4-4.  Antigen-specific CD8 T cells isolated during chronic MHV-GP33 infection 
proliferate well in response to pathogen rechallenge. A) Schematic of experiment. 5#10
5
 
naïve T cells from Ly5.1
+
 P14 Tg mice were adoptively transferred to congenic naïve recipients 
that were subsequently infected with Arm, Cl-13, or MHV-GP33. At 30 days p.i., donor P14 T 
cells were isolated from tissues, pooled from multiple mice, and adoptively transferred to naïve 
recipients (1#10
4
 P14/mouse) that were subsequently challenged with LM-GP33.  Donor P14 T 
cells were quantified in spleen, liver, and PBMC at day 7 post-challenge. B) Plots show the 
population of Ly5.1
+
 P14 donor CD8 T cells in recipient liver. Numbers in plots represent the 
frequency of donor P14 T cells in recipient liver at 7 days p.i.  C) Quantification of MHV-GP33 
donor Ly5.1
+
 P14 T cells in recipient spleen and liver. Data are representative of two independent 
experiments. 
 
 
 
 
! 134 
DISCUSSION 
 As mentioned throughout this report, the LCMV model of acute and chronic viral infection 
suggested a model in which increased levels of virus persistence parallel severity of CD8 T cell 
dysfunction. Acute Arm infection is completely cleared, resulting in highly functional memory CD8 
T cells, while chronic Cl-13 infection, characterized by high levels of replicating virus, results in 
the development of highly dysfunctional exhausted CD8 T cells. Given the phenotypic and 
functional data described, we can now place MHV-GP33, a virus characterized by low level 
persistence of viral RNA in the brain, much closer to the Arm end of the LCMV spectrum due to 
its low viral persistence and high memory functionality. The similarities between Arm and MHV-
GP33 are perhaps most obvious in terms of cytokine production (Fig. 4-3); CD8 T cells isolated 
from MHV-GP33-infected tissues were surprisingly more polyfunctional than their phenotype 
suggested. The severe impairment of cytokine expression by virus-specific CD8 T cells isolated 
from Cl-13-infected tissues, along with the decreased capacity to proliferate following LM-GP33 
challenge, distances this virus considerably from MHV-GP33. Furthermore, MHV-GP33 infection 
in the liver, where virus is completely cleared, is slightly more Arm-like while MHV-GP33 infection 
in the brain during persistence is slightly more similar to Cl-13. Importantly, differences in brain 
versus liver were also apparent during chronic Cl-13 infection, particularly in terms of proliferation 
following LM-GP33 challenge (data not shown); less evidence of CD8 T cell exhaustion was 
observed in the liver consistent with lower levels of replicating Cl-13 in that organ.  
 During chronic Cl-13 infection, virus-specific CD8 T cells undergo an aberrant pathway of 
differentiation compared to cells from Arm-immune mice that is characterized by functional 
impairment, upregulation of PD-1, and failure to respond to the homeostatic cytokines IL-7 and IL-
15. While virus-specific CD8 T cells in Arm-immune mice are maintained long-term via IL-7 and 
IL-15 signaling in the absence of Ag, maintenance of CD8 T cells during Cl-13 infection instead 
relies on Ag stimulation provided by ongoing virus replication (31, 38). While the mechanism by 
which MHV-GP33 RNA persists is not known and viral Ag is not detectable by currently available 
techniques, viral mRNA is present in the CNS at four weeks p.i. (unpublished data), suggesting a 
low level of gene expression and thus low level of viral Ag. This low level expression could be 
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sufficient to modulate CD8 T cell differentiation in the brain during MHV-GP33 infection, resulting 
in the modest defects in cytokine expression and upregulation of PD-1 observed. 
 While our model fits nicely with the data at hand, inherent differences in the pattern of 
virus infection must be considered. In the brain, LCMV likely infects cells of the monocyte lineage 
whereas MHV has a tropism for neurons and glia. Such differences in cellular tropism within a 
highly specialized organ like the brain could have profound impacts on CD8 T cell responses by 
differentially impacting levels of virus replication, Ag release, innate immune responses, and 
interactions with antiviral CD8 T cells. Furthermore, MHV replicates primarily in the liver and brain 
while LCMV strains are more widely disseminated throughout the body resulting in a more 
systemic infection. In light of these differences between LCMV and MHV pathogenesis, it is 
perhaps even more surprising that our model largely holds true when applied to such a dissimilar 
virus. Importantly, the data presented for MHV-GP33 are largely in agreement with previous 
studies evaluating the response to endogenous MHV epitopes during CNS persistence of the 
MHV variant J2.2-V-1. Zhao et al. demonstrated that a proportion of antiviral CD8 T cells retained 
in the CNS during MHV persistence remain multifunctional at days 7, 42, and 70 p.i., as 
evidenced by IFN!, TNF", IL-2, and granzyme B expression (42). Additional studies using this 
MHV variant show that virus persists in oligodendrocytes despite the presence of antiviral CD8 T 
cells and that these CD8 T cells express PD-1 even after control of infectious virus (26). It should 
be noted that this MHV variant differs significantly from MHV-GP33 in terms of tropism, with J2.2-
V-1 replication being restricted to glial cells while MHV-GP33 replicates in both neurons and glia; 
furthermore, J2.2-V-1 does not replicate in the liver while MHV-GP33 does. Thus, the MHV-GP33 
virus used in our studies offers several advantages for these types of studies due to 1) the ability 
to increase precursor cell numbers and monitor donor cell proliferation by adoptive transfer of 
congenic P14 Tg T cells, 2) the ability to directly compare the MHV-GP33-specific CD8 T cell 
responses with LCMV, and 3) the ability to directly compare MHV-specific cells in the liver, where 
virus is completely cleared, and brain where viral RNA persists. Nevertheless, it would be 
informative to compare CD8 T cell quality during infection with these two MHV strains in order to 
evaluate the contribution of acute viral tropism on subsequent antiviral CD8 T cell responses. 
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Furthermore, it would be of value to compare endogenous GP33-specific CD8 T cell responses to 
CD8 T cell responses directed against an endogenous MHV epitope like S598; expression of this 
epitope, which is encoded within the spike glycoprotein, may differ from that of GP33, which is 
expressed in place of nonessential gene 4 and thus could result in yet another comparison of 
CD8 T cell responses to an individual virus.  
 Unique aspects of tissues such as liver and brain must also be considered. The liver, 
which filters blood draining from the gastrointestinal tract and other abdominal organs, is 
continually exposed to a variety of insults whereas brain tissue is typically maintained in a more 
quiescent state with low levels of inflammation. Interestingly, previous studies in which mice were 
immunized against GP33 and then infected with MHV-GP33 revealed that the GP33/GFP region 
of this virus is mutated and/or deleted more rapidly in the liver than in the brain (4). Studies 
isolating LCMV variants from different organs of carrier mice infected at birth with Arm also reveal 
organ-specific differences in selection of viruses; notably, viruses isolated from the CNS 
remained biologically similar to the parental Arm virus whereas viruses isolated from the liver or 
spleen contained reproducible mutations resulting in conversion to a more persistent phenotype 
like Cl-13 (34). Thus, tissue-specific differences likely play significant roles with regard to virus 
infection and host immune responses that are only beginning to be appreciated. Furthermore, the 
distinct CD8 T cell phenotypes observed in liver versus brain with both Cl-13 and MHV-GP33 
suggest there is little fluidity between CD8 T cell populations in the brain and liver. Zhao et al. 
demonstrated using the J2.2-V-1 variant of MHV that virus-specific CD8 T cells in the brain during 
viral persistence are maintained in part by recruitment of cells from the periphery (42); while CD8 
T cells can likely enter the inflamed brain with relative ease, they may become trapped in the 
brain parenchyma, consistent with CD69 expression as mentioned previously. 
 Finally, considering the demyelinating process present in mice chronically infected with 
MHV-GP33, our data raise the question as to whether having antiviral CD8 T cells that are more 
highly functional would be an advantage or disadvantage for the host. One can imagine that 
increasing T cell functionality early during persistence may more effectively clear residual 
infectious virus, thereby limiting the severity of demyelinating disease. In support of this idea, 
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previous studies using adoptive transfer of P14 CD8 T cells prior to MHV-GP33 infection reduced 
the severity of acute CNS disease and demyelination (21). However, contrasting studies suggest 
that antiviral CD8 T cells may contribute to the pathogenesis of demyelination in MHV-infected 
mice. RAG-deficient mice infected with MHV do not develop demyelination; however, adoptive 
transfer of splenocytes from infected immunocompetent mice into RAG-deficient mice restores 
demyelination (36, 40). Furthermore, both CD4 and CD8 T cells alone can restore the 
development of demyelination in RAG-deficient mice (15). These somewhat conflicting studies 
highlight the delicate balance between virus control and immune-mediated pathology that can be 
particularly detrimental if thrown off balance in a delicate tissue like the brain. Thus, additional 
work is needed to delineate the precise mechanisms of viral control and immune-mediated 
pathology in the brain during persistent viral infections in order to guide therapeutic approaches 
for controlling neurotropic infections. As demonstrated here, comparative models of viral infection 
offer a significant advantage for elucidating subtle mechanisms of viral pathogenesis. 
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GENERAL CONCLUSIONS AND DISCUSSION 
 The neurotropic MHV strains rA59 and rJHM.SD differ strikingly in terms of viral 
dissemination, induction of host immune responses, and ultimate disease outcome in the CNS, 
thereby providing a useful comparison for studying viral and host determinants of neurovirulence. 
Two hallmarks of rJHM.SD-induced CNS disease in the mouse are widespread localization of 
viral Ag throughout the brain parenchyma and low numbers of activated antiviral CD8 T cells at 
the site of infection (13, 34). We propose that these features cooperatively contribute to the high 
neurovirulence and uniform lethality of rJHM.SD in adult mice. However, prior to the studies 
described, relatively little was known about how rJHM.SD spreads so extensively in the brain 
while avoiding the induction of a CD8 T cell response.  
 One characteristic of rJHM.SD that has been documented over the years is its capacity to 
spread cell-to-cell in vitro in the absence of the primary MHV receptor CEACAM1a (8, 27, 28, 40); 
yet, it was unclear if this CEACAM1a-independent spread phenomenon plays a role in vivo during 
CNS infection. Addressing the role of CEACAM1a during rJHM.SD infection has been 
complicated by the fact that CEACAM1a expression is difficult to detect on the surface of CNS 
cell types and has thus far only been demonstrated on endothelial cells and microglia (9, 31). In 
Chapter 2, we described a series of studies aimed at identifying expression of MHV receptor 
genes in CNS cell types and utilized primary cell cultures derived from ceacam1a
-/-
 animals to 
address the role of CEACAM1a-independent mechanisms of MHV infection and spread in 
neuronal cells, the predominant target of JHM.SD infection. While low to moderate expression of 
ceacam1a and ceacam1a-related genes was detected in a variety of CNS cell types, the cell type 
distribution of mRNA expression and in vitro functionality of these receptors suggest they are 
unlikely to account for the pattern of rJHM.SD infection observed in ceacam1a
-/-
 mice and cells. 
Thus, rJHM.SD likely utilizes an additional mechanism of CNS entry/spread that is independent of 
previously identified ceacam1a-related receptors.  
 In Chapter 3, we continued to explore the enhanced neurovirulence of rJHM.SD by 
examining the induction of antiviral CD8 T cell responses during CNS infection. Using an adoptive 
transfer model, we showed that few naïve CD8 T cells are primed during acute CNS infection with 
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rJHM.SD, as evidenced by low levels of virus-specific CD8 T cell proliferation in the draining CLN 
and spleen. This lack of CD8 T cell priming is unlikely to be due to an active viral mechanism as 
rJHM.SD did not prevent the induction of a CD8 T cell response to rA59 in co-infected animals. 
Furthermore, peripheral inoculation of rJHM.SD resulted in a robust antiviral CD8 T cell response 
in the spleen, suggesting that the weak CD8 T cell response to rJHM.SD is specific to CNS 
infection. After intracranial inoculation of virus, infectious rJHM.SD was not readily detected 
outside the CNS while rA59 replicated to reasonably high titers in both brain and CLN at early 
times post-infection. Based on these data and the data presented in Chapter 2, we propose that 
cell-to-cell spread of rJHM.SD, predominantly in neurons, and subsequent restriction of rJHM.SD 
replication to the CNS limit the availability of viral Ag to antigen presenting cells (APC) and thus 
result in poor priming of virus-specific CD8 T cells in the CLN.  
 In Chapter 4, we focused on the persistent demyelinating rA59 strain to study the 
relationship between viral persistence and CD8 T cell functionality during chronic disease. We 
presented a model comparing virus-specific CD8 T cell responses during acute and chronic 
LCMV infection as well as infection with a recombinant MHV A59 expressing the GP33 epitope 
(MHV-GP33). This system allowed us to directly test the model that increased viral 
load/persistence corresponds to increased stages of CD8 T cell exhaustion during chronic viral 
infections; importantly, these comparisons were made between different viruses as well as 
between organ systems within an individual mouse. The quality of virus-specific CD8 T cells 
maintained during persistence was evaluated in terms of cell phenotype, effector functionality, 
and proliferative capacity in the face of pathogen rechallenge. Taken together, the low level of 
MHV-GP33 persistence compared to chronic Cl-13 infection resulted in antiviral CD8 T cells that 
were of high quality, similar to but slightly less polyfunctional than cells present after Arm 
clearance. Furthermore, virus-specific CD8 T cells maintained after MHV-GP33 clearance in the 
liver were more functional than cells present in the persistently infected brain. Thus, our data fit 
extremely well within this model of viral persistence, lending further support to the idea that 
persisting virus, whether in the form of RNA, antigen, or infectious virus, can have a direct impact 
on the quality and protective capacity of antiviral CD8 T cells during chronic disease. Together, 
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the studies presented in Chapters 2, 3, and 4 further enhance our understanding of how different 
MHV strains interact with the murine host, from receptor utilization for viral entry/spread to 
shaping of the antiviral immune response during CNS persistence. 
  
RECEPTOR EXPRESSION AND UTILIZATION IN THE CNS  
 The MHV lifecycle typically begins with binding of the viral spike glycoprotein to its 
receptor CEACAM1a on the surface of a host cell (44). This binding triggers a conformational 
change in spike that is thought to reveal an internal fusion peptide that inserts into the host cell 
membrane and mediates fusion for virus entry (2). However, expression of CEACAM1a in the 
CNS is very low compared to other targets of MHV infection like the liver, and only a small subset 
of cells (microglia and endothelial cells) have thus far been demonstrated to express this 
receptor. Yet, we and others have shown that both rA59 and rJHM.SD infect multiple CNS cell 
types including astrocytes, oligodendrocytes, and especially neurons (Fig. 2-1). Using enriched 
primary CNS cell cultures, we assayed mRNA expression of documented MHV receptor genes. In 
our studies, ceacam1a expression was detected in microglia as well as oligodendrocyte, 
astrocyte, and to a much lesser extent neuronal cultures (Fig. 2-2). While we cannot exclude the 
possibility that contaminating microglia may account for the ceacam1a expression observed in 
neuron and astrocyte cultures, our data raise the likely possibility that some CNS cell type(s) 
other than microglia express CEACAM1a in vivo. Based on data from mixed neural cultures, it 
has been proposed that MHV infection is initiated in CEACAM1a-bearing microglia and that 
dissemination to additional CNS cell types occurs via a CEACAM1a-independent mechanism 
(26). Since we have been unable to definitively demonstrate CEACAM1a expression on cells 
other than microglia we cannot rule out this possibility; however, data from our lab and others 
argue against this hypothesis. In wild-type neuron cultures, rA59 infects clusters of neurons (Fig. 
2-4) (30) despite its dependence on CEACAM1a for spread. Furthermore, the striking observation 
that spread of rA59 in ceacam1a
-/-
 neurons is severely hindered compared to spread in wild-type 
cells (Fig. 2-4 and 2-5) indicates that CEACAM1a does indeed play a role in neuronal spread of 
rA59, further suggesting that neurons likely express low levels of CEACAM1a that are not 
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detectable by routine methods. Interestingly, the normally glial-tropic JHM variant 2.2-V-1, which 
is CEACAM1a-dependent, spreads more extensively among glial cells types and also infects 
neurons in mice deficient in type I interferon signaling (IFNAR
-/-
), arguing that it is not an absence 
of CEACAM1a that prevents neuronal infection with J2.2-V-1 in wild-type mice (14). Given that 
CEACAM1a is specifically targeted to cell-cell contact areas and apical surfaces of polarized 
epithelial cells (39), we hypothesize that CEACAM1a may be similarly sublocalized on the surface 
of neurons, for example to synaptic membranes, such that receptor density is sufficient to 
facilitate CEACAM1a-dependent spread to adjacent neurons at these specialized locations. 
Moreover, MHV has previously been reported to spread transneuronally (1, 42). Sophisticated 
amplification techniques combined with traditional immunofluorescence and/or in situ 
hybridization procedures will likely allow for more accurate assessment of receptor expression in 
individual cells.  
 While CEACAM1a clearly plays a role in initial virus entry for both rA59 and rJHM.SD (as 
evidenced by decreased rates of infection in ceacam1a
-/-
 compared to wild-type mice and cells) 
as well as in neuron-to-neuron spread of rA59 (Chapter 2), an additional mechanism appears to 
be at play in the CNS that allows spread of rJHM.SD in the absence of ceacam1a; this 
mechanism is largely dependent on the JHM.SD spike (Fig. 2-5) (25). The capacity of rJHM.SD 
and other highly neurovirulent JHM isolates to spread cell-to-cell in vitro in the absence of 
CEACAM1a correlates with the presence of a long hypervariable region (HVR) within the spike 
(5, 7, 8, 28); notably, rA59 contains a 52 amino acid deletion within the HVR, correlating with its 
inability to spread without CEACAM1a. It remains unclear whether the phenomenon of 
CEACAM1a-independent spread described for rJHM.SD in vitro is the same phenomenon 
observed during infection of ceacam1a
-/-
 mice and cells; however, the availability of a 
recombinant JHM.IA virus with a mutation rendering it capable of CEACAM1a-independent 
spread in vitro (rJIA.S310G) (28) and the prospect of a recombinant JHM.SD virus expressing the 
reverse mutation (rJSD.G310S) should enable this question to be addressed. To begin to 
address the mechanism of CEACAM1a-independent entry/spread, we explored the possibility 
that CEACAM1a-related proteins may facilitate MHV infection in the absence of ceacam1a by 
! 148 
evaluating expression of ceacam2 and psg16 in primary CNS cells. While ceacam2 expression 
was detected at low levels in microglia and oligodendrocyte cultures (Fig. 2-6), neuron cultures 
were strikingly positive for psg16 expression (Fig. 2-7). Based on previous reports of receptor 
functionality (3) and the data presented here (Fig. 2-8), it is unlikely that PSG16 mediates 
rJHM.SD entry or spread. However, as we propose for CEACAM1a, selective localization to a 
particular region of the neuron, either by direct protein targeting to the membrane or association 
with another membrane moiety, may position PSG16 to mediate infection in ways that were not 
appreciated in transfection experiments using cultured cell lines. Furthermore, the possibility that 
PSG16 might be secreted from neurons and/or other cell types during infection could suggest a 
role in intercellular signaling as has been described for PSG17 and PSG18 (12, 43). We cannot 
exclude the possibility that an alternative receptor unrelated to CEACAM1a exists in the CNS and 
functions as a receptor for rJHM.SD; however, such a receptor would be expected to function for 
cell-to-cell spread only as infection rates are significantly reduced in the absence of ceacam1a.  
 Given the range of differences in spike glycoproteins of different MHV strains and their 
impact on viral tropism and virulence (Fig. 1-2, Table 1-1), it is possible that small changes in 
sequence could drastically affect the binding of the MHV spike to an alternate receptor and/or 
lower the threshold required to trigger a conformational change rendering the spike fusion 
competent in the absence of receptor binding. As such, spontaneous activation of the JHM.SD 
spike due to inherent instability of the S1/S2 interaction has been suggested as a mechanism for 
CEACAM1a-independent spread (7). We further postulate that the HE protein expressed on the 
surface of a subset of MHV strains, including rJHM.SD, may enhance viral attachment to a host 
cell via interaction with sialic acid-containing molecules on the surface (33); binding of these 
smaller HE spikes to surface moieties may bring virus and host membranes in close enough 
proximity such that spontaneous activation of the JHM.SD spike could trigger membrane fusion. 
Indeed, expression of the HE gene enhances virulence of a recombinant A59 expressing the 
JHM.SD spike (16). Alternatively, rJHM.SD may be passively transported from neuron to neuron 
within synaptic vesicles, thereby eliminating the requirement for CEACAM1a in cell-to-cell spread; 
virus transport within synaptic vesicles could allow transmission of either whole virions or 
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nucleocapsid complexes to a neighboring cell without the need for a virus receptor, similar to the 
process described for measles virus (22). Importantly, such a mechanism would be specific to 
rJHM.SD (possibly due to characteristics of the long spike, as discussed above) since rA59 
requires CEACAM1a for efficient neuron-to-neuron spread.  
 Since ceacam1a mRNA is alternatively spliced yielding four distinct species in the 
mouse, we compared expression of individual ceacam1a splice variants and showed that 
different organs and cell types express different ratios of short-tailed to long-tailed species (Fig. 2-
3). Notably, splice variants encoding a long cytoplasmic tail predominated in the CNS while short- 
and long-tailed species were more balanced in the liver (Fig. 2-3). Isoforms with long cytoplasmic 
tails contain phosphorylatable serine, threonine, and tyrosine residues that participate in protein-
protein interactions and intracellular signaling cascades, with roles in insulin regulation and tumor 
suppression (17). While short cytoplasmic tails lack these phosphorylatable residues, they have 
instead been shown to bind elements of the cytoskeleton like actin, calmodulin, and tropomysin 
(10). Of particular interest, long-tailed CEACAM1a isoforms expressed on murine dendritic cells 
have been shown to stimulate cell maturation as well as secretion of the chemokines CCL3 
(MIP1!) and CXCL2 (MIP2) and cytokines IL-6 and IL-12 in response to monoclonal antibody 
stimulation (15). Therefore, we hypothesize that binding of the MHV spike to CEACAM1a, similar 
to antibody binding, may trigger release of cytokines from infected CNS cells. Furthermore, MHV 
binding to CEACAM1a on dendritic cells may activate these APC, leading to DC migration and 
priming of naïve T cells in the CLN. Given the functional differences attributed to long- and short-
tailed CEACAM1a isoforms, is tempting to speculate that MHV binding to long-tailed isoforms 
may trigger or modulate intracellular signaling pathways in ways that virus binding to short-tailed 
isoforms may not and that the induction of protective immune responses could be limited in 
situations where MHV spreads in the absence of CEACAM1a. 
 
CD8 T CELL PRIMING DURING ACUTE DISEASE  
 Numerous studies have highlighted the importance of antiviral CD8 T cells in protection 
against coronavirus-induced CNS disease and clearance of infectious virus. During acute CNS 
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infection with rA59 or neuroattenuated JHM variants, activated virus-specific CD8 T cells 
accumulate at the site of infection, peaking in the brain at day 7 p.i. and coinciding with viral 
clearance (21, 45). Interestingly, CNS infection with the highly neurovirulent JHM.SD induces a 
weak virus-specific CD8 T cell response in the brain despite high levels of infectious virus and 
widespread distribution of viral Ag (Fig. 3-5)(13, 34). However, it was unclear why mice fail to 
mount an effective immune response to JHM.SD in the brain. In collaboration with Katherine 
MacNamara, we addressed this issue by comparing CD8 T cell priming during infection with 
rA59, rJHM.SD, and the chimeric rA59/SJHM.SD. Previous studies using an attenuated variant of 
JHM demonstrated that naïve virus-specific CD8 T cells are primed by APC in the draining CLN, 
where they begin to expand and upregulate antiviral effector functions; these activated cells 
increase further in number in the spleen and ultimately traffic to the site of infection, the brain 
(24). Using adoptive transfer of naïve CFSE-labeled P14 cells prior to or early after CNS infection 
with GP33-expressing viruses, we observed significant proliferation of P14 donor cells following 
infection with either rA59 or rA59/SJHM.SD but not with rJHM.SD (Fig. 3-2); these results correlate 
with the accumulation of virus-specific CD8 T cells in the brain during infection with these viruses. 
Interestingly, rJHM.SD did not cause a generalized immunosuppression in the brain, as mice co-
infected with rJHM.SD and rA59 mounted a CD8 T cell response directed solely against rA59 
(Fig. 3-3). Notably, i.p. inoculation of rJHM.SD resulted in a robust antiviral CD8 T cell response 
in the spleen (Fig. 3-7), indicating that the weak CD8 T cell response to rJHM.SD observed in the 
brain is limited to the context of CNS infection. 
 Prior to these studies, we hypothesized that rJHM.SD might actively evade the host 
immune system, as is the case for many other viruses. However, the data in Fig. 3-3 and 3-7 
instead suggest that the failure of rJHM.SD to elicit a robust antiviral CD8 T cell response in the 
brain is more of a passive mechanism. The predominant neuronal tropism of rJHM.SD (Fig. 2-
1)(6), paired with unique mechanisms of neuronal survival in the face of insult, may enable 
rJHM.SD to spread, at least temporarily, without being detected by APC in the brain. The low 
level of rJHM.SD replication in cultured neurons (Fig. 2-4) and delayed viral replication in the 
brain compared to rA59 (Fig. 3-5) support the hypothesis that viral Ag is sequestered away from 
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APC at early times post-infection. Furthermore, rJHM.SD replication was largely restricted to the 
CNS, as infectious rJHM.SD virus (Fig. 3-5) and viral RNA (unpublished data) were barely 
detectable in the draining CLN while replication of rA59 and rA59/SJHM.SD was readily detected in 
the CLN. While virus replication in the LN is not required for priming of a CD8 T cell response, 
one can imagine that additional virus replication at the site of T cell priming could increase the 
amount of viral Ag available for presentation by APC; therefore, minimal levels of rJHM.SD 
replication at sites outside the CNS would further limit the accessibility of viral Ag to APC. 
However, sequestration of virus from APC is unlikely to be complete, and some level of infectious 
rJHM.SD would ultimately be expected to contact APC in the brain; in this case, viral infection 
could lead to lysis of APC or otherwise compromise APC function such that Ag presentation in 
the CLN does not successfully occur. While cytopathic effects and impairment of APC maturation 
have been observed in vitro in bone marrow-derived dendritic cells infected with MHV (48) 
(unpublished data), the data presented in Fig. 3-7 argues against rJHM.SD-mediated impairment 
of APC function as peripheral inoculation elicits a robust antiviral CD8 T cell response. However, 
we cannot exclude the possibility that APC encountering viral Ag under different conditions (CNS 
vs. periphery) may have disparate outcomes with regard to functional maturation and subsequent 
CD8 T cell priming. As such, the inherent instability of the JHM.SD spike could render virions 
noninfectious if they are not immediately engaged by another cell; thus, APC in the periphery 
could potentially encounter exogenous rJHM.SD Ag more readily than in the brain and process it 
via cross-presenation pathways for presentation to CD8 T cells, as opposed to processing of 
endogenous Ag during direct viral infection, thereby avoiding cytotoxic effects of the virus. 
Additional studies are needed to elucidate the mechanisms of Ag processing following different 
routes of viral infection.  
 Regardless of how rJHM.SD avoids the induction of an antiviral CD8 T cell response in 
the brain, the question remains as to whether CD8 T cells could actually protect mice during CNS 
infection with a highly neurovirulent virus like rJHM.SD. Recent studies in our lab suggest that 
antiviral CD8 T cells may be ineffectual against some highly neurovirulent viruses, as evidenced 
by a virus expressing the A59 replicase paired with the structural genes of JHM.SD; this virus is 
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highly virulent despite the induction of a robust virus-specific CD8 T cell response (Timothy 
Cowley, unpublished data). Conversely, induction of antiviral CD8 T cells correlates with delayed 
mortality in mice infected with rA59/SJHM.SD compared to rJHM.SD, despite the fact that these 
viruses have the same intracranial LD50 (13). Furthermore, co-infection of rA59 and rJHM.SD was 
protective against rJHM.SD-induced CNS disease as fewer co-infected animals succumbed to 
infection by day 8 p.i. compared to mice infected with rJHM.SD alone (Fig. 3-4); however, we 
cannot exclude the possibility that some non-CD8 T cell aspect of the host response to rA59 
contributed to this partial protection in co-infected animals. While CD8 T cell-mediated cytolysis is 
important for clearing MHV from astrocytes and microglia (36) and viral clearance from 
oligodendrocytes requires IFN-" ! (29), it is not yet clear what antiviral mechanisms are required to 
clear infectious MHV from neurons. Given the rapid dissemination of rJHM.SD throughout the 
brain and the pathology caused by infiltrating neutrophils early after infection (13), in seems 
unlikely that a primary antiviral CD8 T cell response could completely resolve rJHM.SD infection; 
rather, antiviral CD8 T cells would likely slow the course of CNS disease, as is the case with 
rA59/SJHM.SD. Furthermore, even if virus-specific CD8 T cells were effectively primed during 
rJHM.SD infection, the lower levels of T cell-recruiting chemokines, such as CXCL9 (MIG) and 
CXCL10 (IP-10), expressed in the brains of mice infected with rJHM.SD compared to rA59 or 
rA59/SJHM.SD infected animals (35) could lead to poor recruitment of CD8 T cells to the site of 
infection.  
 
CD8 T CELL DYSFUNCTION DURING CHRONIC INFECTION 
 Persistence of demyelinating MHV strains, such as rA59, in the CNS provides a unique 
model system in which to assess the effect of low-level virus persistence on antiviral CD8 T cell 
differentiation. The LCMV models of acute (Arm) and chronic (Cl-13) infection have been well 
described, as have the quality of CD8 T cells responding to these viruses at late times post-
infection. As outlined in Chapter 4, we utilized a recombinant A59 expressing the GP33 epitope of 
LCMV in place of nonessential gene 4 (MHV-GP33) (4), thereby allowing the transfer of naïve 
P14 (GP33-specific) CD8 T cells and comparison of the quality of these cells during subsequent 
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viral infection. Like parental A59, MHV-GP33 replicated in the brain and liver during the first week 
of infection (Fig. 4-1), after which time virus is completely cleared from the liver but persists in the 
brain in the form of viral RNA accompanied by immune-mediated demyelination. This 
intermediate strategy of viral persistence provided an important comparison to Arm, which is 
cleared by 8-10 days p.i., and Cl-13, which continues to replicate for approximately 2 months p.i. 
Interestingly, GP33-specific CD8 T cells isolated from the liver of MHV-GP33-infected mice at day 
30 p.i. phenotypically resembled cells from the liver of Arm-immune mice while cells isolated from 
MHV-GP33 infected brain looked slightly more like the dysfunctional CD8 T cells isolated from the 
brains of mice chronically infected with Cl-13 (Fig. 4-2); these differences in T cell quality directly 
correlate with tissue differences in MHV-GP33 persistence (complete clearance in liver versus 
RNA persistence in brain). In terms of cytokine production, GP33-specific CD8 T cells from the 
brain and liver of MHV-GP33-infected mice were largely dual functional in terms of IFN" and 
TNF! expression following peptide stimulation; furthermore, granzyme B remained high, 
particularly in cells isolated from the brain (Fig. 4-3). These results are in agreement with previous 
studies using the attenuated 2.2V-1 variant of JHM, where a proportion of antiviral CD8 T cells 
retained in the CNS during viral persistence remained multifunctional at days 7, 42, and 70 p.i., 
as assessed by IFN", TNF!, IL-2, and granzyme B expression (47). Similar studies showed that 
viral challenge following epitope immunization resulted in accumulation of virus-specific IFN"
+
 
cells, half of which co-produced TNF!; a high frequency of these secondary responding cells 
were also granzyme B
+
 (32). 
 In our final experiment, we tested to ability of GP33-specific CD8 T cells from 
persistently-infected mice to proliferate in response to LM-GP33 rechallenge in an otherwise 
naïve host. As expected from our functional data, donor P14 cells isolated from the brain and liver 
of MHV-GP33-infected animals proliferated well in response to Ag re-exposure (Fig. 4-4). 
Together, our results fit exceptionally well with our predictions from the LCMV model that low-
level virus persistence, as with MHV-GP33, will have modest effects of CD8 T cell quality. 
Further, low levels of MHV-GP33 persistence in the brain compared to viral clearance in the liver 
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resulted in CD8 T cells in the brain that were slightly less functional than their liver counterparts. 
Whether the persistent viral RNA allows for low-level translation of viral Ag that continues to 
stimulate CD8 T cells or whether some other aspect of MHV persistence, such as inflammation 
associated with demyelination, is having a direct effect on CD8 T cell differentiation is unclear; 
however, we now have a working model in which to test individual aspects of MHV persistence 
for their effects on T cell responses. Furthermore, additional analyses will be important to more 
fully characterize the subtle T cell defects during MHV persistence and determine if the 
functionality of these cells changes over time.  
 Studies of J2.2V-1 infection in IL-15
-/-
 mice suggest that activated memory-like cells 
undergo a low level of proliferation in the absence of IL-15 in persistently-infected mice (49). 
Previous studies by this group also demonstrated that persistent viral RNA is required to retain 
antiviral CD8 T cells in the brain during persistent J2.2V-1 infection (23). Given that CD127 is 
highly expressed on MHV-specific CD8 T cell in the brain and liver (Fig. 4-2), it is likely that IL-7 
plays a role in driving homeostatic proliferation of GP33-specific CD8 T cells during MHV-GP33 
persistence; however, future studies should address the capacity of these cells to maintain their 
population numbers in the absence of persistent viral RNA and inflammation. Furthermore, 
endogenous comparisons of CD8 T cell responses directed against the GP33 epitope versus the 
naturally occuring S598 epitope will be informative with regard to the integrity of the GP33-
encoding region of the MHV-GP33 genome at late times post-infection. While we did not detect 
gross deletions of consensus mutations, it is possible that the virus-specific CD8 T cells present 
in the brain and/or liver exert selective pressure that could render this epitope nonfunctional; 
since S598 is encoded within a key structural protein, the spike, it is less likely to tolerate 
mutation as well as the nonessential GP33 and thus may result in a different pattern of 
persistence/expression. Another aspect of MHV persistence that is unclear is the role of cellular 
tropism in shaping the antiviral CD8 T cell response during persistent rA59 and J2.2-V-1 infection; 
these viruses have unique cellular tropisms during acute disease but are suggested to persist in 
similar cells, primarily oligodendrocytes, during the chronic phase of infection. If this is the case, it 
would be interesting to test whether acute neurotropism, specifically of rA59 for neurons, plays a 
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role in shaping the differentiation of CD8 T cells observed during chronic infection. Conversely, if 
these viruses persist in different cell types a comparison between the two viruses could reveal 
cell type-specific mechanisms of viral persistence and immune modulation. Inherent differences 
between viruses, even within the same organ, should not be overlooked.  
 Notably, while viral RNA persistence appears to correlate with the differentiation of virus-
specific CD8 T cells during chronic disease, we cannot rule out effects of the demyelinating 
process on CD8 T cell differentiation. MHV-induced demyelination is characterized by infiltration 
of lymphocytes and lipid-containing macrophages (19, 20, 37, 46). Using infections with the 
attenuated JHM 2.2-V-1 variant, it was demonstrated that both monocyte-derived macrophages 
and microglia are present in regions of demyelination in contact with demyelinated axons, 
suggesting that both cell types participate in the demyelinating process (41). Furthermore, while 
infected RAG-deficient mice do not develop demyelination, adoptive transfer of either CD4 or 
CD8 T cells restores the development of demyelination in RAG-deficient mice (18). Chronic 
activation of astrocytes during persistent infection also contributes to demyelination via the 
secretion of macrophage- and T cell-chemoattractants, as well as TNF!, IL-1#, IL-6, and type 2 
nitric oxide synthesis (iNOS) that may directly contribute to the dysregulation of oligodendrocyte 
function and resulting myelin loss (11, 38). While the precise role of these immune cell types in 
MHV-induced demyelination is unknown, it will be important to assess the quality of persisting 
CD8 T cells in the brain at multiple times p.i. as demyelination waxes and wanes in the continued 
presence of viral RNA. 
 
FUTURE DIRECTIONS AND FINAL COMMENTS 
 Many questions remain regarding the precise mechanisms contributing to MHV 
neurovirulence, and these questions will be most effectively addressed utilizing the multitude of 
available MHV strains and variants that differ in tropism, receptor utilization, persistence, and host 
response. All MHV strains analyzed to date utilize CEACAM1a as the primary receptor. 
Therefore, it is unclear why rJHM.SD disseminates so widely in the CNS but is unable to 
establish productive infection in the liver, an organ known to express higher levels of CEACAM1a 
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than the brain. It is clear that the JHM.SD spike can mediate entry into the liver, suggesting that 
early host responses may limit rJHM.SD infection in this organ; these processes are beginning to 
be explored. Furthermore, it is curious that J2.2-V-1 infects only glial cells while other JHM 
isolates infect neurons as well. In terms of MHV receptor expression, it remains unclear whether 
neurons express CEACAM1a, though several lines of evidence suggest this is the case. It is also 
unknown if PSG16 is expressed on the surface of neurons and whether this protein can actually 
function as a receptor for MHV. It is likely that CEACAM1a-independent spread of rJHM.SD in 
neurons also occurs independently of CEACAM1a-related proteins, though this mechanism of 
spread must be more carefully explored. Additionally, the impacts of virus replication on neuronal 
function, both direct and indirect, have yet to be examined. Overall, it will be important to more 
fully characterize how different MHV strains enter individual CNS cell types and how infection is 
subsequently recognized and combated by the host while maintaining the integrity of the delicate 
CNS tissue. Finally, much remains unknown regarding the establishment of viral persistence in 
the CNS and interactions of virus with CD8 T cells during chronic disease. The diversity of 
neurotropic strains and recombinants available combined with the relative ease of genetic 
manipulation makes MHV an important tool for studying virus-induced pathogenic processes in 
the CNS, dissecting the development of antiviral immune responses during acute and chronic 
disease, and elucidating viral and host determinants of neurovirulence. 
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